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Abstract
22 patients with de novo or relapsed Acute Myeloid Leukaemia (AML) were
recruited into a Phase I/II clinical trial aimed at vaccinating with autologous
Dendritic-like Leukemia Cells (DLLC) once in complete remission. At trial entry
leukaemia cells were harvested and tested for their permissiveness to cytokine-
induced dendritic cell differentiation. Study patients were then treated with induction
chemotherapy. Five patients achieved both complete remission and had leukaemia
cells that were permissive to differentiation, and were therefore eligible to proceed to
vaccination. Four escalating doses of DLLC were administered weekly by
subcutaneous injection. Levels of minimal residual disease were measured by Wilms
tumour-1 gene expression. Development of anti-leukaemic T-cell responses was
assessed by ELIPSOT analysis of gamma interferon secreting T-lymphocytes and by
measurement ofWT1 specific T-cells by HLA tetramer analysis. An increase in anti-
leukaemic T-cell responses was demonstrated in four patients. Vaccination was
generally well tolerated with the only significant side effect being the development
of extensive eczema in one patient. Two patients relapsed during or shortly after the
vaccination schedule. In the remaining three patients, one relapsed at 12 months with
two in continued remission more than 12 months post vaccination.
In a parallel investigation, the potential of Tumour Cell / Dendritic Cell Fusion
Hybrids to generate in vitro anti-leukaemic T-cell responses following co-culture
with autologous remission lymphocytes was assessed in six patients with AML.
Comparison was made to anti-leukaemic responses induced by mature Dendritic
Cells (mDC) co-cultured with autologous, irradiated myeloid blasts. Fusion Hybrids
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induced anti-leukaemic T-cell immune responses in three out of six patients.
Tumour pulsed mDC induced T-cellular responses in two other patients. Only one of
six patient's remission lymphocytes failed to develop leukaemia directed immune
responses following stimulation with either construct. Anti-proliferative properties
of Fusion Hybrids against allogeneic lymphocytes were observed in mixed
lymphocyte-leukaemia reactions (MLLR) and were found not to be specific to the
cell fusion partners and do not prevent the ability of AML-mDC heterokaryons to
induce autologous anti-leukaemic cytotoxicity. In conclusion, Tumour Cell /
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Chapter 1: Introduction
1.1 Current concepts of immune-mediated treatment
modalities for Acute Myeloid Leukaemia
Acute Myeloid Leukaemia (AML) is a biologically and clinically heterogeneous
disease characterised by a clonal, neoplastic proliferation of haematopoietic
progenitor cells. Immunological control of this disease, resulting in spontaneous
remission, is exceedingly rare, but has been reported (Muller et al, 2004) after
bacterial infections, suggesting that immune recognition of leukaemic cells is
possible under certain circumstances. The discovery of tumour-related antigens,
recognized by cytotoxic lymphocytes, has been a significant advance in
understanding the role of an immune response seen in patients with leukaemia.
Intensive multi-agent chemotherapy, however, has been the backbone of AML
treatment for decades. Complete remissions are achievable with this approach in 70-
80% of patients below 60 years of age. However, disease relapse originating from
minimal residual disease (MRD) (Yin & Tobal, 1999) results in an overall 5-year
survival of less than 30%. Autologous transplantation in AML confers some degree
of benefit in respect of improved disease-free survival, but is associated with a not
insignificant risk of treatment related mortality (Burnett et al, 1998;Ravindranath et
al, 1996). Superior long-term disease free survival of 50-60% can be achieved in
patients that have undergone allogeneic haematopoietic stem cell transplantation
(HSCT), and in recent years evidence has emerged that much of the therapeutic
benefit of this procedure is derived from an immunologically mediated graft versus
leukaemia (GvL) effect (Korngold et al, 1994;Falkenburg et al, 1997). This has led
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to the development of reduced intensity, non-myeloablative transplant conditioning
regimes, designed to allow donor engraftment rather than direct tumour cytotoxicity,
and the use of donor-lymphocyte infusion (DLI) (Kolb et al, 1995) (Mackinnon et al,
1995;Helg et al, 1998;Collins, Jr. et al, 1997)as a means to treat relapse following
allogeneic HSC transplantation, proving that immune surveillance of residual
leukaemic blasts by donor T-lymphocytes is possible.
Recently, a number of specific peptides have been identified that may represent
appropriate targets for immune responses in the context of allogeneic HSCT. The
haematopoiesis -specific minor histocompatibility antigens HA-1 and HA-2 may act
as malignancy-specific targets in the context of allogeneic HSCT (Mutis et al,
1999a;Mutis et al, 1999b;Marijt et al, 2003).
Newer evidence points towards the role of Natural Killer (NK) cells in controlling
and eradicating leukaemia in a situation of haplotype mismatched transplantation.
Mismatch for killer immunoglobulin-like (KIR) receptors between donor and
recipient pairs in this particular subgroup is associated with activation of donor
derived NK cells that contribute to immune control of MRD and lower relapse risk
compared to KIR matched donor-recipient pairs (Ruggeri et al, 1999;Ruggeri et al,
2002;Farag et al, 2002).
These treatment modalities provide a model for the successful integration of
immuno-therapeutic approaches to MRD in current clinical practice and have
improved long-term clinical outcomes. However, there is a need for novel treatment
strategies, in particular for older patients, because of the unacceptably high morbidity
and mortality associated with HSC transplantation approaches. In clinical practice,
the development of GvL is often associated with significant Graft versus Host
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Disease (GVHD). Unfortunately, GVHD remains a major cause of transplantation-
related mortality (TRM) and still limits the use ofHSCT in older patients.
In recent years a better understanding ofmechanisms involved in the immune escape
of tumours together with the identification of tumour associated antigens (TAA) in
AML, such as the Wilms tumour gene product WT1 (Mailander et al, 2004;Elisseeva
et al, 2002;0ka et al, 2004), proteinase 3 (Gao et al, 2000) (Molldrem et al,
1996;Ohminami et al, 2000)and protein products of abnormal fusion genes, e.g.
BCR-ABL in Chronic Myeloid Leukaemia (CML) and PML-RARa in AML (Clark
et al, 2001) (Osman et al, 1999)have promoted new immunotherapeutic approaches
to leukaemia outside the setting of HSC transplantation. Dendritic cells (DC), as
professional antigen presenting cells (APC) able to elicit a cytotoxic response from
naive T-cells, have been at the centre of interest in developing a cellular vaccine for
AML.
1.2 Dendritic cell development and T-cell interaction in vivo
In vivo DCs form a heterogeneous group of subsets, continually produced from
myeloid and lymphoid haematopoietic precursors in the bone marrow, and widely
distributed as immature DCs into lymphoid and non-lymphoid tissues (Banchereau &
Steinman, 1998;Cella et al, 1997;Sousa et al, 1999;Moser & Murphy, 2000).
Immature DCs, including epidermal Langerhans cells, splenic marginal zone DCs
and interstitial DCs in non-lymphoid tissues, continually sample self-antigen to
maintain T-cell tolerance. However, immature DC's can also take up foreign
antigens. When triggered by pathogens, the pattern-recognition receptors expressed
by immature DC's cause them to mature in the presence of inflammatory "danger
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signals", such as Tumour Necrosis Factor (TNF), Interferon (IFN) a or bacterial
lipopolysaccharide (LPS) (Matzinger, 1998). Mature DCs are able to initiate primary
T-cell immune responses by activating nai've T-cells (Steinman, 1991;Banchereau &
Steinman, 1998), because they express high amounts of cell surface major
histocompatibility complexes (MHC) and co-stimulatory molecules (Banchereau &
Steinman, 1998;Cella et al, 1997;Sousa et al, 1999;Moser & Murphy, 2000), as well
as adhesion molecules and chemokine receptors such as CCR-7 and 8(Qu et al,
2004), enabling them to migrate to the secondary lymphoid tissues where they
present antigen to T-cells. The APC are thought to take up exogenous antigens,
including apoptotic tumour cells and present these to lymphocytes via a classical
MHC class II pathway, but "cross-presentation" of these antigens through MHC
class I molecules has also been demonstrated. Such cross-presentation has been
associated with the stimulation of CD4+ T-helper cells and CD8+ cytotoxic T-cells
(CTL), together providing the best conditions for cell-mediated cytotoxicity. T-cell
activation requires two different signals (Fig. 1.1). The first signal is provided by the
interaction of the MHC molecule-peptide with the corresponding T-cell receptor.
The second signal consists of the binding of co-stimulatory molecules on the APC
with their respective ligands on the T-cell. CD40 and B7 on the APC interact with
CD40 ligand and CD28 on the T-cell to mediate T-cell activation.
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Figure 1.1: Mechanisms of T-cell activation
A : Recognition of MHC/peptide complexes on the surface of an antigen
presenting cell by a T-cell receptor in the presence of a second co-
stimulatory signal mediated by B7 leads to T-cell activation and proliferation
B : Absence of B7 expression by leukaemia cells results in absent co-
stimulatory signal following T-cell receptor binding of MHC/peptide complex
with consequent T-cell anergy
The remarkable functional heterogeneity of DC subsets rests on their maturational
state, the microenvironment to which the DCs are exposed in various tissues in vivo
and a variety of other factors, such as the strength of the T-cell receptor-MHC class
II interaction and antigen density, which are also known to influence the ability of
DC to induce a) an Interleukin (IL)-12 driven type 1 T-helper cell (Thl) response,
promoting T-cellular cytotoxicity, b) a Th2 T-cell response, polarizing towards
antibody-mediated immunity, or c) to induce anergy of a T-cell following a tolerizing
interaction with a DC. Any immuno-therapeutic approach utilising DC will have to
consider whether DC function, in their interaction with other components of the
immune system (T-cells, NK-cells), may be altered or defective in patients with
AML, favouring tumour escape from immunological surveillance as previously
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demonstrated in animal models of malignancy and in cancer patients (Chaux et al,
1996;Chaux et al, 1997;Nestle et al, 1997;Thurnher et al, 1996).
1.3 Dendritic cells in leukaemia: part of the problem or part of
the solution?
The role of DCs in cancer has been described in numerous studies in various types of
tumours (Ambe et al, 1989;Fox et al, 1989;Schroder et al, 1988), postulating an
association of good clinical prognosis with presence of DCs in tumour tissues.
However, functional defects, mainly due to lack of expression of co-stimulatory
molecules in tumour associated DCs, have also been identified in more recent animal
model studies and also in cancer patients (Chaux et al, 1996;Chaux et al, 1997;Nestle
et al, 1997;Thurnher et al, 1996). In leukaemia, similar to other malignancies,
release of immunosuppressive cytokines, such as Interleukin (IL)-IO (Gastl et al,
1993;Maeda & Shiraishi, 1996), transforming growth factor beta (TGF-P) (Nagy &
Vanky, 1998;Espinoza-Delgado et al, 1994;Luscher et al, 1994), vascular endothelial
growth factor (VEGF), other known soluble factors, such as soluble IL-2 receptor
(Nakase et al, 1992), soluble tumour necrosis factor receptor (Vinante et al, 1998)
and soluble Fas ligand (Tanaka et al, 1996), as well as other, yet unspecified factors
(Buggins et al, 1999)have been implicated in creating an immunosuppressive
microenvironment that may not favour the induction of an effective immune
response. Recent investigations (Ma et al, 2004) (Mohty et al, 2001)have shone
more light on the ontogeny of both myeloid and plasmacytoid DC in the peripheral
blood of patients with AML and Myelodysplastic Syndrome (MDS). While in MDS
both DC subsets are present, albeit in lower numbers compared with those in normal
blood, both populations are demonstrably derived from the malignant clone (Ma et
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al, 2004). Likewise, in the peripheral blood ofAML patients both subsets have been
identified (Mohty et al, 2001), however, the identification of subsets by
immunophenotypic characteristics may be complicated by the fact that DCs and
leukaemic blasts share many markers, hence leukaemic blasts can be misidentified as
DC on the basis of abberant expression of DC associated markers on the surface of
leukaemic blasts that are not DC.
In vitro, cytokine driven differentiation of AML blasts to a dendritic-like phenotype
(AML-DC) can be achieved in a proportion of patients (Robinson et al,
1998;Panoskaltsis et al, 2002;Harrison et al, 2001;Choudhury et al, 1999;Roddie et
al, 2002). As these AML-DCs arise from the leukaemic clone, they offer potential as
autologous cellular vaccines, expressing both leukaemic antigens and also DC-
characteristic, co-stimulatory molecules that are mostly lacking in native leukaemic
blasts. Co-culture experiments of AML-DC with autologous T-cells have induced
anti-leukaemic cytotoxicity (Charbonnier et al, 1999). However, as DC populations
originating from leukaemic blasts in vivo are part of the malignancy and may
potentially also produce "tolerogenic" signals, the question arises ifAML-DC in vivo
might be implicated in the disease process and, if so, would their use in therapy be
advisable? The fact that the malignant cells are DC precursors and therefore
components of the immune interaction one attempts to study complicates the
characterisation of immune responses to AML. Studies of anti-leukaemic T-cell
responses in leukaemic patients in remission (Panoskaltsis et al, 2002) (Molldrem et
al, 2000)and those with fulminant disease (Molldrem et al, 2003) (Elisseeva et al,
2002)have been undertaken. Cytotoxic T-lymphocytes (CTL) directed against
tumour-associated antigens, such as WT1 and proteinase 3 have been demonstrated
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at some point of the disease process. Such observations have led some investigators
to the suggestion that immune responses to tumour might be actively inhibited in
advancing disease (Staveley-O'Carroll et al, 1998;Takasugi et al, 1977), while others
have postulated that in patients with malignancy immune responses to tumour
associated antigens (TAA) are only initiated in disseminated, overwhelming disease
and are only detectable at low levels in a situation of low tumour burden (Mintz et al,
2003;Valmori et al, 2000). In either case, immune control of the tumour ultimately
would be ineffective, but the exact immunosuppressive mechanisms remain unclear
(Panoskaltsis, 2005).
1.4 Cellular vaccine design strategies in AML
Any successful cellular vaccine needs to overcome the reduced immunogenicity of
leukaemic cells. This requires the generation of vaccine cells in large numbers to
express leukaemia-specific antigens in the context of adaequate co-stimulation. Two
principal strategies have been pursued in DC based leukaemia vaccine generation.
1) Improving the antigen-presenting capacity of leukaemia cells themselves:
This can be achieved either by :
a) transfer of genes that encode the necessary co-stimulatory molecules into
leukaemic blasts (Rousseau et al, 2006);(Chan et al, 2005;Nakazaki et al,
1998;Stripecke et al, 2000;Dilloo et al, 1996;Hirst et al, 1997;Boyer et al,
1997;Mutis et al, 1998;Saudemont et al, 2002), or
b) cytokine-driven leukaemic blast maturation into dendritic-like leukaemic cells
(AML-DC) (Buhmann et al, 1999;Cardoso et al, 1997;Charbonnier et al,
1999;Choudhury et al, 1997;Choudhury et al, 1999;Eibl et al, 1997;Kohler et al,
2000;Mohty et al, 2002;Robinson et al, 1998).
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2) Utilising the superior T-cell stimulatory capacity of non-leukaemic DCs:
either
a) by adoptive immunotherapy, using ex vivo generated CTL specific for TAAs, or
b) through vaccination protocols with professional APCs expressing leukaemic
antigens (Fig. 1.2).
To deliver leukaemia-associated antigens, DCs can be generated ex-vivo from either
monocytes (Thurner et al, 1999) (Bender et al, 1996)or CD34+ haematopoietic
progenitor cells (Ferlazzo et al, 2000;Ye et al, 1996;Fujii et al, 1999). They can be
pulsed as immature DCs ex vivo with tumour antigens, matured with cytokines, and
then injected as cellular vaccines. Reported approaches for this purpose include the
following:
(a) Loading DC with leukaemic blast lysates (Lee et al, 2004;Schui et al, 2002)
(b) Loading DC with irradiated or apoptotic blasts (Spisek et al, 2002;Fujii et al,
1999)
(c) Loading DC with synthetic peptides from tumour-associated antigens, such as
WT1 in AML, PR1 in AML/CML (Mailander et al, 2004;Elisseeva et al, 2002;0ka
et al, 2004;Gao et al, 2000;Molldrem et al, 1996;Ohminami et al, 2000;Menssen et
al, 1995), or
(d) Loading DC with tumour-specific antigens derived from protein products of
abnormal fusion genes, such as BCR-ABL in CML, PML-RARa and DEK-CAN in
AML (Clark et al, 2001;Osman et al, 1999;Ohminami et al, 1999)
(e) Loading DC with tumour derived RNA or DNA (Zeis et al, 2003)
(f) Fusing DC with leukaemic blasts, generating AML-DC Hybridomas (Galea-Lauri
et al, 2002)
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1.5 Adoptive immunotherapy with ex-vivo generated CTL
This approach has been exploited in several clinical and pre-clinical studies. Mutis
et al (Mutis et al, 1999b) have built on the recognition of minor histocompatibility
antigen (mHags) mismatch as important factors in the development of GvHD and
GvL in allogeneic HSC transplantation. Some mHags show ubiquitous tissue
distribution, others, such as the mHags HA-1 and HA-2 are only expressed in
haematopoietic cells (de Bueger et al, 1992). These antigens are therefore attractive
TAAs for immunotherapy, as they should direct an allogeneic cytotoxic response
selectively against the patient's haematopoietic cells, whether neoplastic or not.
Donor-derived DCs from an HA-1 or HA-2 mismatched donor are pulsed with HA-1
or HA-2 peptides corresponding to the recipient's mHag type. These DCs are co-
cultured, ex vivo, with donor lymphocytes to generate CTL specific for these
peptides. Subsequently the patients undergo an allogeneic HSC transplantation from
their HLA-compatible, but HA-1 or HA-2 mismatched donor. After complete
engraftment of donor derived haematopoiesis the ex vivo generated mHag-specific
CTLs are infused into the patient to antileukaemic cytotoxic effect, without causing
GvHD. This approach is limited to a small number of patients that are undergoing an
allogeneic HLA-matched HSC transplantation from a donor with HA-1 or HA-2
disparity. More widely applicable strategies have used the characterisation of TAAs
demonstrated to induce CTL responses specific to tumour cells in haematological
malignancies. The transcription factor WT1, which is widely expressed on the
leukaemic cells from patients with AML and CML has been shown to be a potential
target for in vitro CTL generation. Using APCs pulsed with HLA-A2 restricted WT1
peptides, CTL were generated from peripheral blood mononuclear cells that showed
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exquisite specificity of action against CD34+ leukaemia cells, but spared normal
CD34+ progenitors (Gao et al, 2000). Some of the limiting factors to successful
translation of this type of ex-vivo CTL generation into clinical practice are the very
prolonged period of culture necessary to obtain clinically relevant numbers of CTL,
with all the attendant difficulties that this entails, and the limitations set by HLA
class-restricted DC presentation of tumour peptides that may not always be available
for every HLA type.
1.6 AML-DC as cellular vaccine
A strategy explored by several investigators over the last decade (Buhmann et al,
1999) (Cardoso et al, 1997;Charbonnier et al, 1999;Choudhury et al,
1997;Choudhury et al, 1999;Eibl et al, 1997;Kohler et al, 2000;Mohty et al,
2002;Robinson et al, 1998)is the differentiation and maturation of leukaemic blasts
into dendritic-like cells (AML-DC). It followed the emerging knowledge of DC
development from myeloid progenitors. A variety of different cytokine cocktails
including GM-CSF, IL-4, IL13, TNF-a, FLT3 ligand and immunomodulators, such
as soluble CD40 ligand have been proposed to induce dendritic-like differentiation
and maturation. The "essential cocktail", identified for generating DC from blood
monocytes, consisting of GM-CSF and IL4(Sallusto & Lanzavecchia, 1994), has
been complemented by CD40 ligand or TNF-a to induce differentiation in 18/19
primary AMF samples in a seminal study by Choudhury et al (Choudhury et al,
1999). The resulting AML-DC showed the characteristic morphology,
immunophenotypic properties and T-cell stimulatory properties of mature DC.
Importantly, co-culture of autologous T-lymphocytes with the AML-DC induced
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cytotoxic responses directed against the native leukaemic blasts, but not against
normal autologous cells. Several other studies have confirmed these findings in a
proportion of AML blasts investigated (Brouwer et al, 2000;Harrison et al, 2001).
There are to date no published clinical vaccination studies utilising AML-DC as
cellular vaccines in AML. We have therefore initiated a Phase I/II clinical
vaccination study using autologous dendritic-like leukaemic cells (AML-DC) in
adult patients with AML in remission, following multi-agent chemotherapy, which is
the subject of this thesis, in an attempt to evaluate the clinical feasibility of this
approach and to demonstrate anti-leukaemic immune responses following AML-DC
vaccination.
1.7 DC-based vaccination
Clinical phase I/II study protocols utilising tumour-antigen loaded DC have in
principle documented the feasibility of this approach and demonstrated variable
degrees of immunological and clinical in vivo responses in patients with melanoma,
prostate and ovarian cancer (Nestle et al, 1998;Brossart et al, 2000;Banchereau et al,
2001;Marchand et al, 1999;Murphy et al, 1996;Hernando et al, 2002). Partial
regressions of solid tumours have been demonstrated in a proportion of patients in
these studies, with occasional complete responses demonstrated. These early reports
are encouraging, but difficult to compare and reproduce, due to methodological
differences in all aspects of study design.
Few clinical vaccination trials in leukaemia are published. T-cellular cytotoxic
responses to TAA derived peptides have been studied in most depth. Molldrem et al
(Molldrem et al, 1996) have demonstrated that HLA-A2 restricted CTL, raised
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against PR1 peptide, a human leukaemia-associated antigen derived from
proteinase3, an aberrantly expressed protein in myeloid leukaemia cells,
preferentially killed leukaemic over normal haematopoietic precursors (79%
cytotoxicity against CML cells, 54% lysis of AML blasts). A later study (Molldrem
et al, 2000) investigated the correlation between the presence of PR1 specific T-cells,
detected by PR1/HLA-A2 tetrameric complexes in the peripheral blood of leukaemic
patients following treatment with Interferon alpha and allogeneic bone marrow
transplantation, giving first time evidence of the role of T-cell immunity in clearing
malignant leukaemic cells. A subsequent clinical vaccination study with PR1
peptide and adjuvant GM-CSF in 35 patients with AML, CML and MDS elicited
both immunologically demonstrable (60% of patients) and clinical responses in
patients with refractory and relapsed myeloid leukaemia (Qazilbash et al, 2004).
In AML there are to date no published clinical trials exploiting DC based vaccination
strategies as an adjuvant therapeutic approach for Minimal Residual Disease
following multi-agent intensive chemotherapy, where, in our opinion, the chances of
immunological control of disease recurrence appear most promising. The only
clinical DC vaccination study, undertaken by Lee et al (Lee et al, 2004) utilised
blast cell lysate-pulsed DC in two patients in relapse following autologous HSC
transplantation. In this setting, immunological responses to vaccination are difficult
to differentiate from those directed against advancing leukaemic tumour burden, but
evidence of delayed hypersensitivity and increased mixed lymphocytes responses
(MLR) were attributed to the subcutaneous vaccination protocol.
A larger number of pre-clinical studies have been conducted, exploiting various DC-
loading protocols.
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Schui et al (Schui et al, 2002) pulsed DC with tumour lysates and have induced
autologous anti-leukaemic cytotoxicity in co-cultured T-cells in 5 out of 25 patients
only, while in other patients an inhibitory effect was seen. Spisek et al (Spisek et al,
2002) demonstrated the ability of non-leukaemic DCs loaded with late apoptotic
leukaemic blasts to induce in vitro leukaemia-specific T-cellular cytotoxicity in 3
patients; direct comparison to the cytotoxicity induced by AML-DC was only
possible in one patient and found to be similar. An earlier study by Fuji et al showed
the induction of anti-leukaemic CTL's by CD34+ derived DC-clusters pulsed with
autologous, irradiated blasts (Fujii et al, 1999).
In AML and ALL, HLA-A2-binding peptides derived from the Wilms tumour gene-
encoded transcription factor WT-1 (Inoue et al, 1997) stimulate a specific anti-
leukaemic T-cell response (Ohminami et al, 2000;Gao et al, 2000;Scheibenbogen et
al, 2002). Similarly, DCs loaded with MUC1 protein, an epithelial mucin that is
overexpressed in AML and multiple myeloma, facilitate the generation of anti-
tumour T-cell responses in vitro.
In a subgroup of leukaemia patients, chromosomal translocations are demonstrable in
the leukaemic clone, resulting in gene rearrangements and giving rise to fusion gene
protein products, such as BCR-ABL in Chronic Myeloid Leukaemia (CML) and
PML-RARa in AML (Clark et al, 2001;Osman et al, 1999). These proteins are
potential targets of an immune response. They are attractive for immunotherapy,
because they represent true tumour-specific antigens. Furthermore, as some of these
fusion proteins are essential for the malignant transformation of the clone, tumour
escape through antigen loss in response to selective immunological pressure is
unlikely. However, in spite of these attractive features, the potentially immunogenic
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site of a fusion protein is only located in the aminoacid sequences immediately
flanking the fusion site. Cleaving by proteases is necessary to arrive at candidate
antigenic peptides. Those peptides will have to fit the binding motif of a given
patient's HLA molecules in order to elicit cytotoxic T-cell responses. This HLA
restriction makes it unlikely to find a universal antigenic peptide sequence derived
from a fusion protein that would be useful in the majority of patients presenting with
a given chromosomal translocation.
Fusion Hybrids of tumour cells and monocyte-derived DC have been investigated as
possible cellular vaccine constructs in a variety of malignancies (Gong et al,
2000;Vasir et al, 2005;Raje et al, 2004;Avigan et al, 2004). In principle, remission
monocytes can be matured into DCs and then fused to autologous tumour cells, using
either Polyethyleneglycol (PEG) as the fusing agent or electro-poration protocols.
The resulting constructs express the full repertoire of tumour antigens on their
surface in conjunction with DC-derived co-stimulatory molecules. There is no need
to establish the HLA type of the patient, in contrast to approaches using pulsing of
DC's with specific peptides or antigens, no prior identification of TAAs expressed by
the individual tumour cells is required, and the fusion technology using PEG is well
established and simple, making this approach more easily applicable. It also avoids
the technical difficulties and safety concerns that surround the use of viral vectors to
generate genetically modified cells for vaccination. The use of Fusion Hybrids of
remission Monocyte-derived DC with autologous AML blasts has so far not been
reported and pre-clinical experimental experience is limited to a single report (Galea-
Lauri et al, 2002), prompting their further exploration as potential cellular vaccine
constructs in this thesis.
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1.8 Monitoring responses to DC vaccination in AML
The use of objective criteria to describe clinical responses, as codified by the World
Health Organisation and in solid tumour response evaluation schemes (RECIST)
(Therasse et al, 2000) would advance the field of DC immunotherapy. Many early
studies are compromised by a lack of standardisation of clinical responses and no
demonstration of specific anti-neoplastic immune responses.
In a proportion of myeloid leukaemias recurrent chromosomal abnormalities
(translocations and inversions) can be detected. Those can be used to quantify the
residual tumour burden using highly sensitive, quantitative Reverse Transcriptase
(RT)-PCR assays. In cases without demonstrable cytogenetic defects, stably
expressed TAAs, such as WT-1 (Inoue et al, 1997), have been used to quantify MRD
from blood and bone marrow. These assays represent minimally invasive, sensitive
and validated tools, applicable to the monitoring of treatment responses post
chemotherapy and HSCT. They can be utilised to objectively quantify treatment
responses to DC-immunotherapy in a similar way.
Any future attempt to increase the effectiveness of vaccination will also depend on
the ability to measure the development of anti-leukaemic T-cell immune responses
with a high degree of sensitivity and specificity. In recent years, it has become
possible to visualise antigen-specific T-cells under flow cytometry by using soluble,
fluorescently labelled multimeric HLA-peptide complexes (Altman et al, 1996) that
bind stably, specifically and avidly to antigen-specific cells. We proposed to
combine tetramer assays for WT1-recognising T-cells with highly sensitive assays of
T-cellular IFN-y responses to autologous AML blasts (ELISPOT) together with RT-
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1st generation T cell assays: bulk assays
Proliferation
Fig.1.3(a): T-cell assays: 1st generation bulk assays
measuring either overall T-cell proliferation after exposure to target
(standard readout: [3H]thymidine uptake) or lysis of target cells after
sxposure to an effector population (standard readout: 51 Cr release from
target cells into the supernatant).
2nd generation T cell assays: "ex vivo" quantification
Fig.1.3(b): T-cell assays: 2nd generation: using single cell-based
analysis of T-cell properties. T-cell receptor analysis using major
histocompatibility multimers or assesment of cytokine production
capacity of T-cells after exposure to antigen (readouts: intracellular
cytokine accumulation in T-cells by flow cytometry assays, or secretion
of cytokine captured by antibodies bound to cell surface or plate
(ELISPOT assay). GraB= Granzyme B; ICC=intracellular cytokine;
TCR=T-cell receptor (modified from Keilholz etal, Clin.Cane.Res. 2006)
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PCR for WT-1 assays of tumour burden in order to monitor the impact of AML-DC
vaccination in the clinical study undertaken for this thesis.
Regulatory T-cells (Treg) have been investigated in many recent studies because of
their apparent immuno-modulatory role in infection, auto-immunity and inhibitory
effect on anti-cancer immune responses (Casares et al, 2003a;Mesel-Lemoine et al,
2005;Morse et al, 2002;Wolf et al, 2003a). Conversely, evidence has emerged that
effective anti-cancer immunity can be restored by suppression of Treg numbers
(Ghiringhelli et al, 2004;Morse et al, 2002). Correlating the number of Treg cells
before, during and following DC vaccination with the variation of measurable anti-
leukaemic cytotoxicity and MRD burden may provide insight into the role of these
cells in dampening anti-leukaemic immune responses.
1.9 Considerations for delivering a DC-based vaccine for AML
Many facets of DC-based vaccines in AML remain unknown, as the clinical
application of this approach is in its infancy. From experiences with earlier DC
vaccination studies in solid tumour malignancies it may be deducted that the state of
minimal residual disease (MRD), achieved following conventional chemotherapy or
HSCT, is a desirable setting for the trial of leukaemia cell vaccines. Patients with
MRD have a low tumour burden. DC-induced CTL responses are likely to be
overwhelmed by rapidly advancing leukaemia (Haining et al, 2005) and, importantly,
immunological control ofMRD has been demonstrated to be associated with superior
long-term survival and lower relapse rates originating from residual leukaemia in
allogeneic HSCT. Pre-clinical studies have emphasized the importance of
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vaccinating with fully mature DCs in order to avoid tolerogenic responses associated
with immature or semi-mature forms. Optimal dose, scheduling and route of
delivery remain controversial. DCs are frequently administered subcutanuously,
intradermally or by direct injection into lymphatics / draining lymph nodes. Recent
studies suggest that immature DCs migrate less than mature DC's. De Vries et al
(De Vries et al, 2003) demonstrated that in general, less than 5% of intradermally
administered mature DCs reach the draining lymph node. From this data it can be
speculated that increased migration would increase the efficacy of DC vaccines.
Attempts to increase migration include the concomitant use of inflammatory
cytokines to condition tissues (Martln-Fontecha et al, 2003). Matrix
metalloproteinases and Toll-like receptor (TLR) ligands might also enhance DC
migration (Ratzinger et al, 2002).
Any ex-vivo manipulation of human cells must be undertaken conforming to good
manufacturing practice (GMP) standards laid down in North America and the
European Union. Facilities complying with these standards are regulated in the US
by the Center for Biologies Evaluation and Research (CBER). In the UK the
Department of Elealth, through the Medicines and Elealthcare Products Regulatory
Authority, had established an inspectorate whose remit included cellular therapy.
Investigators have to ensure that clinical vaccination studies using cellular products
are compliant with standards that are already established in the commercial
pharmaceutical industry. This includes cytokines used in the process that must be of
clinical grade standard and cell culture media, which should only contain human
serum protein, or ideally be serum free. The use of fetal calf serum (FCS) is no
longer deemed appropriate.
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For any vaccination approach that uses leukaemia derived DCs, prevention of re-
engraftment of viable, potentially proliferating cells is of importance. We
established that 25 Gy of y-irradiation from a Caesium 137 source, routinely used for
irradiation of blood products, completely abolished the proliferative potential of
AML blasts in tissue culture and irradiated all AML-DC vaccine with this dose prior
to inoculation (Appendix VIII).
1.10 Objectives and scope of the clinical and pre-clinical
studies undertaken for this thesis
The work outlined in this thesis encompassed a multi-centre clinical stage I/II study
of vaccination with Dendritic-like Leukaemia Cells (DLLC) generated from primary
acute myeloid leukaemia blasts as immuno-therapy for Acute Myeloid Leukaemia.
The main objectives of this clinical trial were to establish the feasibility, safety and
tolerability of this approach. Clinical endpoints included the assessment of cellular
immune responses, impact of the vaccination on Minimal Residual Disease and
evaluation of remission duration, leukaemia free survival and overall survival.
In an attempt to develop the next generation of cellular AML vaccines, a pre-clinical
assessment of alternative DC-based constructs was undertaken in parallel to the
clinical vaccination trial. The approaches explored include the addition of the
differentiation agents Calcium Ionophore and Bryostatin-1 in an attempt to overcome
blast resistance to cytokine induced DLLC maturation. The ability of Tumour Cell /
Dendritic Cell Fusion Hybrids to generate in vitro anti-leukaemic T-cell responses
following co-culture with autologous remission lymphocytes was investigated in six
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AML patients. Comparison was made to anti-leukaemic responses induced by
mature dendritic cells (mDC) loaded with autologous, irradiated myeloid blast
tumour bodies in vitro.
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Chapter 2: Materials and Methods
2.1 Study Protocol: A Clinical Phase l/ll Study of Vaccination
with Dendritic-like Leukaemia Cells Generated From Primary




• To establish the feasibility of generating clinically-relevant numbers of
DLLC from primary AML blasts ex vivo and the safety/tolerability of
subcutaneous injection
2.1.1.2 Secondary Clinical Endpoints
• To assess the immune function in AML
• To assess cellular immune responses to autologous leukaemia prior to and
following DLLC vaccination
• To gain evidence of reduction in minimal residual disease (MRD) level by
real time quantitative RT-PCR in patients using suitable molecular markers
• To assess for inversion in remission durations for relapsed patients
• To ascertain the duration of leukaemia free survival
• To ascertain the duration of overall survival
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2.1.2 BACKGROUND
2.1.2.1 Generation of Dendritic-Like Leukaemia Cells from Patients with
AML
Peripheral blood or bone marrow samples were taken from patients with newly
presenting or relapsed AML. Mononuclear cells were prepared over Ficoll-Hypaque,
washed in RPMI medium, resuspended in RPMI with 5% AB serum, 20ng/ml IL-4
and lOOng/ml GM-CSF and transferred to plastic tissue culture flasks. After 4 days
culture medium and cytokines were replaced with fresh RPMI supplemented with
GM-CSF lOOng/ml and TNFa 25ng/ml and cells cultured for a further 4-7 days.
Using this regimen, based on our own experience and on data from previously
published studies, between 50-70% of AML cases would be expected to show
evidence of dendritic cell-like differentiation based on morphology, expression of
costimulatory molecules CD40, B7.1, B7.2, and the expression of the dendritic cell-
associated marker CD83 (Appendix V). The remaining AML cases that fail to show
differentiation, in our pre-clinical experience, often had associated poor risk
karyotypic features.
2.1.2.2 Pre-clinical Functional Analysis ofDLLC
The immunostimulatory properties of DLLC have been tested in pre-clinical studies
preceeding the clinical trial. Results of these MLLR and CTL assays are attached in
Appendix VI.
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2.1.3 PATIENT SELECTION AND ENROLMENT
We proposed to recruit adult patients to a phase I/II clinical trial of vaccination with
autologous dendritic-like leukaemic cells:
2.1.3.1 Inclusion Criteria
• Adult patients with newly presenting AML or with relapsed disease
• The predicted survival should exceed 3 months
• Patients must be fit enough to undergo leucapheresis or to have lOOmL of
blood removed by iso-volaemic venesection or a 1 OmL bone marrow aspirate
• Patients must give written informed consent
2.1.3.2 Exclusion Criteria (Initial Enrolment)
• Patients with acute promyelocyte leukaemia and a 15-17 translocation
• Patients, whose predicted survival is less than 3 months
• Patients unfit for leucapheresis or to have lOOmL of blood removed by
isovolaemic venesection or a 1 OmL bone marrow aspirate
• Patients who decline informed consent
• Patients who fail virological screening
2.1.3.3 Exclusion Criteria (Vaccination Programme)
• Patients who, following chemotherapy, fail to go into complete remission (as
defined by a cellular marrow showing <5% blasts)
• Patients who fail to achieve good haematological recovery (as defined by
haemoglobin >120g/L, neutrophils >lxl09/L and platelets >l00xl09/L)
• Patients whose AML blasts do not mature into DLLC on pre-screen
29
• Those who decline consent
Patients who enter complete remission but whose AML blasts do not mature into
DLLC on pre-screen were offered continued monitoring of immune function and
minimal residual disease.
2.1.4 DESIGN OF CLINICAL TRIAL
2.1.4.1 Harvesting of Leukaemia Cells
At trial entry patients underwent a single leucapheresis, or lOOmL isovolaemic
venesection or lOmL bone marrow aspirate depending on the peripheral blood blast
count as shown in Table 2.1.
Table 2.1: Summary of leukaemia harvest methods depending on peripheral
blast count
Peripheral blood blast count (xl09/l) Method of leukaemic cell harvest
>10 lOOmL peripheral blood
>1 <10 Leucapheresis
<1 1 OmL bone marrow aspirate
• Patients with peripheral blast counts >10 x 109/L underwent isovolaemic
venesection of lOOmL of peripheral blood - volume replacement was with
normal saline.
• Patients with peripheral blast counts of >1 but <10 x 109/L underwent a
leucapheresis procedure performed. Patients were evaluated prior to the
30
procedure by a blood transfusion physician to ensure they were fit enough to
undergo the procedure.
• Patients with low peripheral blast counts (<1 x 109/L) underwent a lOmL
marrow aspiration. This was performed under local anaesthesia, and sedation
with Midazolam was offered.
All patients underwent routine virological testing, in line with the UK requirements
for the handling of autologous donations. In addition, 50mL of peripheral blood
were used for assessment of baseline immune function including peripheral blood
count, flow cytometry and proliferative responses to mitogens and recall antigens.
2.1.4.2 Pre-Screen and Cryopreservation of the Leukaemia Cell Harvest
The leukaemia cell harvest was transferred to the Scottish National Blood
Transfusion Service Tissue Bank at Liberton, Edinburh, where it could be handled in
Good Manufacturing Practice (GMP) grade sterile clean room facilities. The
majority of the harvested cells were cryo-preserved using standard techniques. A
portion of the harvest was used for a pre-screen. The purpose of the pre-screen was
to establish whether it was possible to induce differentiation of the patient's
leukaemia cells into DLLC. Only patients whose leukaemic cells pass the pre-screen
were deemed eligible for the vaccination programme.
2.1.4.3 Induction and Documentation ofRemission
Patients received intensive chemotherapy. The number of courses given and
regimens used were at the discretion of the treating consultant. Patients achieving
complete remission (a cellular marrow showing <5% blasts) then underwent a
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marrow aspirate following haematological recovery (Hb >120g/L, neutrophils
>1x109/L and platelets >100xl09/L) from the last cycle of chemotherapy and those
confirmed to be in continuing complete remission were eligible to receive the
vaccination therapy (Figure 2.1). DLLC vaccination was performed at least 2 weeks
from the time of haematological recovery.
Fig.2.1: Clinical trial outline: The top half of the diagram outlines the steps
required to fulfil the laboratory requirements for DLLC vaccination whilst the bottom
half represents the clinical requirements. CR=complete remission NR=no
remission.
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2.1.4.4 Generation of Clinical Grade DLLC
Generation of DLLC for clinical use was performed once the patient had been
confirmed to be in remission, based on bone marrow examination. Initiation of
culture was timed so that DLLC for vaccination were available 2 weeks following
the marrow examination. Cell manipulation, culture and storage was undertaken
within the SNBTS Tissue Bank facility at Ellen's Glen Road, Edinburgh, according
to a standard operating procedure (Appendix VII).
For patients in Edinburgh, cultured DLLC were washed and re-suspended in a small
volume (lmL) of RPMI with 5% AB serum. The DLLC were then subjected to
25Gy y-irradiation and transferred to the administering hospital in a capped syringe
enclosed in a protective sterile container. DLLC for subsequent doses were cryo-
preserved at the Tissue Bank, and thawed, washed, re-suspended and irradiated prior
to transfer to the administering hospital as above.
For patients in other centres, all doses of DLLC were transferred post thawing,
washing, re-suspension and irradiation, undertaken at the Scottish National Blood
Transfusion Service tissue bank facility.
Irradiation was undertaken at 25-50Gy from an MCA accredited caesium 137 source
in accordance with national guidelines and local Standard Operating Procedures.
This irradiation dose has been validated to eliminate the proliferative potential of any
residual AML blasts in the inoculum (Appendix VIII).
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2.1.4.5 Re-administration and Dosage/Scheduling
DLLC were administered in lmL of carrier medium by a subcutaneous injection
under the direct supervision of an experienced physician in an appropriate clinical
facility where resuscitation and supportive care facilities were available. An intra¬
dermal test dose of lxl06 irradiated DLLC was administered prior to the vaccination
protocol and after completion of the DLLC vaccination schedule. Patients were
maintained under close observation in the ward for 4 hours following vaccination.
Patients received 4 escalating doses of DLLC at weekly intervals of 0.125xl06/kg,
0.25xl06/kg, 0.5x106/kg and lxl06/kg.
Expected Toxicity
Our previous experience from using autologous dendritic cells pulsed with MUC-1
peptide in patients with breast cancer has failed to show any significant systemic
toxicity (Appendix IX). Inflammation and ulceration at the local site of injection has
been described in other clinical studies of dendritic cell vaccination. In this study the
sites of inoculation were rotated.
2.1.4.6 TREA TMENT MONITORING
a) Data Collection
Case Report Forms were provided for each patient. Each page was to be completed
in blue or black ink. Any errors were crossed out with a single line and the correct
value entered alongside. The change was to be be dated and initialled by the person
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making the correction with the original entry still being legible. Snopake, Liquid
Paper etc. was not be used.
b) Patient Details
• Name, date of birth
• Height and weight
• French-American-British Classification (FAB) AML subtype
• Newly presenting or relapsed disease
• Cytogenetic and Fluorescent in situ Hybridisation (FISH) analysis
• Chemotherapy given to achieve remission
• Concomitant disease
• Drugs taken in the 7 days prior to DLLC infusion
• Karnofsky score
c) Pre-Treatment Assessment (at presentation)
• Clinical evaluation
• Full Blood Count (FBC), renal function, biochemistry and liver function tests
• Flow-cytometric evaluation of T-and B lymphocytes, CD4:CD8 ratios.
• Immunoglobulin electrophoresis, complement, C-reactive protein (CRP)
• Bone marrow examination
• Human Leucocyte Antigen (HLA) type




• FBC, renal function, biochemistry and liver function tests
• Bone marrow examination including evidence ofMRD (Appendix XI)
• Immune function monitoring (Appendix X)
• Skin test for delayed type hypersensitivity (DTH) response to autologous
irradiated leukaemia cells
e) Immediate Post-Vaccination Assessment
Monitoring of vital signs (pulse, BP, temperature) !4 hourly for first hour, hourly for
the next 4 hours. Patients were monitored for adverse events.
An enquiry was made about post treatment morbidity
Clinical and laboratory parameters as outlined in the Trial Schedule (Table 2.2) were
evaluated at 14, 28, 42 and 84 days following the first DLLC vaccination. Patients
were monitored for adverse events.
A patient diary was kept
f) Monitoring of disease activity
Disease activity was monitored on a weekly basis by FBC measurement and
examination of a blood film. Bone Marrow examination, including examination for
evidence of MRD, was to be performed at 3 monthly intervals or if there was a
suspicion of relapse based on FBC findings.
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2.1.4.7 STATISTICAL DESIGN
Descriptive statistical analysis were performed where appropriate
2.1.4.8 TRIAL TERMINATIONS
The study was to be terminated if
• Recruitment was too slow to allow accrual of an adequate number of patients in
the anticipated length of time,
• Evidence was gained that patients were being exposed to an unacceptable risk
• For any reason it proved not possible to continue to produce the trial material.
2.1.4.9 PATIENT WITHDRAWAL
Patients were able to withdraw from the study at any time without giving a reason.
Patients experiencing any kind of adverse reaction were able to be withdrawn by the
investigator at his/her discretion.
2.1.4.10 INFORMED CONSENT
Fully informed written consent was obtained from the patients with the option that
they may refuse to take part or withdraw from the study at any time without giving a
reason and without affecting their treatment in any way. Copies of the Information
for Patients and Patient Consent Form are attached as Appendices I & II. Patient
confidentiality was strictly maintained. Patients' names appear only on internal
documentation and in any external report or publication relating to the study patient
anonymity was ensured. Data relating to the study was stored in compliance with
Good Clinical Practice and the Data Protection Act 1998.
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With the patient's consent their general practitioner was informed of their
participation in the study. A letter for this purpose is attached as Appendix IV.
2.1.4.11 ETHICAL CONSIDERATIONS
The protocol has received approval by the Multi-Centre Research Ethics Committee
and the Local Research Ethics Committee prior to entry of any patients into the study
The trial was performed in accordance with the requirements of the ICH Tripartite
Guideline for Good Clinical Practice, which is consistent with the principles laid
down in the Declaration of Helsinki as adopted by the 18th World Medical
Assembly, Helsinki, Finland, 1964 and amended by The 29th World Medical
Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice,
Italy, October 1983, the 41st World Medical Assembly, Hong Kong, September
1989, the 48th World Medical Assembly, Republic of South Africa, October 1996



































































































































































2.2 Laboratory Materials and Methods
2.2.1 Cells and culture conditions
2.2.1.1 Harvesting ofprimary leukaemic blasts
Leukaemic blasts were harvested as per study protocol either from peripheral blood,
bone marrow or a leukapheresis procedure using a COBE spectra apheresis machine
(Gambro BCT, Lakewood, CO, USA) was performed. Diagnosis was established
both by cytological criteria based on the FAB classification and by
immunophenotypic analysis following staining of leukaemia cells with a panel of
mAb. This acute leukaemia diagnostic panel comprised of mAb directed against
CD13, CD14, CD15, CD33, CD34, and HLA class II molecules. Karyotypes were
defined according to criteria of the International System for Human Cytogenetic
Nomenclature. Samples of peripheral blood and bone marrow were taken into 50 ml
polypropylene tubes containing 100 iu/ml preservative-free heparin (Leo,
Risborough, UK). Leukapheresis harvests were sent for further processing in the
original apheresis bag. Cell manipulation, culture and storage was undertaken within
the SNBTS Tissue Bank facility at Ellen's Glen Road, Edinburgh, according to a
standard operating procedure in Good Manufacturing Practice (GMP) grade sterile
clean room facilities. (Appendix VII). An aliquot of the leukaemic blast sample was
transferred to the John Hughes Bennett Laboratory, Edinburgh to pre-screen the
differentiation potential of the blasts into DLLC under identical conditions to those at
the Tissue Bank facility. Blast samples were diluted at 1:1 ratio with RPMI 1640
culture medium (Sigma-Aldrich, Gillingham, UK). The blast suspension was layered
at volume ratio 3:1 in 50 ml polypropylene conical tubes onto Ficoll (Histopaque
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1077, Sigma Diagnostics, St.Louis, MO) for density-gradient centrifugation. Cells
were centriguged for 25 minutes at 400g and the mononuclear cell layer aspirated
from the Ficoll / Serum interface using sterile pipettes. The mononuclear cell layer
containing enriched leukaemic blasts was transferred to 15 ml conical tubes and re-
suspended with 10 ml RPMI 1640 culture medium and centrifuged at 400 g for 5
minutes. After decanting of the supernatent the cell pellet was re-suspended by
flicking of the tube and subsequently re-suspended to 15 ml medium for a second
centrifugation at 400 g for 5 minutes. Finally, blast samples were re-suspended to 10
ml using RPMI 1640.
2.2.1.2 Counting of viable cell numbers
10pl of cell suspension to be counted was mixed with 90pl of 0.4% trypan blue. 10pl
of the subsequent dilution was placed in a Neubauer haemocytometer. The numbers
of cells excluding trypan blue in 16 squares were counted. Viable cell count/ml =
number of cells in 16 squares x 104/ml xlO.
2.2.1.3 Cryopreservation
X • •
Cells were aliquoted not exceeding 1x10 / 500pl culture medium in cryovials
(cryotube™, Nunc, Denmark). An equal volume of freezing medium consisting of
90% fetal calf serum (FCS) and 10% tissue culture grade DMSO (Sigma-Aldrich,
Gillingham, UK) was added drop-wise and samples placed in sequence into a -20°C
freezer for 2 hours, followed by -70°C freezing overnight and finally transfer to a
-140°C freezer for storage.
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2.2.1.4 Thawing of cryopreserved cells
Cryopreserved cells were thawed rapidly at 37°C in a water bath. The cell suspension
was diluted by initial drop-wise addition of RPMI supplemented with 5% heat-
inactivated human AB serum and then by accelerating suspension up to 20 mis
followed by centrifugation at 400g for 5 minutes. The resulting supernatant was then
discarded and the pellet was re-suspended in medium supplemented by 5% human
AB serum for cell culture.
2.2.1.5 Cell culture medium and culture conditions
All cell culture was performed using Complete Medium (CM), RPMI 1640 (Sigma-
Aldrich, UK) supplemented with 5% heat inactivated human AB serum, 100 U/ml
Penicillin/Streptomycin (Sigma-Aldrich, UK) and 2mM/l L-glutamine (Sigma-
Aldrich, UK), and the medium was supplemented with cytokines and maturational
agents as directed by the work undertaken. Plastic-ware used for tissue culture (25-
and 75cm2 culture flasks and 6-well plates) was resourced from Corning, NY, USA.
All cultures were incubated at 37°C in a humidified incubator (Heraeus) containing
5% C02.
2.2.2 Generation of Dendritic-Cell vaccine constructs
2.2.2.1 Generation of Dendritic-Like Leukaemic Cells (DLLC) from AML
blasts
Complete medium as described above was used. Cell density was adjusted to lx
106/ml and GMCSF lOOng/ml (Sandoz, Surrey, UK) and IL-4 20ng/ml (R+D
Systems, Abingdon, UK) were added. After 3 days of culture at 37°C / 5% C02
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fresh GMCSF (100 ng/ml) and Tumour Necrosis Factor-a (TNF-a) 25ng/ml
(Peprotech, Rocky Hill, NJ, USA) was added. At day 6 of culture further
maturational agents Polyriboinosinic polyribocytidylic acid (Poly I: C) at 12.5 mcg/1
(Sigma-Aldrich, UK) and Interferon-gamma at 30ng/ml (Boehringer, Ingelheim,
Germany) were added and cells were harvested at day 7 of culture for immuno-
phenotypic characterisation by flow-cytometry and microscopic analysis of cytospin
preparations.
In addition to the outlined standard cytokine combination, various concentrations of
IL4, GMCSF with or without the addition of the Bryostatin-1, 10-20 ng/ml, as well
as blast culture in medium supplemented with calcium ionophore A23187 100 ng/ml
(Sigma-Aldrich) were explored in an attempt to overcome differentiation resistance
ofAML blasts to a dendritic-like phenotype.
2.2.2.2 Determination of successful DLLC differentiation of leukaemic
blasts
Confirmation of successful DLLC differentiation was determined by flow-cytometric
analysis using a FACSCalibur flow-cytometer (Becton Dickinson, San Jose, CA,
USA) following staining of the cells with the following monoclonal antibodies:
CD40, CD80, CD86, CD83, CD1 lc (all Caltag, Burlingame, CA, USA). DLLC
differentiation was deemed to have occurred, ifmore than 20% of cells expressed
two or more of the above markers. This phenotype was based on previous studies
that demonstrated that this correlated with the acquisition of functional dendritic cell
characterisitics, such as increased allo-stimulatory capacity and production of IL-
12(Roddie et al, 2002). The acquisition of a characteristic Dendritic Cell
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morphological phenotype was confirmed by light microscopy of cytospin
preparations ofAML blasts before and after attempted cytokine maturation. These
assessments were performed each time in pilot screening cell cultures and also in
subsequent bulk cultures for vaccine generation.
2.2.2.3 Generation of mature DCs from Peripheral Blood Monocytes of
patients in complete morphological remission or from healthy donors.
Mature DCs (mDC) were generated from the adherent fraction of PBMCs collected
after the resolution of cytopenias following combination intravenous chemotherapy
or from healthy donors. PBMCs were suspended at 107/ml in Complete Medium
(CM), RPMI 1640 (Sigma-Aldrich, UK) supplemented with 10% FCS, 100 U/ml
Penicillin/Streptomycin (Sigma-Aldrich, UK) and 2mM/l L-glutamine (Sigma-
Aldrich,UK), and incubated for 2 hours at 37°C / 5% CO2 in 75cm2 culture flasks
(Corning, NY,USA). Non-adherent lymphocytes were subsequently removed and
cryo-preserved. Adherent monocytes were re-suspended with CM in the presence of
granulocyte-macrophage colony stimulating factor (GMCSF; Sandoz, Surrey, UK) at
lOOng/ml and IL-4 (R+D Systems, Abingdon, UK ) at 15ng/ml for 5 days. DCs were
then matured for further 2 days by the addition of tumour necrosis factor-alpha
(TNF-a; Peprotech, Rocky Hill, NJ) at 25ng/ml, Poly I:C (Sigma-Aldrich, UK) at
12.5 mcg/1 and Interferon-gamma (IFN-y; Boehringer, Ingelheim, Germany) at
30ng/ml.
44
2.2.2.4 Generation of AML-mDC Fusion Hybrids
Thawed AML blasts and fresh mDC were mixed at a ratio of 1:1, not exceeding 5 x
106 each in 37°C CM and centrifuged for 5 min at 400g to pellet. After removal of
all supernatant, cells were fused by drop-wise addition of 500pl of 50% Polyethylene
Glycol (PEG)/10% DMSO (Sigma) over 1 min in a 37°C water-bath . The reaction
was stopped after a further minute by adding 1 ml of CM and further dilution to 15 ml
with 37°C heated CM prior to use as stimulators in autologous cytotoxicity assays
and allogeneic mixed lymphocyte leukaemia reactions (MLLR).
2.2.3 Morphological and flow-cytrometric assessment of cells
2.2.3.1 Cytospin preparations
Cytospin preparations for photography purposes were prepared as follows. Cells
were resuspended in PBS to give a cell density of l06/ml. Cytospin cups were
assembled with Shandon glass slides (Cytoslide™, Shandon) and filter cards. 200pl
of the cell suspension was then transferred to the cytospin cups placed within a
cytospin centrifuge (Shandon, Southern). These were then centrifuged at 200rpm for
5 minutes. The slides were then removed and allowed to air dry for 10 minutes. The
slides were then stained with May-Grunwald-Giemsa stain (BDH, Poole, UK) using
an automatic slide stainer (Varistain 24-2, Shandon). Digital photographs of
cytospin preparations of native AML blasts at diagnosis prior to cell culture and post
attempted cytokine differentiation into DLLC were taken using a Leica Microscope
(Leitz, Wetzlar, Germany) and Zeiss Axiovision Digital Image Archive System
(Jena, Germany).
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2.2.3.2 Assessment of AML-mDC fusion efficiency
A series of experiments was conducted to establish the efficiency of PEG induced
AML-DC hybrid formation. Prior to fusion the AML blasts were labelled with the
red fluorescent linker dye PKH 26 (Sigma) according to manufacturer's instructions.
Cells were pelleted by centrifugation and all supernatant removed. 0.5ml of
manufacturer's diluent and 0.5ml of 0.004 mMol PKH26 was added and cells left to
stain for 3 minutes. The reaction was then stopped with 1ml FCS and cells were left
for a further lmin incubation prior to re-suspension with 10 mis of PBS and
centrifugation at 1200rpm for 5 minutes. Cells were then re-suspended and
transferred to a fresh centrifugation tube and washed and pelleted by centrifugation
three times, as outlined above. Final re-suspension was in 1ml PBS.
DCs were labelled using the green Cell Tracker CMFDA. Cells were pelleted by
centrifugation and all supernatant removed from the pellet. 1ml of lmicromolar
CMFDA was added in a 37°C water-bath and left to stain for 15 minutes. The
stained cells were then re-suspended with PBS up to 10 mis and centrifuged at 12000
rpm for 5 minutes. The supernatant was again discarded and further fresh 10 ml PBS
was added, followed by a post-stain incubation period of 30 minutes in a 37°C water-
bath. After a further 5-minute centrifugation the pelleted cells were finally re-
suspended in 1 ml PBS.
Un-fused and fused cells were analysed by flow-cytometry. Cells presenting both
membrane dyes after fusion, therefore fluorescing in both the FL1 and FL2 channels,
were scored as fusion hybrids. In addition, fluorescent microscopy using motorised
micro-focussing through the generated heterokaryons was undertaken to visualise
double fluorescent membrane of AML-DC Fusion Hybrids. Separate images of
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cytospin preparations were created using FITC, Texas Red and DAPI excitation
filters in a Zeiss Axioplan fluorescence microscope with motorised focus and images
were subsequently combined. Chroma filter sets, Vector shield mountant and a
Princeton Instruments Micromax digital camera were used.
2.2.3.3 Immunophenotypic characterisation ofmyeloid cells
Myeloid cells underwent immunophenotypic analysis using a panel of mAb directed
against co-stimulatory molecules, HLA molecules and dendritic cell-associated
markers, prior to and following attempted dendritic cell differentiation (Table 2.3).
Table 2.3: Panel of immuno-phenotypic markers used to characterize
leukaemia cells and DLLC
CD marker or
name
Brief description of function








Expressed on Monocytes and Macrophages- binds bacterial lipopolysacharide
Dendritic cell associated marker-highly restricted to mature DC populations. May have a role in
mediating adhesion to monocytes and a subset of activated and/or stressed T cells
Costimulatory molecule-when bound by CD40 ligand, present on T cells, induces the
upregulation of costimulatory and HLA molecules
Costimulatory molecule-binding to CD28 provides second signal forT cell activation
Costimulatory molecule-binding to CD28 provides second signal forT cell activation
MHC molecule involved in antigen presentation to CD8+ T lymphocytes
MHC molecule involved in antigen presentation to CD4+ T lymphocytes
Cells were harvested and pelleted by centrifugation at 400g for 5 minutes. A viable
cell count was performed and 2xl05 cells were taken and added to 12x75mm plastic
tubes for staining with murine monoclonal antibodies (mab) pairs, either fluorescein
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isothiocyanate (FITC) conjugated or phycoerythrin (PE)-conjugated: CD14/CDllc,
CD40/CD83, CD86/CD80, HLA Class I/HLA Class II (all Caltag, Burlingame, CA,
USA). 20pl was used of each antibody. Phosphate buffered saline (PBS) with 0.1%
sodium azide was added to give a final volume of lOOpl. Tubes were then incubated
for 20 minutes at 4°C. The cells were washed with 3 mis PBS and then pelleted by
centrifugation at 400g for 4 minutes. The supernatant was decanted and lOOpl
PBS/0.1% sodium azide was added. After 5 minutes incubation analysis was
performed on a FACSCalibur flow-cytometer (Becton Dickinson, San Jose, CA,
USA). Appropriate isotype controls for the monoclonal antibodies were used in all
immunophenotypic stains. Non-viable cells were identified by Propidium Iodide (PI)
uptake of cells in a separate sample tube and viable cells were defined with a forward
scatter (FS)/PI gate. Data analysis was performed using WinMDI software (Scripps,
La Jolla, CA, USA).
2.2.3.4 Characterisation of lymphoid responder cells
Cells were harvested and pelleted by centrifugation at 400g for 5 minutes. A viable
cell count was performed and 2xl05 cells were taken and added to 12x75mm plastic
tubes for staining with murine monoclonal antibodies (mab) pairs, either fluorescein
isothiocyanate (FITC) conjugated or phycoerythrin (PE)-conjugated (all Caltag,
Burlingame, CA, USA). The T-cells were characterised by estimating numbers and
proportions of CD3 positive cells, CD4:CD8 ratio, HLA Class I and II expression,
regulatory T-cell profile (CD4/CD25 expression) and activation status
(CD25/CD45RO expression). B-cell numbers and proportions were determined by
their expression of CD 19. Flow-cytometry protocols and data analysis were
performed according to methods outlined above.
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2.2.4 Assessment of immuno-stimulatory properties of
vaccine constructs
2.2.4.1 Stimulation of leukaemia-specific lymphocytes by co-culture
with autologous DLLC, AML, Fusion Hybrids ofAML with mature DC, or
mature DC co-cultured with irradiated AML blasts
The non-adherent fraction of fresh or thawed remission blood samples provided the
source of autologous responder cells. Unmodified AML blasts, DLLC, AML-mature
DC (mDC) Fusion Hybrids and mDC mixed 1:1 with irradiated (26Gy) AML blasts
were used as autologous stimulators. PBMC cultured in the absence of stimulators
or primed by un-pulsed mDCs and AML-AML fusions served as negative controls,
as these are not expected to stimulate leukaemia directed cytotoxicity.
• 7
All stimulators received 26Gy of irradiation from a Csl37source. Co-culture of 10
responder cells with 106 irradiated stimulators was prepared in 12-well plates at a cell
density of 106/ml effectors. CM was supplemented with IL-2 5ng/ml and IL-7
5ng/ml (Peprotech, Rocky Hill, NJ). For subsequent Chromium51 cytotoxicity
assays, responder cells were re-stimulated at day 7 and day 14 using the same
stimulators that had been added at the beginning of co-culture. CM and cytokines
were half exchanged weekly. Effectors were harvested on day 21 for subsequent
Chromium5'cytotoxicity assays against native, autologous AML blasts.
2.2.4.2 Allogeneic Mixed Leukaemia-Lymphocyte Reactions (MLLR)
Responder T-cells for allogeneic MLLR were obtained from the non-adherent
lymphocytes of healthy, unrelated donors, whose PBMC had been separated by
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gradient density centrifugation followed by 2hrs plastic adherence. Adherent donor
monocytes were matured in a 7-day culture into mature DC (mDC) as described
above and subsequently fused to patient AML blasts to generate AML-DC fusion
hybrid stimulators. Un-fused AML blasts and mDC as well as AML co-cultured with
mDCs served as stimulator controls. AML-AML or mDC-mDC fusions and titrating
concentrations of polyethyleneglycol (PEG) were also assessed regarding their
ability to stimulate the proliferation of lymphocytes allogeneic to the AML blasts
used. Responder cells were plated at 1 x lOVwell in CM in U-bottomed 96 well
plates. Stimulators were added at graded Responder/ Stimulator ratios of 5:1, 10:1,
25:1 and 100:1. The proliferation of lymphocytes was determined by the uptake of
[3H]-thymidine (ICN Biochemicals, Basingstoke, UK), added for the final 18 hours
of a 5 day co-culture at 37°C / 5% C02. Results were expressed as mean counts per
minute ± standard deviation in triplicates.
2.2.4.3 Cr51-release cytotoxicity assays
Following re-stimulation co-culture with a variety of autologous stimulators the
resulting leukaemia directed in vitro cytotoxicity was measured in a 4 hr 3lCr-release
cytotoxicity assay in patients, where uptake of the isotope by their native AML blasts
was demonstrable. 1 x 106 AML blasts were incubated for 1 hr at 37°C / 5% CO2
with lOOpCi 5ICr (ICN Biochemicals, Basingstoke, UK), washed three times with
CM and 1 x 104 labelled targets were subsequently co-cultured with autologously
activated lymphocytes in 200pl CM in 96 well U-bottomed plates at Effector:Target
ratios of 50:1, 25:1, 12.5:1 and 6.25:1. After 4 hours 25pl of cell free supernatent
were collected and mixed with 150pl of scintillant (Ecolite+, ICN Biochemicals,
Basingstoke,UK). Scintillation was analysed using a liquid scintillation and
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luminescence counter (1450 microbeta trilux, Wallac, Finland). Specific lysis was
calculated using the following formula: [(cpm experimental release — cpm
spontaneous release) / (cpm maximal release - cpm spontaneous release)] x 100.
Spontaneous 51Cr release was determined from wells containing target cells and
medium only. Maximum 51Cr release was gained by lysing target cells with 100 pi
of 2% Triton x 100 / sample well. Spontaneous release was less than 15% of
maximum release. All assays were performed in triplicates and expressed as mean
counts per minute ± standard deviation.
2.2.4.4 Measurement of IFN-y secreting CTL by enzyme linked
immunospot essay ( ELISPOT).
Peripheral blood mononuclear cells (PBMNC) were used as a source of T-cells for
7 f\
the purposes of the assay. 10 cells were co-cultured with 10 irradiated autologous
stimulators: AML, DLLC, Fusion hybrids of AML with mature DC, or mature DC
co-cultured with irradiated AML blasts in complete medium (CM), supplemented
with IL-2 5ng/ml and IL-7 5 ng/ml (both Peprotech). Cells were harvested on day 7
for subsequent enzyme-linked immunospot essay (ELISPOT). Sterile Multiscreen-IP
plates (PVDF membranes, Millipore, UK) were coated overnight at 4°C with 50pl /
well anti-human IFN-y antibody (Bender MedSystems, Vienna, Austria) diluted to
10pg/ml in carbonate buffer. Coated plates were washed 4 times with PBS / 0.05%
Tween 20 and blocked with CM for 2 hours at 37°C / 5% CO2. Effector cells (lOOpl)
were added to triplicate wells at graded concentrations, followed by 1 x 104 target
cells/well (lOOpl) to Effector:Target ratios of 20:1, 10:1, 5:1 and 2.5:1. After co-
culture for 36 hours at 37°C / 5% CO2, cells were removed from the assay and
biotinylated, anti-IFN-y avidin conjugated alkaline phosphatase and BCIP NBT
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substrate (Sigma Aldrich, St Louis,MO) were used for the calorimetric reaction.
Spots were quantitated using an automated ELISPOT reader (AID Systems,
Strassberg, Germany).
2.2.4.5 Wilms Tumour 1 (WT1) HLA-A2 tetramer-positive CTL analysis
Numbers of WTl specific CTL were measured in the peripheral blood of unique
patient number (UPN) 18, who was HLA-A*201 positive. WT1-HLA-A2 tetramer
(Beckman Coulter, Fullerton, CA, USA) was custom-made for the WTl26 peptide
(sequence RMFPNAPYL) (Gao et al, 2000). PE-conjugated WT1/HLA-A2 tetramer
was incubated with lxlO6 PB MNCs at final concentration of 50pg/ml in phosphate
buffered saline at 4°C. After washing, cells were incubated with FITC-labelled CD8
mab (Caltag, Burlinghame, CA, USA) for 30 mins at 4°C. Cells were then washed
and then analysed on a FACSCalibur Flow-Cytometer.
2.2.5 Measurement of Minimal Residual Disease (MRD)
Monitoring for MRD was performed by real-time quantitative PCR (RT-PCR) for
WTl gene expression prior to and then at time-points 14, 28 and 84 days following
vaccination. In four patients WTl expression was measured in BM with the
remaining patient having PB WTl expression measured due to practical
considerations. Total RNA was extracted from mononuclear cells using TRI-Reagent
(Sigma-Aldrich, UK). Reverse transcription was carried out using random hexamers
(GE Healthcare, Amersham UK) and Superscript II (Invitrogen, Paisley UK).
Relative quantitation of WTl expression was performed by realtime PCR using the
AACt method on an ABI 7900 HT thermal cycler. cABL was used as the
52
endogenous control. The WT1 primers and Taqman probe were as previously




Fifty cycles of PCR were performed. Absolute quantitation of WT1 transcript was
performed using the ProfilzQuant (Ipsogen, Marseille, France).
2.2.6 Measurement of T regulatory cell numbers
At the same time points as measurement of antileukaemic CTL responses were
measured, T regulatory (Treg) cell numbers were assessed. 2 x 105 peripheral blood
mononuclear cells were stained with the following combinations of monoclonal
antibodies; CD3-FITC alone, CD4-FITC + CD25-PE and CD8-FITC + CD25-PE (all
Caltag, Buringame, CA, USA) and cells analysed by flow-cytometry on a
FACSCalibur flow-cytometer. Treg were gated on the basis of CD4 positivity and
bright expression ofCD25.
2.2.7 Statistical methods
Statistical analysis of Cr51 cytotoxicity, ELISPOT and [3H]-thymidine uptake assay
results was performed using Student's t-test.
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Chapter 3: Clinical Results
3.1 Results of the clinical DLLC vaccination study
3.1.1 Feasibility and safety
Patients were recruited from several clinical centres throughout the United Kingdom
during a 2-year period from November 2001 and DLLC vaccination schedules for 5
eligible patients were completed by October 2004. There were no protocol violations
throughout the study duration. The clinical details of the 22 patients recruited into
the study are summarised in Table 3.1.
Only five patients were eligible to enter the vaccination program. Failure to proceed
to vaccination was due to one or more of the following reasons; induction death or
failure to achieve complete remission (27%), insufficient cell numbers in the initial
leukemia cell harvest (22%, including 5 of 6 marrow harvests) and failure of
leukemia cells to undergo DLLC differentiation (68%). Vaccination was generally
well tolerated. Only one patient, UPN 20, developed any side effects likely to be
attributable to the vaccination. At day 14 post vaccination she had an extensive
recurrence of eczema. In addition her anti-nuclear factor (ANF) which was positive
at a titre of 1/40 pre vaccination, increased to a titre of 1/160 (nucleolar pattern) at
day 84 and remained at this level following the end of the vaccination course. Two of
the patients, UPN 12 and UPN 14, had clinical relapse of their leukaemia shortly after
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the start of vaccination. The clinical details of the five vaccinated patients are
summarised in Table 3.2.
Table 3.2: Clinical details of the five patients who underwent the DLLC
vaccination program. Patient and AML characteristics; type of induction
chemotherapy; disease status at time of vaccination; current status; duration
of leukemia free survival and overall survival from start of DLLC vaccination
UPN12 60 M MO 46.XY FLAGxl CR3 t 0 28
UPN14 62 F M5 46,XX FLAGx2/idACx2 CR1 t 2 3
UPN16 40 M M5 46,XY DAx2/hdACx2 CR1 CR1 14* 14'
UPN18 67 F M1 46,XX DAx2/MidAC+ICE CR1 t 12 13
UPN20 43 F M5 46,XY DAx2/MACE+MidAC CR1 CR1 11* ir
CR=complete remission f =dead
FLAG=fludarabine, cytarabine and G-CSF idAC=intemnediate dose cytarabine DA=daunorubicin and cytarabine hdAC=high dose cytarabine
MidAC=mitoxantrone and cytarabine ICE=idarubicin, cytarabine and etoposide MACE=amsacrine, cytarabine and etoposide
LFS=leukaemia free surwval from start of vaccination OS=overall survival from start of vaccination
'alive and remains in CR1
3.1.2 Cytokine induced DLLC maturation of AML blasts
The optimal cytokine cocktail to achieve DLLC maturation from AML blasts of
different subtypes of myeloid leukaemia has been subject of much scientific debate.
In this study an approach of minimal interference during the seven day cytokine
incubation, adding further cytokines to medium at day 3 (GMCSF and TNF-a) and
day 6 (Poly I:C and Interferon-y) achieved best DLLC maturation results in most
permissive blasts, compared to centrifuging and re-suspending maturing AML blasts
in fresh cytokine enriched medium at these time-points. Previous investigators have
reported a low likelihood of patients with complex karyotypic abnormalities to
undergo blast differentiation to DLLC (Roddie et al, 2002) and this study reproduces
these findings. Out of seven patients whose blasts were permissive to cytokine
induced DLLC differentiation, only one had a complex karyotypic abnormality
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(UPN4), a further patient was found to have a trisomy of Chromosome 8 (UPN6).
These two patients showed a myelodysplastic phenotype and did not enter remission
of their leukaemia with induction chemotherapy, and therefore were not eligible for
subsequent DLLC vaccination. All five patients receiving the DLLC vaccination
showed a normal male or female karyotype. Three of these patients had a monocytic
subtype ofAML (WHO: AML, not otherwise classified, FAB M5).
Details of the immuno-phenotypic profiles of AML blasts prior to and following
cytokine incubation are shown in Table 3.3. Marked apoptosis (>75%) in response
to cytokine culture was observed in several maturation resistant cases (UPN5,
UPN11), limiting the immuno-phenotypic workup of these patients blasts.
Most of the cases permissive to cytokine maturation to DLLC did show some
expression of one or several co-stimulatory markers of their blasts in the native state,
but up-regulation in more than 20% of blasts together with the development of the
characteristic DC-morphology, showing loosely adherent clumps of large cells with
round or bean-shaped nuclei, a relatively low nuclear-cytoplasmatic ratio and
characteristic dendritic processes on microscopic examination of MGG stains of
cytospin preparations was only seen after 7 days culture with the cytokine maturation
cocktail. Morphological changes of native AML blasts following DLLC maturation



















































































































































































































































































































































































Fig. 3.1: AML blasts acquire Dendritic Cell-like morphology
following cytokine culture
Shown are microscopic images of cytospin preparations of native AML
blasts prior to and after successful cytokine-induced DLLC maturation
for UPN 12, UPN 14, UPN 16 and UPN 18
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The acquisition of a characteristic dendritic-like immuno-phenotype was
accompanied by a marked increase in forward- and side scatter compared to native
AML blasts on flow-cytometric analysis. This feature helped to differentiate those
patients, whose blasts showed strong DLLC maturation from those with a weak
immuno-phenotype. Fig. 3.3 shows the characteristic features of a differentiation
permissive case in comparison to blasts from a patient resistant to cytokine induced
blast maturation. A further helpful characteristic accompanying successful cytokine
induced DLLC maturation was the observation of increased expression of CDllc
compared to native AML blasts, which was, in cases with a monocytic or myelo-
monocytic AML phenotype, associated with decreased expression of the monocytic
marker CD 14.
3.1.3 Use of additional differentiation agents
Previous studies have reported that AML resistance to cytokine induced maturation
using GM-CSF, IL-4 and TNF-a can be overcome with the addition of Bryostatin-1,
a differentiation agent that exerts its action by interfering with protein kinase C
activity (Roddie et al, 2002).
In parallel to the standard cytokine maturation cocktail, additional experiments were
undertaken to investigate the effect of adding Bryostatin at the beginning of the
culture period to the combination ofGM-CSF and Il-4, then adding further
maturational agents TNF-a, Interferon-y and Poly I:C at day 3 and 6 respectively of
the culture period, as in the standard maturation protocol used in the clinical trial.
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Calcium Ionophore has, likewise, been reported to induce dendritic like maturation in
leukaemic blasts in the literature(Waclavicek et al, 2001;Kharfan-Dabaja et al,
2005). Calcium Ionophore was used as sole differentiation agent (UPN6, UPN8-
UPN15) and in addition to the cytokine maturation cocktail (UPN16, UPN18-22) in
parallel cultures to the standard pilot maturation assays to assess the potential of this
molecule in overcoming differentiation resistance in the study patients AML blasts
(Fig.3.2). No Bryostatin-1 or Calcium-Ionophore-treated blasts were used to
vaccinate patients in the clinical trial.
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3.1.3.1 Bryostatin-1
Bryostatin-1 was initially used in a concentration of 20 ng/ml, added at day 1 of
culture to the cytokine maturation cocktail (UPN3-UPN5). In view of marked
apoptosis observed, later experiments were conducted using a reduced dose of 10
ng/ml. Morphologically the addition of Bryostatin-1 to the maturation cocktail
provoked the development of a plastic adherent phenotype with cytoplasmatic
processes resembling those of dendritic cells in some AML blast samples
(differentiation resistant or permissive cases). However, in flow-cytometric analysis,
consistent up-regulation of co-stimulatory molecules as a consequence of Bryostatin-
1 addition was not observed and no differentiation resistant cases were rendered
permissive by the addition of Bryostatin-1. In two cases (UPN6, UPN14) that
showed cytokine induced DLLC differentiation, the resulting immuno-phenotype
was accentuated by Bryostatin-1 in further increasing expression of CDllc and
reducing expression of the monocytic marker CD14 in these AML cases with
monocytic- and myelomonocytic morphology respectively. A similar effect on
CDllc was observed on a differentiation resistant case (UPN9, FAB type M2), but
co-stimulatory markers were not up-regulated by Bryostatin-1 (Fig.3.4). In
summary, the addition of Bryostatin-1 did not lead to DLLC differentiation in this
cohort of patients. It did,however significantly increase apoptosis in the seven-day
cytokine culture (Fig. 3.5), further limiting its usefulness.
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CD40 CD83 CD86 CD80 CD14 CD11C
Immuno-phenotypic markers
□ UPN9 Day 0
□ UPN9 Day 7 cytokine maturation
■UPN9 Day 7 cytokine maturation +
Bryostatin
□ UPN6 DayO
□ UPN6 Day 7 cytokine maturation
■ UPN6 Day 7 cytokine maturation +
Bryostatin
CD40 CD83 CD86 CD80 CD14 CD11c
Immuno-phenotypic markers
70.0
CD83 CD86 CD80 CD14
Immuno-phenotypic markers
□ UPN14 Day 0
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Fig.3.4: Results of Bryostatin addition to cytokine maturation cocktail.
The addition of Bryostatin to the cytokine maturation cocktail enhanced the
loss of CD14 and promoted gain of CD11c in AML blasts resistant (A) and
permissive (B, C) to DLLC differentiation. Bryostatin did not, however,
consistently up-regulate co-stimulatory markers and did not overcome












26 ■Apoptosis Day7 cytokines +
Bryostatin
□ Apoptosis Day 7 cytokine culture
□ Apoptosis Day 0
Fig.3.5: Addition of Bryostatin-1 to cytokine culture increased levels
of apoptosis.
Mean of apoptosis is determined by flow-cytometric analysis of PI uptake
and is shown for the AML blasts of study subjects prior to and after 7 days
of cytokine culture with or without the addition of Bryostatin-1.
3.1.3.2 Calcium lonophore
Calcium Ionophore was used as described in previous studies(Waclavicek et al,
2001) as sole agent added at Day 1 of 7 Day culture in 9 AML samples (UPN6,
UPN8-UPN15). No morphological change indicative of DLLC conversion and no
increase in expression of co-stimulatory markers was seen after the 7 day culture
period. In subsequent experiments Calcium Ionophore was added to the cytokine
cocktail of GM-CSF and IL-4 at Day 1 of culture (UPN16, UPN18-UPN22). No
other maturational agents were added during the culture period. Again, no evidence
of DLLC conversion was seen in cytokine resistant cases. 3 cases with AML blasts
permissive to cytokine maturation were compared to results achieved with GM-
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CSF/IL4/ Calcium-Ionophore culture (UPN 16, UPN18, UPN20). Significant
differences in expression of co-stimulatory molecules were only seen in UPN 20,
where Calcium-Ionophore maturation resulted in higher expression of CD80 and
CD83 compared to the standard maturational agents (Fig 3.6).
UPN 20
120,0
CDC40(%) CD83(%) CD86(%) CD80(%) CD11c(%)
Immuno-phenotypic markers
Fig 3.6: Calcium-lonophore addition to GM-CSF/ IL-4 increased
expression of CD80 and CD83 compared to maturation with TNF-a,
Interferon-y and Poly l:C (UPN 20)
3.1.4 Immune responses to DLLC vaccination
3.1.4.1 Delayed Type Hypersensitivity (DTH)
This was assessed by an intra-dermal test dose of lx 106 irradiated autologous DLLC
at the beginning and the end of the vaccination course. No significant erythema or
swelling was observed in any of the five vaccinated subjects. The injection site was
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scored by the patients themselves and recorded 48 hours following test dose injection
in their patient diary. Likewise, none of the trial subjects experienced significant
erythema, swelling or tenderness around the subcutaneous sites of vaccination.
5, I2-3.1.4.2 Chromium - release cytotoxicity assay results (UPN 14J
A Chromium51 - release cytotoxicity assay was used to assess the development of
anti-leukaemic cytotoxicity in response to DLLC in the first patient to be vaccinated
(UPN 12), but was subsequently replaced by enzyme- linked immunospot (ELISPOT)
assay of Interferon-y secreting CTL. Problems associated with using a Chromium5'-
based assay centre around the lack of sensitivity, partly due to unreliable isotope
uptake by AML blasts in some cases and high spontaneous release in others, leading
to subsequent poor labelling of target cells and poor signal-to-background ratio,
respectively. UPN 12 experienced a relapse of his leukaemia during the vaccination
program and we could not show a measurable increase in anti-leukaemic cytotoxicity
responses using CR51-CTL assaying.
3.1.4.3 Measurement of Interferon-y secreting CTL by ELISPOT assay
For the estimation of anti-tumour specific immune responses following DLLC
vaccination in patients UPN14, UPN16, UPN18 and UPN20, ELISPOT technology
was utilised, as it provided the required assay sensitivity and reproducibility.
Interferon-y release of mononuclear effector cells was measured in response to
native, autologous blasts and DLLC prior to the vaccination course and at set
timepoints during and following the vaccination course. For UPN 14 an additional
correlation between the release of Interferon-y and Granzyme B, a cytotoxic T-
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cellular effector molcule was possible for two time-points during DLLC vaccination
in parallel ELISPOT secretion assays.
Measurable increases in the frequency of anti-leukaemic CTL were demonstrable in
all four patients at some timepoints during or following the vaccination course, when
compared to pre-vaccination levels. The secretion of Interferon-y correlated well
with that of Granzyme B in response to autologous AML and DLLC at two time-
points, Day 28 and Day 49 during vaccination of UPN 14, further validating the use
of Interferon-y secretion in the assessment of anti-tumour immune responses (Fig
3.8).
♦ IFNg V5 Granzyme B responses
Linear (IFNg vs Granzyme B
responses)
IFNg vs Granzyme B responses:


















Fig 3.8: Correlation of Interferon- y and Granzyme B-release
Parallel ELISPOT assays of Interferon- y and Granzyme B release by T-
cells in response to autologous AML and DLLC were conducted. Results of
corresponding assay wells show good correlation.
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3.1.4.4 Analysis ofWT1/HLA-A2 tetramer positive CTL
It has been demonstrated that WT1 can serve as a target for CTL and that these WT1
specific CTL have particular activity against leukaemic blasts(Gao et al, 2000) The
presence of WT1 specific CTL was measured using fluorochrome labelled HLA
tetramer bound to a HLA-A*201 restricted 9mer WT1 peptide. Only one of the five
vaccination patients was HLA-A*201 positive and therefore suitable for study. In
this patient (UPN18) at the start of vaccination there was a very low frequency of
WT1 specific CTL. Following vaccination there was a progressive rise in WT1
specific CTL in the PB with a maximum value of 0.35% of total T cell numbers on
day 84 (Fig. 3.9).
Fig.3.9: T-cells specifically recognising the WT1 leukaemic antigen
increase following DLLC vaccination.
Peripheral blood CD8+ve T-cells of patient UPN 18 with WT1-expressing
AML; Binding of WT1 HLA-Tetramer is expressed as percentage of all
lymphocytes in a flow-cytometric assay.
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3.1.4.4 Regulatory T-cell numbers
Frequencies of regulatory T-cells (Treg) were monitored though the vaccination
programme. There was no consistent pattern either in the Treg frequency pre-
vaccination or in the change in this frequency following vaccination between the five
patients (Figure 3.7.C). In particular initial Treg frequencies did not appear to be
appreciably different between the two patients who had received fludarabine based
induction regimes (UPN12 and UPN14) compared to those that has received an
anthracycline based regime (UPN16, UPN18 and UPN20). On selected time-points
there did appear to be a relationship between the level of anti-leukemia CTL and
Treg frequency in two of the patients. For cases UPN18 and UPN20 the peak in anti¬
leukemic CTL occurring at day 28 was associated with a dip in the Treg frequency.
The subsequent fall in CTL numbers in these two patients at day 84 was
accompanied by a rise in Treg numbers.
3.2 Discussion of the clinical study
This study has demonstrated that vaccination of patients with AML in CR with
autologous DLLC is feasible. It was possible to generate clinically relevant numbers
of DLLC in a GMP grade facility. In those cases, where the blast number in the
peripheral blood exceeded 109/l, sufficient malignant cells for the planned
vaccination course could mostly be gained from a peripheral blood aliquot of up to
100 ml. Bone marrow harvests for cases with a lower peripheral blood blast count,
however, failed to yield sufficient cell numbers in five out of six cases and should be
replaced by a leucapheresis procedure in cytopenic patients and those with blast
counts below 109/l.
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It remains impossible to predict, which patient's blasts might be permissive or
resistant to cytokine-induced DLLC differentiation. Morphological categorisation
according to FAB subtypes of AML did not co-segregate with successful DLLC
differentiation. Marked cytokine-induced apoptosis in culture or failure to
differentiate was seen in all morphological AML variants. The observed
differentiation resistance in those patients with complex karyotypic abnormalities
will be an obstacle to the application of this vaccine-generation stategy in many
elderly AML patients and those with an antecedent myelodysplastic presentation.
Further individualisation of cytokine concentrations and incubation periods may
improve the results of DLLC differentiation in selected cases, an approach taken by
previous investigators (Harrison et al, 2001). These procedural variations would,
however, further complicate the standardisation and comparability of results
achieved by this immuno-therapeutic intervention. The study did not show a clear
benefit of adding Bryostatin-1 to the cytokine cocktail, nor could DLLC maturation
be achieved by the substitution of TNF-a, IFN-y and Poly I:C by Calcium-Ionophore.
Vaccination was generally safe with only one of five patients developing side effects
potentially attributable to the vaccination program. Interestingly in this patient the
side effect was eczema that might have been as a consequence of the induction of
autoimmunity through presentation of self-antigens by the DLLC. This same patient
also developed an increasing ANF titre supporting this hypothesis. In terms of
specific anti-leukaemic CTL activity four patients developed increased numbers of
leukaemia specific gamma-interferon secreting CTL following vaccination. In the
one HLA-A*201 positive patient this was also accompanied by an increase in WT1
specific CTL numbers.
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However, despite the development of these anti-leukaemia immune responses,
evidence of clinical benefit has not been established. Indeed, in one patient, UPN 14,
leukaemic relapse developed despite an increase in anti-leukaemia CTL activity.
There could be several reasons, why this increase in anti-leukaemic activity failed to
prevent relapse in this patient. It is known that regulatory T cells inhibit anti-cancer
immune responses (Casares et al, 2003b;Wolf et al, 2003b;Morse et al, 2002;Mesel-
Lemoine et al, 2005;Brouwer et al, 2000) The rise in Treg numbers seen in this
patient may have abrogated the anti-leukemic response to a degree that relapse could
take place. Evidence suggest that suppression of Treg numbers can restore effective
anticancer immunity (Morse et al, 2002;Ghiringhelli et al, 2004). It has been
suggested that fludarabine may be a useful drug in terms of creating a favourable
background for anti-tumor vaccination due to its activity against Treg. (Beyer et al,
2005). However, in our study we did not see any appreciable difference in pre-
vaccination Treg frequency, or in the development of anti-leukemic activity, between
those patients receiving prior fludarabine therapy compared with those receiving an
anthracycline based regime. It may be therefore that type of the AML induction
regime used prior to vaccination is not of fundamental importance in determining the
probability of developing an anti-leukemic immune response following vaccination.
Interestingly, the cytotoxic agent Cyclophosphamide has been shown to suppress
Treg activity, allowing immunotherapeutic approaches for established malignancies
(Ghiringhelli et al, 2004). An early vaccination time-point following high dose
cytotoxic chemotherapy may be also of value in avoiding Treg mediated suppression
of anti-tumour directed cytotoxicity. Although Treg may have a role in suppression
of anti-leukaemia immunity, a more likely explanation for a lack of clinical benefit is
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that DLLC vaccination is not sufficiently effective to generate a clinically relevant
level of anti-leukemia immune response. If this is the case then it will be necessary to
augment the vaccination method in order to generate clinically relevant immunity.
Possible ways of achieving this are by improving the potency of the dendritic cell
based vaccine through use of agents that promote dendritic cell maturation and/or
polarisation or by supporting any anti-leukemia T cell responses by systemic
administration of cytokines such as IL-12 (Napolitani et al, 2005;Portielje et al,
2005). It might then be possible to convert subclinical immune responses into ones
that are clinical effective. However, as DC populations originating from leukaemic
blasts in vivo are part of the malignancy and may potentially also produce
"tolerogenic" signals, in particular if a fully mature DLLC phenotype can't be
achieved, the question arises if AML-DC in vivo might be implicated in the disease
process and, if so, whether their use in therapy would be advisable? The fact that the
malignant cells are DC precursors and therefore components of the immune
interaction one attempts to study complicates the characterisation of immune
responses to AML. Could DCs derived from malignant precursors, one of the unique
features of AML, be part of the pathology of AML? If AML-DC respond to stimuli
in their environment with a capacity similar to that of normal marrow precursor
derived DC, then the pathology in AML may not be at the level of the DC itself, but
with the responder T- and NK cells. In this case, the use of AML-DC in therapy of
AML may be of benefit. In cases, where AML-DCs differ from normal DCs in their
responses to stimuli, AML pathology may in part be attributed to the AML-DC itself
and their use in therapy of the disease may be less effective. Studies of anti-
leukaemic T-cell responses in leukaemic patients in remission (Panoskaltsis et al,
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2002;Molldrem et al, 2000)and those with fulminant disease (Molldrem et al, 2003)
(Elisseeva et al, 2002)have been undertaken. Cytotoxic T-lymphoeytes (CTL)
directed against tumour-associated antigens, such as WT1 and Proteinase 3 have
been demonstrated at some point of the disease process. Such observations have led
some investigators to the suggestion that immune responses to tumour might be
actively inhibited in advancing disease (Staveley-O'Carroll et al, 1998;Takasugi et
al, 1977), while others have postulated that in patients with malignancy immune
responses to tumour associated antigens (TAA) are only initiated in disseminated,
overwhelming disease and are only detectable at low levels in a situation of low
tumour burden (Mintz et al, 2003;Valmori et al, 2000). In either case, immune
control of the tumour ultimately would be ineffective, but the exact
immunosuppressive mechanisms remain unclear (Panoskaltsis, 2005). Semi-mature
DC may trigger regulatory T-cells (TReg) like IL-10 producing CD4+ CD25+ cells,
capable of silencing the immune response, whereas specific manipulation of
malignant cells into APCs with a mature phenotype may trigger the immune system
to suppress or eradicate leukaemia.
Any future attempts to increase the effectiveness of vaccination will depend upon the
ability to measure to a high degree of sensitivity the development of anti-leukaemic
T cell immune responses and the impact of vaccination on the levels of leukaemia
burden. This study has demonstrated that by using techniques such as ELISPOT and
HLA tetramer analysis in combination with RT-PCR for WT1 to measure MRD it is
possible to sensitively monitor the impact of DLLC vaccination. This means that as
dendritic cell based vaccination approaches are refined their impact on improving
immunological and clinical effectiveness of the vaccine can be carefully followed.
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Whilst this study has demonstrated that vaccination with DLLC is feasible, it is not
an approach that would be broadly applicable. This is because the number of patients
who were eligible to proceed to vaccination in comparison to those recruited into the
study was only in the order of 25%. This was not unanticipated given the stringent
requirements that had to be met in order to proceed to vaccination. The reason for
these requirements was that it is believed that for cellular vaccination strategies to be
effective they are best performed in a state of MRD. Conversely it is unlikely that
any vaccination approach would be successful where the patient has active and
uncontrolled leukemia (Haining et al, 2005). Given that CR is possible in >50% of
patients suitable for intensive chemotherapy, this in itself would not necessarily
prove a barrier to more widespread the adoption of this type of treatment approach.
Unfortunately the additional requirement that the patient's leukemia cells need to be
permissive to DLLC differentiation does restrict this approach to a minority of
patients. It has been shown previously that in only around 25-40% of AML cases are
leukemia cells are permissive to DLLC differentiation (Brouwer et al, 2000;Cignetti
et a/;Robinson et al, 1998). Unless methods for improving the proportion of AML
cases that are permissive to DLLC differentiation can be found, different approaches
to vaccination will need to be tried. Other methods, such as loading monocyte-
derived dendritic cell with autologous leukaemia antigens or utilising fusion hybrids
of tumour cells with autologous monocyte-derived DC may yield a potentially more
broadly applicable cell based vaccine and are explored in the further laboratory
studies undertaken for this thesis.
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Chapter 4: Results of laboratory studies-
Fusion Hybrids of Dendritic Cells and
autologous Myeloid Blasts as possible cellular
vaccine for AML
4.1 Overview of experimental strategy
Dendritic-like leukaemic cells (DLLC) generated from primary AML blasts by
cytokine induced differentiation offer potential as autologous cellular vaccines as
they acquire co-stimulatory and adhesion molecules and thereby stimulate cytotoxic
T-lymphocyte (CTL) responses to leukaemic tumour antigens (Choudhury et al,
1997;Choudhury et al, 1999;Charbonnier et al, 1999;Choudhury et al,
1999;Charbonnier et al, 1999). In a significant number of cases, however, AML
blasts prove resistant to cytokine driven differentiation into DLLC (Brouwer et al,
2000;Choudhury et al, 1999;Harrison et al, 2001;Robinson et al, 1998), therefore
limiting this approach, in the experience of our clinical trial using DLLC as cellular
vaccine constructs, to about 30% of cases.
To overcome these limitations, an alternative approach to generate potent anti-
leukaemic cytotoxic responses was investigated by fusing autologous AML blasts to
mature dendritic cells derived from peripheral blood monocytes of 6 AML patients in
complete morphological remission (CR), thus generating heterokaryons that express
leukaemic antigens derived from the blast fusion partner as well as co-stimulatory
and adhesion molecules of mature dendritic cells. The aim of this strategy was to
explore the potential of these AML-Dendritic Cell Fusion Hybrids to induce in vitro
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T-cellular responses against the patient's unmodified leukaemic cells. Where
possible, the potency of these constructs was compared to that of mature DCs co-
cultured with irradiated autologous leukaemic blasts, previously shown to generate
leukaemia specific T-cellular cytotoxicity (Galea-Lauri et al, 2002;Spisek et al,
2002).
Samples from 6 patients (median age: 54 years, range: 24-70 years) were used in this
study. Table 4.1 shows relevant clinical and laboratory characteristics of these
patients, in whom DLLC maturation was either not achievable (n=5), or DLLC
proved ineffective in stimulating anti-leukaemic CTL (UPN3).
Table 4.1: Patient characteristics
Patient Sex/Age Sample origin WHO/FAB classification Karyotype DLLC maturation
UPN1 M/66 PBa M4 46,XY No
AML with trilineage 46,XY No
UPN2 M/48 PB dysplasia / M5a
UPN3 F/61 PB M5a 46,XX Yes
UPN4 F/24 PB M5a 46,XX No
UPN5 M/39 PB M4 46,XX No
UPN6 F/70 PB M5 46,XY No
PB, peripheral blood
a) Leukaemic Blasts were taken with informed consent at the time of diagnosis. A
highly purified population of leukaemic blasts (> 95%) was generated through Ficoll
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density-gradient centrifugation and cells were immediately cryopreserved in 90%
fetal calf serum/ 10% DMSO.
b) Remission samples were obtained after CR was confirmed (defined as less than
5% of blasts in the bone marrow). Ficoll density-gradient centrifugation was used to
separate monocytes for generation of mature Dendritic Cells (mDC) and isolate
responder T-cells for subsequent incubation with various autologous stimulators.
c) Generation of mature DCs from Peripheral Blood Monocytes of Patients in
Complete Morphological Remission. Mature DCs were generated from the adherent
fraction of PBMCs collected after the resolution of cytopenias following
combination intravenous chemotherapy using a cytokine cocktail containing GMCSF
at lOOng/ml and IL-4 at 15ng/ml for 5 days. DCs were then matured for further 2
days by the addition of TNF-a at 25ng/ml, Poly I:C at 12.5 mcg/1 and Interferon-
gamma at 30ng/ml. Mature dendritic cells were then used fresh for the generation of
fusion hybrids with thawed autologous AML blasts and also co-incubated with
irradiated AML blasts to generate an alternative vaccine construct.
d) Generation of Dendritic Like Leukaemic Cells (DLLC) from AML blasts.
Maturation to DLLC was attempted in all cases to compare the immuno-stimulatory
capacities of these constructs to that of AML-DC fusion hybrids and DCs loaded
with AML tumour bodies in co-culture with autologous remission T-cells. Cytokine
concentrations and culture conditions were identical to those used in the DLLC
clinical vaccine trial.
e) Generation ofAML-mDCfusion hybrids. Thawed AML blasts and fresh mDC
were mixed at a ratio of 1:1, pelleted by centrifugation and fused by drop-wise
addition of 50% Polyethylene Glycol (PEG)/10% DMSO. They were then used as
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stimulators in autologous CTL assays and allogeneic mixed lymphocyte leukaemia
reactions (MLLR) in comparison to other vaccine constructs and nai've AML blasts.
f) Stimulation of leukaemia-specific lymphocytes by co-culture with autologous
AML-mDCfusion hybrids, mDc cocultured with irradiated AML and DLLC. The
non-adherent fraction of fresh or thawed remission blood samples provided the
source of autologous responder cells. Unmodified AML blasts, AML-mDC Fusion
Hybrids and mDC mixed 1:1 with irradiated (26Gy) AML blasts were used as
autologous stimulators. Dendritic-like differentiation was achieved from the
leukaemic blasts of one of six patients. DLLC were generated as stimulators to
autologous responder T-cells in this case. PBMC cultured in the absence of
stimulators or primed by un-pulsed mDCs and AML-AML fusions served as
negative controls, as these are not expected to stimulate leukaemia directed
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cytotoxicity. Co-culture of 10 responder cells with 10 irradiated stimulators was
prepared in 12-well plates at a cell density of 106/ml effectors. CM was
supplemented with IL-2 5ng/ml and IL-7 5ng/ml. Responder cells were re-
stimulated at day 7 and day 14 for 3lCr-release cytotoxicity assays, using the same
stimulators that had been added at the beginning of co-culture. CM and cytokines
were half exchanged weekly. Effectors were harvested on day 7 (ELISPOT assay) or
on day 21 for subsequent 51Cr-release cytotoxicity assays against native, autologous
AML blasts.
g) Allogeneic Mixed Leukaemia-Lymphocyte Reactions (MLLR). Responder cells
for allogeneic MLLR were obtained from the non-adherent lymphocytes of healthy,
unrelated donors, whose PBMC had been separated by gradient density
centrifugation followed by 2hrs plastic adherence. Adherent donor monocytes were
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matured in a 7-day culture into mDC as described above and subsequently fused to
patient AML blasts to generate AML-DC Fusion Hybrid stimulators. Un-fused AML
blasts and mDC as well as AML co-cultured with mDCs served as stimulator
controls. AML-AML or mDC-mDC fusions and titrating concentrations of PEG
were also assessed regarding their ability to stimulate the proliferation of
lymphocytes allogeneic to the AML blasts used.
h) 5lCr-release cytotoxicity assay and Interferon-y ELISPOT Immuno- assay.
Following re-stimulation co-culture with a variety of autologous stimulators the
resulting leukaemia directed in vitro cytotoxicity was measured in a 4 hr 3lCr-release
cytotoxicity assay in 2 patients (UPN1, UPN2), where uptake of the isotope by their
native AML blasts was demonstrable. Interferon-y (IFN-y) ELISPOT assays were
used in 4 patients (UPN3-UPN6) to assess in vitro T-cell responses to autologous
AML blasts.
4.2 Flow-Cytometry and Fluorescence Microscopy confirm
AML-mDC fusion
Before testing the immune-stimulatory function of AML-mDC Fusion Hybrids a
series of experiments was conducted to assess the efficiency of fusion using PEG /
DMSO.
Flow-cytometric analysis following membrane staining of the fusion partners with
different fluorescent dyes (CMFDA for DC's and PKH 26 for AML blasts
respectively) allowed identification of fusion hybrids as double stained cells. Fusion
efficiency was between 20% and 30% (mean 26%). Fig.4.1 shows a representative
result.
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a: AML blasts stained with PKH26 b: Dendritic Cells stained with CMFDA
97.6%
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post AML-DC Fusion
Fig. 4.1: Flow-cytometric analysis of fusion efficiency
Fluorescence microscopy provides confirmation of membrane derived from both
fusion partners on the membrane stained heterokaryons generated. Motorised micro-
focussing sections through fusion hybrids on cytospin preparations were visualised.
Fig.4.2 shows sections through a fusion hybrid. As the common membrane of the
Fusion hybrid comes into focus, red (AML) and green (mDC) stained membrane
elements are seen.
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Fluorescence microscopy provides confirmation ofmembrane derived from both
fusion partners on the membrane stained heterokaryons generated. Motorised micro-
focussing sections through fusion hybrids on cytospin preparations were visualised.
Fig.4.2 shows sections through a fusion hybrid. As the common membrane of the
Fusion hybrid comes into focus, red (AML) and green (mDC) stained membrane
elements are seen.
29
Dual staining on fused membrane
Fig.4.2: Fluorescent microscopic sections through an AML-DC fusion
cell. A series of fluorescent microscopic images are cross-sectioning a
membrane-stained AML-DC fusion cell. Motorised focussing through the
heterokaryon reveals dual membrane staining from both fusion partners.
The Dendritic Cell was stained with the green fluorescent membrane dye
CMFDA. The AML blast was stained with the red membrane dye PKFI26.
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Fig.4.3: AML-DC fusion hybrids express a bi-phenotypic flow-
cytometric profile.
AML blasts and DCs were stained before and after fusion using a panel of
monoclonal antibodies against AML and DC associated antigens. The fusion
hybrids express AML derived antigens (CD34) as well as DC associated
antigens and co-stimulatory molecules (CD 86,CD 80). Results of a
representative experiment are shown. Fusion hybrids are not gated.
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Additionally, a bi-phenotypic flow-cytometric profile of fusion hybrids was
demonstrated by analysis of the fusion partners before as well as fusion hybrids after
fusion. Fig.4.3 shows representative results of one patient. Un-fused AML blasts
and mDC are stained with mABs against the leukaemia associated antigens CD34
and CD33 and the DC associated antigens CD86 and CD80 prior to PEG fusion.
Immediately after fusion the Hybrids express both AML and DC associated
membrane antigens.
4.3 Fusion Hybrids induce AML-directed T-cell responses
3lCr-release cytotoxicity assays were performed in two patients, where good 3lCr
uptake by autologous AML blast targets was shown (UPN1, UPN2).
In the remaining four patients (UPN 3-6) an interferon-y ELISPOT assay was used to
demonstrate T-cell responses against native, autologous AML blasts induced by
priming co-culture with the various autologous stimulators (Table 2).
Table 4.2: Immuno-assays performed and results generated
Patient Immuno-assay performed Best Stimulator Construct Results
UPN 1 51-Chromium release AML-DC Fusion Hybrids Fig.4.4
UPN 2 51-Chromium release AML-DC Fusion Hybrids Fig.4.4
UPN 3 Interferon-y ELISPOT AML-DC Fusion Hybrids Fig.4.5a
UPN 4 Interferon-y ELISPOT AML pulsed mDC Fig.4.6
UPN 5 Interferon-y ELISPOT AML pulsed mDC Fig.4.6
UPN 6 Interferon-y ELISPOT No stimulators Not
shown
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In three patients AML-mDC fusion hybrids proved the strongest inducers of anti¬
leukemic T-cell responses, using 51Cr-release cytotoxicity assays (UPN1, UPN2)
and ELISPOT interferon-y assay (UPN3), respectively. In UPN1 (Fig.4.4), PBMC
primed with Fusion Hybrids, but not with either unfused AML blasts (pO.OOOl) or
mDC (pO.OOOl), resulted in 47% target lysis at the Effector:Target ratio of 50:1 in a
3lCr-release assay. Cytotoxicity induced by mDC pulsed with tumour-cell bodies




















Effector : Target ratio
50:1 25:1 12.5:1
Effector : Target ratio
Fig.4.4: AML-mDC Fusion Hybrids generate anti-leukaemic cytotoxicity
in co-culture with autologous remission PBMCs.
Cr51-release assays of UPN 1 and UPN 2 are shown
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In UPN2 Fusion Hybrids generated 7.3% AML directed cytotoxicity, compared to
3.8% induced by to un-fused AML ( p =0.005), 1% cytotoxicity induced by
unstimulated PBMC (p=0.001) and 0.4% by inappropriate AML-AML fusion
hybrids (p=0.003) at the highest Effector/ Target ratio of 50:1 (Fig. 4.4).
In a third patient (UPN3) Interferon-y responses to autologous AML blasts increased
more than 3.5 fold in effectors primed by co-culture with Fusion Hybrids compared
to those primed with AML blasts alone (p=0.0002), DLLC (p=0.0003) or un-primed




















Fusions AML DLLC Unstimulated
Fig.4.5a: Anti-leukaemic T-cell responses induced by AML-DC Fusion
Hybrids (UPN3) exceed those of other autologous stimulators in an
Interferon-y ELISPOT assay.
Results of triplicate wells at the Effector /Stimulator ratio of 20:1 are shown.
Co-culture with AML-DC fusions ( □ ) induces a more than 3-fold increase in
T-cell Intereron-y release, compared to T-cells stimulated by AML ( ■ ),
DLLC ( □ ) and unstimulated (□ ) T-cells.
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4.4 mDC co-cultured with irradiated whole tumour cell bodies may
provide an alternative cellular vaccine construct
In two patients (UPN4, UPN5) AML-pulsed mDC proved better stimulators of anti-
leukaemic T-cell responses than AML-DC Fusion Hybrids in Interferon- y ELISPOT
assays (Fig.4.6). The stimulatory differences observed between these constructs














AML pulsed AML AML-mDC Unpulsed
inDC' Fusions mDC:
700.0
AML pulsed AML AML-mDC Unpulsed
mDC Fusions mDC
Fig.4.6: In two patients (UPN4, UPN5) AML pulsed mDC (■) prove better
stimulators of anti-leukaemic T-cell responses than AML-DC fusion hybrids (£g
), autologous AML blasts ( □) and unpulsed mDC (□) . ELISPOT Interferon-
Y release assay counts at the EffectonTarget ratio of 20:1 are shown.
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However, mDC pulsed with tumour cell bodies showed a significant advantage over
immune responses induced by unmodified AML blasts only in UPN 5 (p=0.02),
whereas the differences observed did not reach statistical significance in UPN 4
(p=0.15). In both patients Fusion Hybrids failed to induce T-cell responses
exceeding those to unmodified AML blasts.
4.5 Suppression of lymphocyte proliferation by Fusion
Hybrids is not specific to fusion partners
Assessing the immune-stimulatory properties of fusion hybrids it was observed that
the proliferation of lymphocytes was suppressed by AML-DC fusion hybrids in [3H]-
thymidine uptake assays, where AML blasts allogeneic to the mDC and responder
lymphocytes were used. A representative result of three experiments is shown in
Fig.4.7a. This anti-proliferative property, however, was shown to be not specific to
AML-DC fusion, but was also induced by allogeneic AML-AML as well as
autologous mDC-mDC heterokaryons (Fig.4.7b,c). Polyethyleneglycol did not
contribute to this effect (results not shown). Importantly, the induction of tumour
specific T-cell cytotoxicity by AML-DC fusion hybrids was maintained regardless,







































Fig.4.7: a) AML pulsed mDC (II), but not AML-mDC Fusion Hybrids (■)
stimulate proliferation of T-cells autologous to the mDC and allogeneic to the
AML blasts, b) A similar antiproliferative effect is induced by allogeneic AML-
AML fusion (0) and c) autologous mDC-mDC hybrids (0), suggesting a
mechanism not specific to individual fusion partners. PBMC controls (□) are
cultured without stimulators.
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4.6 Discussion of laboratory studies
The heterogeneity of the Acute Myeloid Leukaemias poses a challenge for the
generation of a dendritic cell based vaccine, as few leukaemia specific or tumour
associated antigens can be expected to be expressed in all cases and remain stable
over the course of the disease and chemotherapy treatment courses. Strategies
focussing on the generation of CTL responses against single, specific tumour
antigens are therefore fraught with the risk of possible tumour immune escape due to
clonal evolution and tolerance to known and also unknown tumour antigens,
resulting in relapse originating from minimal residual disease.
Whole tumour based vaccine strategies attempt to circumvent this problem by
inducing polyvalent immune responses against a large number of antigens expressed
by leukaemic blasts. DLLC derived from AML blasts by sequential cytokine
incubation have been demonstrated to acquire co-stimulatory molecules that are
mostly lacking in native AML blasts and are necessary to induce CTL responses.
This approach to generation of a cellular vaccine is, however limited by the
resistance to cytokine maturation in a significant number of cases (Roddie et al,
2002;Choudhury et al, 1997;Harrison et al, 2001).
In this pre-clinical study the approach of fusing whole tumour cells to autologous DC
was investigated. Thus hybridomas were constructed which express both tumour
derived antigens and DC-derived co-stimulatory molecules. It was shown that AML-
mDC fusion hybrids and, to a lesser degree, mDC co-cultured with irradiated AML
blasts are capable of inducing leukaemia directed in vitro cytotoxic responses in
autologous remission PBMC. Both of these vaccine constructs can be readily
92
generated with little technical difficulty and are therefore attractive alternatives to
DLLC.
Spisek et al have previously described the induction of leukaemia-specific response
by cross-presentation of late-apoptotic leukaemic blasts by autologous dendritic cells
of non-leukaemic origin (Spisek et al, 2002). Tumour-mDC fusion hybrids have
been generated and successfully used as vaccines in the prevention and treatment in
murine models of breast carcinoma (Gong et al, 1997;Gong et al, 1998;Gong et al,
2000;Chen et al, 2003) and induction of in vitro cytotoxicity has been demonstrated
in B-CLL (Kokhaei et al, 2003) and Multiple Myeloma (Raje et al, 2004). Evidence
for their effectiveness as vaccine constructs in AML, however, is limited. Galea-
Lauri et al have previously reported one case of successful in vitro induction of CTL
responses to AML blasts by autologous Fusion Hybrids and supported this finding by
assessment of DC loading strategies with antigens derived from the U937 leukaemic
cell line, including U937-DC Fusion Hybrids (Galea-Lauri et al, 2002).
In the pre-clinical assessment conducted for this thesis it was possible to elicit
leukaemia directed T-cell responses in three out of six patients whose remission
PBMC were co-cultured with autologous AML-mDC fusion hybrids. In two cases
anti-leukaemic cytotoxicity generated by fusion hybrids was demonstrated by Cr51-
release assay (Fig4.4), in a third case T-cell responses to fusion hybrids exceeded
those to other autologous stimulators in an Interferon-y ELISPOT assay (Fig.4.5a).
In a further two out of three patients, where AML-mDC Fusion Hybrids proved
ineffective in stimulating leukaemia directed cytotoxicity above the level induced by
native AML blasts, however, mDC co-cultured with irradiated AML blasts did
induce anti-leukaemic T-cell responses (Fig.4.6).
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The determinants of successful CTL generation by either strategy require further
investigation. MLLR experiments showed that PEG generated Fusion Hybrids exert
anti-proliferative effects on co-cultured lymphocytes. This appeared to be
independent of the fusion partners and was not induced by titrated addition of PEG to
cultured PBMC alone. In spite of this anti-proliferative property, AML-mDC Fusion
Hybrids remained capable of generating potent anti-leukaemic cytotoxic responses,
further emphasizing the potential of these heterokaryons as cellular vaccines. Their
efficacy might be further enhanced by exclusion of non-viable Hybrids by means of
immuno-magnetic selection prior to co-culture, while positive selection of fused
from un-fused cells based on their characteristic forward and side scatter profile
(Galea-Lauri et al, 2002) could be achieved using a cell sorting facility. Purified
hybrid cells from dendritic cell and tumour cell fusions have previously been shown
to be more effective in inducing an immune response (IFN-y) when compared to
fusion mixture (Li et al, 2001). Furthermore residual un-hybridised AML blasts may
anergise T-cells. All these parameters could affect the proliferation response when
using DC Fusion Hybrids to stimulate autologous anti-leukaemic T-cells.
A recent study in a murine model confirmed that DCs fused or pulsed with AML
cellular antigen provide comparable in vivo anti-tumour protective responses (Weigel
et al, 2006) .
In conclusion this laboratory study provides pre-clinical data on developing a DC
based vaccination strategy for Acute Myeloid Leukaemia. AML-mDC Fusion
Hybrids can be generated with relative ease and hold promise as a novel potential
cellular vaccine, providing an alternative to whole tumour cell-pulsed mDC or
DLLC.
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Chapter 5: Concluding Remarks
This study has investigated the feasibility and safety of generating a cellular vaccine
for the treatment of AML derived from autologous myeloid blasts by means of ex-
vivo cytokine-maturation to Dendritic-like Leukaemic Cells in a Phase I/II clinical
trial. The study suggests a body of tests to monitor immune responses to the
vaccination and to measure the impact on minimal residual disease. It explores the
possible role of regulatory T-cells in the eventual dampening of anti-tumour
cytotoxicity following DLLC vaccination.
Pre-clinical laboratory investigations aimed to develop the next generation of "whole
cell" DC-based vaccine constructs:
• The use of the agents Bryostatin-1 and Calcium-Ionophore, in an attempt to
overcome blast resistance to cytokine-mediated DLLC differentiation,
• Co-culture ofmonocyte-derived DC with autologous, irradiated blasts, and
• Generation of fusion hybrids from AML blasts and autologous monocyte-
derived DC
In my opinion "whole cell" based DC vaccines, e.g. fusion hybrids, non-leukaemic
DC pulsed with autologous tumour lysates or apoptotic tumour cell bodies provide
the most promising therapeutic strategy in the immediate future. These constructs
circumvent the obstacle of differentiation resistance encountered when using AML-
DC and provide "polyvalent" immune stimulation, making tumour immune escape
by antigen drift less likely. They do not require detailed analysis of the individual
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leukaemic antigens presented and are not HLA restricted, thereby representing an
easier, albeit individualised vaccine design.
The clinical study of DLLC vaccination confirmed feasibility and safety of these
constructs, however, the approach is limited by the resistance to cytokine induced
AML blast differentiation in the majority of patients. Previous investigators
(Harrison et al, 2001) have attempted to individualise and optimise cytokine
cocktails and sequencing of agents. Our study could not demonstrate that such
modifications reliably convert differentiation resistant cases into permissive ones.
Likewise, the use of Bryostatin-1 and Calcium Ionophore, with or without other
cytokines, has not overcome differentiation resistance in our hands. Questions about
the functional ability of AML blast derived DLLC remain. In some cases a not fully
mature phenotype is generated, that might not induce clinically beneficial anti-
tumour cytotoxicity. The heterogeneity of AML contributes to the complexity of the
task, and the response to cytokine maturation remains essentially unpredictable in
individual cases.
Immune monitoring of vaccine responses is essential in order to improve the next
generation ofAML vaccines. The combination of assessing minimal residual disease
with quantitative PCR for WT1 or leukaemia-specific chromosomal translocations,
sensitive and specific Interferon-y and Granzyme-B immune assays and HLA-
tetramer studies of tumour-specific CTL in the peripheral blood in patients with a
suitable HLA type, proved fruitful in evaluating the vaccine impact in our clinical
study, but has highlighted the short-lasting nature of immune responses seen in the
vaccinated patients. The analysis of Treg, gated on the basis of CD4 positivity and
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bright expression of CD25, showed a dip in their frequency at the height of
measurable anti-tumour responses in two patients (UPN18, UPN20) and a
subsequent rise in Treg numbers, as CTL responses weakened.
Treg have been investigated in many recent studies because of their apparent immuno¬
modulatory role in infection, auto-immunity and inhibitory effect on anti-cancer
immune responses (Casares et al, 2003a;Mesel-Lemoine et al, 2005;Morse et al,
2002;Wolf et al, 2003a). Conversely, evidence has emerged that effective anti¬
cancer immunity can be restored by suppression of Treg numbers (Ghiringhelli et al,
2004). A better characterisation of Treg, using the now available marker FOXP3 may
help correlate the number of Treg cells before, during and following DC vaccination
with the variation of measurable anti-leukaemic cytotoxicity and MRD burden. This
may provide insight into the role of these cells in dampening anti-leukaemic immune
responses.
The challenge for future vaccine approaches will be to translate the anti-leukaemic
immune responses observed into demonstrable clinical benefit. This may be achieved
by optimizing dosing, timing and sequencing of vaccine administration as well as
potentiating the vaccine through use of adjuvants and addressing the suppressive
effect of Treg. Any future vaccination strategy will have to address the possibility of
various immunological tumour escape mechanisms and the problem of targeting
dormant tumour cells (Saudemont & Quesnel, 2004). It remains uncertain, if the anti-
leukaemic role of NK cells observed in allogeneic stem cell transplantation can be
replicated in autologous vaccine constructs, but a recent study in a murine model
suggests that NK cells activated by CXCL10 can kill dormant tumor cells that resist
CTL-mediated lysis (Saudemont et al, 2005).
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Approaches based on transducing an autologous cellular vaccine with genes
encoding co-stimulatory molecules and IL-2 (Rousseau et al, 2006;Chan et al, 2005)
also appear promising, provided safety concerns about using a virally transduced
vaccine can be addressed. Looking further ahead, the emerging knowledge of
important, immunogenic leukaemia associated antigens, in particular those that are
integral to the leukaemogenic process, might well reveal a number of peptides
loadable to a wide range of HLA types, making this vaccine approach more widely
applicable. Ultimately, in vivo loading of leukaemic antigens and achieving
activation of the patient's own DCs by targeting specific DC toll-like receptors
(TLRs) would seem an ideal mode of vaccine delivery. New, emerging adjuvants
might greatly enhance the immune stimulation achieved by in vivo DC targeting.
Regardless of the chosen vaccine design, standardization of DC generation, antigen
loading and maturation as well as evaluation of the vaccination response will be
essential to allow observations from different clinical studies to be compared. Only
then might an effective cellular vaccine, delivering a sustained clinical benefit to
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A STUDY OF USING CHEMOTHERAPY AND A VACCINE DEVELOPED
FROM PATIENTS' OWN LEUKAEMIA CELLS TO TREAT ACUTE myeloid
leukaemia
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully and discuss it
with friends, relatives and your GP if you wish. Ask if there is anything that is not
clear or if you would like more information. Take time to decide whether or not you
would like to take part.
What is the purpose of the study?
The study is part of a research project involving 50 patients aimed at the
development of a new type of treatment for Acute Myeloid Leukaemia. Treatment
of leukaemia with special drugs (chemotherapy) is often successful in making
patients better for a period of time, this is called remission. However, small numbers
of leukaemia cells are able to survive and these may cause the leukaemia to come
back. We are trying to develop an alternative form of treatment which aims to use
your body's own defences to destroy these residual leukaemia cells. The new
treatment is therefore like a vaccine against leukaemia and will be used in
combination with standard drug treatments.
Why am I being asked to take part in this study?
You are being asked to participate in this study as you have acute myeloid leukaemia
that may be difficult to cure by chemotherapy alone.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you
will be give this information sheet to keep and be asked to sign a consent form. If
you decide to take part you are still free to withdraw at any time and without giving a
reason. This will not affect the standard of care you receive.
What will it involve?
You will have some of your leukaemia cells removed either by taking a blood sample
or, if this is not possible because of low numbers of leukaemia cells in your blood, by
taking a sample of your bone marrow or by going onto a cell separator machine. If
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you need to go on the cell separator machine your doctor will give you a separate
leaflet explaining what this involves.
A portion of the leukaemia cells that we collect will be tested to see if they are
suitable to be used as a vaccine for you. The remaining leukaemia cells will be
stored down for later use. Your blood will also be tested for HIV and the viruses that
cause hepatitis as this is routinely required for this type of treatment.
You will then receive drugs aimed at achieving remission of the leukaemia. The
consultant in charge of your care will make the decision as to which treatment you
receive. If this treatment is successful we will take some of the leukaemia cells that
were stored at the start of the study and grow them under special conditions in the
laboratory to make them able to help your body recognise any remaining leukaemia
cells in order to destroy them. These cells are then specially treated to prevent them
growing again once they are given back. The cells will be given to you by a series of
four injections at weekly intervals under the skin. Following each injection you will
need to stay in the ward for four hours for routine monitoring.
Before you receive the first injection you will be given the opportunity to consider
whether you wish to continue in the study and receive the injections. If you do wish
to receive the injections you will be asked to sign a form consenting to this
procedure.
A blood sample (15mL/3 teaspoons) will be taken before each of these injections and
at 1 week, 3 weeks and 9 weeks after the last injection to count your blood cells and
check that your liver and kidneys are working properly.
In addition, to check how the treatment is working, you will have the following
samples taken
• A blood sample (50mL/10 teaspoons) before the first injection of the cells and at
2 weeks, 4 weeks, 6 weeks and then every 12 weeks after the first injection.
• A sample of bone marrow (5-10mL/l-2 teaspoons) before the first injection and
at 2 weeks, 4 weeks and 12 weeks after the first injection.
You will also be given a simple patient diary, asking questions about discomfort at
the injection site, which you will be asked to fill in daily for seven days after each
injection.
After the treatment you will have blood samples (10mL/2 teaspoons) taken at regular
intervals and bone marrow samples every three months to check that the leukaemia
has not come back.
If all your cells are not used for your treatment, with your permission they will be
destroyed.
You will be given a card saying that you are taking part in a research project and
giving details of the study. You will be asked to carry this card with you at all times.
What treatment will I receive ifI do not take part in the study?
You will receive drugs aimed at achieving remission of the leukaemia. The
consultant in charge of your care will make the decision as to which treatment you
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receive. You will not have some of your leukaemia cells stored at the start of the
study for growing in the laboratory to try and make a vaccine, so you will not receive
the four injections at weekly intervals. You will have blood samples (lOmL/2
teaspoons) taken at regular intervals and bone marrow samples every three months to
check that the leukaemia has not come back.
What risks are involved in takingpart in the study?
Your own doctor will not admit you to the study unless he/she thinks you are fit
enough to have the cell harvest procedure performed and undergo treatment.
There is a small risk of allergic reactions, dizziness or tingling sensations
associated with having the cell harvest procedure but a doctor will assess
you beforehand to ensure that you are fit enough to undergo it. In common
with all people who give blood donations you will be tested for viruses such
as HIV and those causing hepatitis. In the event that you test positive for any
of the viruses you will be informed about the results and their potential
significance.
We cannot guarantee that you will be able to receive your cells back. Your leukaemia
cells may not be capable of undergoing the change needed to help your body
recognise any remaining leukaemia cells. Also, there is a risk that your cells could
become infected while being grown in the laboratory, in which case it would be
dangerous for you to receive them back. However, every effort is made to prevent
such infections occurring.
You may experience some temporary discomfort and redness at the injection site.
What are the possible benefits of taking part in the study?
We hope the treatment will help you. However, this cannot be guaranteed. The
information we get from this study may help us to treat future patients with leukaemia
better.
Will my takingpart in this study be kept confidential?
All information obtained from this study which can be identified with you will remain
confidential. Although you will be named in internal study documentation, your
name will not be disclosed in any external reports or publications.
Your medical notes may be examined by responsible staff from the hospital, study
team or from regulatory authorities where it is relevant to the research but all
information in your records will be treated in strict confidence.
Your GP will be informed about your taking part in this study with your permission.
What ifsomething goes wrong?
If you are harmed by taking part in this research project, there are no special
compensation arrangements. If you are harmed due to someone's negligence, then
you may have grounds for a legal action but you may have to pay for it. Regardless of
this, if you wish to complain about any aspect of the way you have been approached
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or treated during the course of this study, the normal National Health Service
complaints mechanisms may be available to you.
What will happen ifnew information becomes available during the study?
Sometimes during the course of a study new information becomes available. Your
doctor will talk to you about this and discuss with you whether you want to continue
in the study. If you decide to withdraw, your doctor will make arrangements for
your care to continue. If you decide to stay in the study you may be asked to sign an
updated consent form.
Will takingpart in this study affect my insurance?
If you have private medical insurance you should let the insurers know you intend to
take part in a research project. They will be able to tell you if this will affect your
medical insurance.
Who is organising the study?
The study is being organised by the Department of Oncology, University of
Edinburgh, the Scottish National Blood Transfusion Service (SNBTS) Cell
Therapeutics Group and the Department of Clinical and Laboratory Haematology
Oncology, Western General Hospital, Edinburgh in collaboration with your local
hospital.
Who has reviewed the study?
The study protocol has been reviewed by the Leukaemia Research Fund Clinical
Trials Committee, by the Medicines Control Agency and by the Scottish Multicentre
Research Ethics Committee and Local Research Ethics Committee.
Can I discuss the study with a Doctor who is not involved with running the
study?
Dr (name of local contact) is a Doctor working within the Department of
Haematology who is not directly involved in the running of the study but who is
available to answer questions about the study if required.
How can Ifind out the results of the study?
Once the study is complete the results will be published in a medical journal. Your
doctor will be able to tell you whether the new treatment works better than drugs
alone and will let you have a copy of the published results if you wish to see them.
Contact for further information
(Insert name oflocal investigator)
(Insert contact details oflocal investigator)
You can contact your local clinical investigator or a member of his/her team
at any time, the staff will be able to help you.
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Thank you for taking the time and trouble to read this information sheet and consider
taking part in the study, your co-operation is appreciated.
If you agree to take part, you should sign the standard consent form that is presented
with this document. You will be given a copy of this information sheet and the
signed consent form to keep.
TO BE KEPT BY THE PATIENT
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APPENDIX II - PATIENT CONSENT FORM
Hospital Headed Paper
A STUDY OF USING CHEMOTHERAPY AND A VACCINE DEVELOPED
FROM PATIENTS' OWN LEUKAEMIA CELLS TO TREAT ACUTE myeloid
leukaemia
Please initial box
1. I confirm that I have read and understood the information sheet dated 16/7/01 (version
Two) on the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw at any
time, without giving a reason and without my medical care or legal rights being
affected.
^ I linHprstanH that spptinns r*f mv mpHical nntPQ mav hp IooWpH at hv rpsnnnsihlp staff
hospital, study team or from regulatory authorities where it is relevant to my taking
part in research.
I give my permission for these individuals to have access to my records, and
understand that any
infr*rmotiAn ir» m\/ rar<r\r/^c xx/i 11 Ka fraofprl in ctrinf nnnfIrlanpp
4. I agree to my GP being notified ofmy participation in this study
5. I agree to take part in the above study
Name of Patient (Block Capitals) Signature Date
Name of Doctor Signature
Date
Telephone number(s) where patient can be contacted:
Home: ( ) Work: ( )







APPENDIX III - PATIENT CONSENT FORM - REINJECTION OF
LEUKAEMIA CELLS
Hospital Headed Paper
A STUDY OF USING CHEMOTHERAPY AND A VACCINE DEVELOPED
FROM PATIENTS' OWN LEUKAEMIA CELLS TO TREAT ACUTE myeloid
leukaemia
Please initial box
1. 1 confirm that I am still content to participate in the above study and have had the
opportunity to ask further questions.
2. 1 consent to re-iniection ofmv cells □
Name of Patient (Block Capitals) Signature Date






APPENDIX IV - GP LETTER
Hospital Headed Paper
Dear Dr
RE: A PHASE I/II Study of vaccination with dendritic-like leukaemia cells
generated from primary acute myeloid leukaemia blasts as immunotherapy for acute
myeloid leukaemia
I am writing to inform you that the person named below, who is registered with you,
has agreed to take part in this research project as a patient, and has consented to my
contacting you.
Please keep this as a permanent record of their involvement. I will also inform you





The study aims to examine the utility of autologous cultured dendritic-like
leukaemia cells as adoptive immunotherapy in patients over the age of 60 with
newly presenting, or over 50 with relapsed, acute myeloid leukaemia.
The patient's own leukaemia cells are cultured ex vivo in order to induce their
differentiation into dendritic-like cells, which can then be used as autologous
vaccines. Clinical studies using dendritic cells to treat a variety of malignant disease
have not shown any serious adverse events.
Your patient will be asked to donate either a lOOmL sample of blood or 5mL of bone
marrow aspirate or have a leucapheresis procedure performed, depending on
peripheral blood blast cell count. Leukaemia cells derived from this sample will be
cultured in the laboratory to see if they undergo dendritic cell differentiation. If they
do, the patient will be eligible for the vaccination part of the study. Patients will be
treated with chemotherapy to induce remission using treatment regimens decided by
the physician in overall charge of the patient's care. The patient will then be
vaccinated with autologous dendritic-like leukaemia cells that have been prepared in
a tissue culture environment dedicated to the use of human cells, using standard
aseptic techniques. Infection of the product during the culture period is a potential
risk, and sterility and close monitoring will be employed.
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This is a phase I/II study designed to assess feasibility and tolerability of this
treatment approach. If you would like to discuss the study with one of the principal
investigators or the local investigator please contact them as detailed below:
Yours sincerely,
(Insert local investigator details)
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APPENDIX V: Induction of dendritic cell differentiation in
primary AML blasts derived from patients with Acute Myeloid
leukaemia
Peripheral blood or bone marrow samples were obtained from 42 patients presenting
with newly diagnosed or relapsed Acute Myeloid Leukaemia.
Leukaemia cells were cultured with GM-CSF (50ng/mL) and IL-4 (15ng/Ll) for 4
days followed by a further 3-7 days culture with GM-CSF (50ng/mL) and
TNFa (15ng/mL) or CD40 ligand (lpg/mL). Evidence for dendritic cell
differentiation was based on changes in morphology and flow cytometric analysis of
costimulatory molecule and dendritic cell associated marker expression.
Of 42 patients in 4 cases poor viability over the culture period prevented further
evaluation. 22 cases showed evidence for dendritic cell like differentiation based on
their acquisition of characteristic dendritic cell morphology and expression of
costimulatory molecules CD40, CD80, CD86 and the dendritic cell associated
marker CD83. (Fig 1+2). In 19 patients the leukaemia cells appeared to be resistant
to dendritic cell differentiation.
Figure 1.
Characteristic dendritic cell morphology following cytokine-induced
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Figure 2. Expression of costimulatory molecules following dendritic
differentiation on leukaemia cells derived from three individual AML cases
APPENDIX VI: Functional analysis of dendritic-like leukaemia
cells
Dendritic-like leukaemia cells derivedfrom primary AML blasts by cytokine induced
differentiation were tested for their ability to stimulate allogeneic T lymphocytes in
mixed leukaemia lymphocyte reactions.
Mitomycin-C treated dendritic-like leukaemia cells were cultured in wells of a 96
well plate at various responder:stimulator ratios with lymphocytes derived from
allogeneic normal volunteer donors. As controls, freshly thawed leukaemia cells,
derived from the same patient as the dendritic cell like leukaemia cells, were used as
stimulators in the same way. After 4 days culture lpCi of thymidine was added to
each well and the cells were cultured for a further 18 hours. Activity per well as





Allogeneic mixed leukaemia lymphocyte reactions for 6 AML cases in which the
leukaemia cells underwent dendritic cell differentiation. Responders: allogeneic
peripheral blood lymphocytes. Stimulators: leukemic cells either unmodified (AML)
or following DLLC differentiation (DLLC) derived from the same patient.
Conclusions
The data from the allogeneic mixed leukaemia lymphocyte reactions demonstrates
that, in contrast to unmodified leukaemia cells, dendritic-like leukaemia cells are
potent stimulators of allogeneic lymphocytes.
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Dendritic-like leukaemia cells can induce the development of autologous
cytotoxic T lymphocytes that can recognise and destroy unmodified
leukaemia cell targets
Co-culture of mitomycin-C treated dendritic-like leukaemia cells with autologous T
lymphocytes could induce the development of cytotoxic T lymphocytes that were




LDH release cytotoxicity assay for 2 AML cases. Autologous T lymphocytes co-
cultured for 3 days with dendritic-like leukaemia cells are capable of destroying
unmodified leukaemia cells targets. Controls are T cells that have been cultured
either with IL2 alone or with unmodified autologous leukaemia cells.
Conclusions
Dendritic-like leukaemia cells have the ability to prime autologous T lymphocytes
such that they are able to specifically recognise and destroy unmodified leukaemia
cell targets.
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APPENDIX VII: Tissue Bank Standard Operating Procedures
SOP Document 1
SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE
SOUTH EAST REGIONAL CENTRE & DEPARTMENT OF TRANSFUSION
MEDICINE
SOP NoTSD 256 01
Tissue Service
Master Document
Preparation of Autologous Dendritic-like Leukaemia Cells
for Infusion into Acute Myeloid Leukaemia Patients
1. OBJECTIVE
To generate dendritic-like leukaemia cells from acute myeloid leukaemia blasts.
2. EQUIPMENT
Microbiological Safety Cabinet (MSC)
C02 incubator (LEEC) at 37°C
Inverted microscope (Leitz)
Benchtop centrifuge, Model BR401 (Denley)
Neubauer haemocytometer and coverslip
Automatic pipetter
Mr Frosty cell freezer (Nalgene)
A range of Gilson pipettes
A range of pipettes
A shaking table (Denley)
Gammacell 3000 Elan Irradiator with double caesium -137 source
3. MATERIALS
RPMI 1640 without phenol red (Sigma and PFC)
L-glutamine, 200mM , (Sigma)
Sterile sachets containing Tryptic Soy Broth (TSB) and Thioglycollate (THIO)
universals (Cherwell)
Nigrosin (5% w/v) (NRU)
Sterile AB serum (SEBTS)
15% (w/v) di-potassium EDTA (BDH)
IL-4, 5og vial, (R&D Systems), catalogue no 204-IL/CF
Saline for injection (Baxter)
GM-CSF, 400og vial, (Sandoz)
Lymphoprep (Nycomed), 300ml vial
TNF-a (R&D systems)
IFN-y 0.5 ml vial (Boerhinger Ingelheim)
Poly:IC (Sigma)
DMSO, sterile filtered and tissue culture tested (Sigma)
Settle Plates (Cherwell)
4. DISPOSABLES
Accuspin tubes, c/n A2055, (Sigma)
Selection of syringes and needles
50ml sterile universals
15ml sterile centrifuge tubes
sleeve of 25cm2 flasks with filter cap (Costar)
sleeve of 25cm2 flasks, non TC treated (Iwaki)
sleeve of 75cm2 flasks with filter cap (Costar)
selection of single wrap pipettes and pastettes
2ml sterile Cryovials
white and yellow Gilson tips (autoclaved in-house)
Sterets
Sterile drapes
Sterile syringe caps (Avon)
selection of Sterile surgeons' gloves
Sterile disposable scalpel blades
5. PROCEDURE
5.1 PREPARATION OF REAGENTS
5.1.1. RPMI-1640 + 5% AB serum
5.1.1.1 This medium bought from Sigma (500ml bottle) is used as diluent for
the stock cytokine solutions and for the growth medium base.
5.1.1.2 Before use, 25ml of AB serum and 5ml of glutamine are added to each
bottle in the MSC using 5 ml disposable pipettes.
5.1.1.3 This medium once made up is used in the following steps and
referred to as complete RPMI.
5.1.1.4. Where RPMI is referred to, then PFC RPMI 1640 without phenol red or
ANY OTHER ADDITIONS is to be used.
GM-CSF is prepared as stock and kept frozen (-70°C) until required
for use. IL-4 is reconstituted when required
5.1.2. IL-4
5.1.2.1 IL4, supplied by R&D Systems, is presented as sterile 5ug vial.
5.1.2.2 A stock solution must be made at 500ng/ml.
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5.1.2.3 The solution is prepared within the MSC in the General Laboratory.
5.1.2.4 1ml of sterile complete RPMI is added using Gilson and sterile tip to
the vial to dissolve the powder.
5.1.2.5 This solution is removed and transferred to a universal container.
Steps 5.1.2.4 and .5 are then repeated until the IL4 vial has been
rinsed out with a total of 5ml complete RPMI.
5.1.2.6 A further 5ml complete RPMI is added to the universal container, and
the contents mixed by gentle swirling.
5.1.2.7 2 x 250pl aliquots are removed into TSB and Thioglycollate for sterility
testing.
5.1.2.8 The remainder is used immediately and any small residue discarded
for R&D use (dispensed as 1ml aliquots into 2ml sterile cryovials)




date of expiry (one year from date of formulation)
batch number
The stock solutions must be stored at -70°C prior to use.
5.1.2.10 Batch formulation record must be completed.
5.1.3 GM-CSF
5.1.3.1 GM-CSF (Leucomax), supplied by Sandoz, is presented as a vial
containing 400pg powder.
5.1.3.2 A stock solution must be made at 10,000ng/ml.
5.1.3.3 The solution is prepared within the MSC in the General Laboratory.
5.1.3.4 1ml of sterile complete RPMI is added to the vial to dissolve the
powder.
5.1.3.5 The solution is removed and a further 39ml of complete RPMI is added
to a universal container.
5.1.3.6 2 x 1 ml aliquots are removed into TSB and THIO for sterility testing
5.1.3.7 1ml aliquots are then dispensed into 2ml sterile cryovials.





date of expiry (one year from date of formulation)
batch number
5.1.3.9 The tubes are stored at -70°C until required.
5.1.3.10 Batch formulation record must be completed.
5.1.4 TNF-a
5.1.4.1 Add the appropriate volume of RPMI to the vial to give a working
solution of 15pg/ml
5.1.4.2 Process as in 5.1.2.7 - 5.1.2.10.
5.1.5 IFN-y
5.1.5.1 Add the appropriate volume of RPMI to the vial to give a working
solution of 200pg/ml
5.1.5.2 Process as in 5.1.2.7 - 5.1.2.10.
5.1.6 Poly l:C
5.1.6.1 Add the appropriate volume of RPMI to give a working concentration
of Img.ml
5.1.6.2 Process as in 5.1.2.7 - 5.1.2.10.
5.1.7 Growth Medium
5.1.7.1 Calculate the volume required.
5.1.7.2 The basal medium used is complete RPMI prepared as in 5.1.1.
For each 10ml required take:
300pil IL-4 stock solution to give 15ng/ml final concentration
50pl GM-CSF stock solution to give 50ng/ml final concentration
10pl TNFa stock solution to give 15ng/ml final concentration
5.1.7.3. The vials of cytokines should be thawed immediately prior to use, and
any unused reagents discarded, not refrozen.
5.2 REFERRALS AND VIROLOGY TESTING
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5.2.1 Blood samples will be withdrawn from the patient no more than seven
days prior to the planned date of harvest.
Referring Consultant must complete a Donor Referral Form (see
Appendix 2). which must accompany the blood samples to the relevant
centre for the testing of mandatory virology markers.
Testing for mandatory markers will be repeated when the donation for
dendritic cell preparation is withdrawn.
5.2.2 The blood will be processed as per SOP No TSD 22401 and a unique
tissue number will be attached to the referral form.
5.3 Preparation of the Leukaemia cell harvest
5.3.1 Leukaemia cell harvest will take the form of either an apheresis pack,
or 100ml of peripheral blood or 10ml of bone marrow and clearly
labelled with the patients name, donation number, date of birth, date
and total volume withdrawn.
5.3.2 The donation will be collected by a member of staff and taken to
Tissue Services.
5.3.3 On arrival the TS must verify the identity of the donor and enter the
time of arrival in the Tissue Processing Log (see Appendix 3).
5.3.4 The donation must be sprayed with 70% (v/v) alcohol before placing it
in the transfer hatch to the general laboratory.
5.3.5 Either the virology testing laboratory, or components production area
should be telephoned to obtain the virology screening results on the
patient's donation, and the results entered in the patient's records
(Appendix 3)
5.4 MANIPULA TION IN THE GENERAL LABORATORY
5.4.1 Using a sterile medium sized drape, prepare a sterile field within the
MSC.
5.4.2 Using a syringe and needle add 15ml of Lymphoprep to the Accuspin
tubes, (the number required depends on the sample taken) .Ensure
that the Lymphoprep is equilibrated to ambient temperature. When
using an apheresis pack use a sterile plunger to depress the sinter in
the Accuspin tube to the tube shoulder before adding lymphoprep.
5.4.3 Spin at 450 x g for 30 seconds to position the Lymphoprep at the base
of the centrifuge tube.
5.4.4 Swab one access port of the donation several times using fresh
sterets.
5.4.5 If the donation is in a blood pack use a sterile scalpel blade and with
very great care, cut the tail and dispense the donation equally
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between the four tubes. Make up each tube up to 50ml with RPMI if
required (which has not had serum or glutamine added).
5.4.6 Retain 2 x 1ml aliquots for sterility testing and place in TSB and Thio
respectively.
5.4.7 Centrifuge the Accuspin for 30 minutes at 450 x g with thermostat set
to control the temperature at 18°C.
5.4.8 Remove 2 x 1ml aliquots of supernatant for sterility testing and place
in TSB and Thio respectively.
5.4.9 Using the automatic pipettor remove supernatant to within 0.5cm of
the leukocyte layer and discard the supernatant.
5.4.10 Using a plastic pastette loosen any cells adherent to the walls of the
tubes.
5.4.11 Pour the leukocyte suspension from the Accuspin tubes into 2 x 50ml
centrifuge tubes.
5.4.12 Make up to 50ml per tube with RPMI.
5.4.13 Wash by centrifugation for 5 minutes at 160 x g and remove
supernatant to waste.
5.4.14 Retain 2 x 1ml aliquots for sterility testing and place in TSB and Thio
respectively. If there appears to be a white platelet layer on the pellet,
resuspend in RPMI and centrifuge as before.
5.4.15 Re-suspend in 10ml volume complete RPMI per tube.
5.4.16 Disaggregate the pellet by pipetting up and down as 5.4.14 and
transfer the contents to one tube.
5.4.17 Perform a viable cell count:
Make a 1 in 20 dilution of the cell suspension by removing 50pl and
adding it to 950pl RPMI in a small tube. Add one volume (eg.100pl) of
this to the same volume of Nigrosin stain in a fresh tube (this need not
be done under sterile conditions). Mix and count this suspension on a
Neubauer Haemocytometer.
Count the number of lymphocytes in the 25 small squares in the
centre of the counting chamber. The cell count is calculated as follows:
Cells per ml = Number of cells in 25 squares x 104 x dilution factor 20 x
2 (addition of nigrosin and record in the patient notes -appendix 3)
The mononuclear cells will then be cryopreserved (see section 5.6)
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When the dendritic-like leukaemia cells are required the cryopreserved
cells will be thawed and a viable cell count performed
5.4.18 From the cell count the number of flasks required must be calculated.
A total of 180 x 106 cells are required to seed a 75cm2 flask, 360 x 106
cells for a 175cm2 flask and 60 x 106 cells for a 25cm2 flask. 1 x 25cm2
is required for FACS analysis.
5.4.19 Dispense the appropriate volume of cells into the flasks and label the
flasks with the unique number, date and patient's name.
The leukaemia cells will be cultured with 1000ng/mI GM-CSF and
20ng/ml IL-4. After 4 days the TNFa will be added at 25ng/ml. The
cells will then be cultured for a further 3 days. IFN-y (30ng/ml) and
polyl;C (12.5/ug/ml) will be added 24 hours prior to the end of culture.
At the end of the culture period the cells will be cryopreserved.
Refer to SOP NO TSD 236 01
5.4.20 Observe the cells on a daily basis and note their integrity. Also, note
any signs of contamination. Note any observations in appendix 4.
5.4.21 Record batch numbers of all reagent used on appendix 3.
5.5 HARVESTING AND PREPARING THE CELLS FOR INJECTION
AND CRYOPRESERVATION
Each patient will received four escalating dose injections at
weekly intervals. The doses will be 0.125x106/kg, 0.25x106/kg,
0.5x106/kg and 1x106/kg.
5.5.1 Check that the individual flasks show no signs of overt infection. The
25cm2 flask is transported to John Flughes Bennett.Laboratory,
Western General Hospital. This flask will be evaluated using the
FACS machine to establish the percentage dual positive CD40/CD83
cells present in the population. The WGH staff will phone the Tissue
Bank with the results which must be entered in the Tissue Processing
Log (appendix 5).
5.5.2 Using a sterile pipette, sample and count a 50pl volume of cell
suspension from each 75cm2 flask. Calculate the number of viable
cells per ml of culture as in 5.4.18. (record on appendix 4).
5.5.3 The cell number for vaccination is to be based on total nos. of cells
NOT on CD40/83 percentages.
5.5.4 Remove from one flask the volume containing the required number of
cells and transfer to one or more sterile centrfuge tubes as
appropriate.
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5.5.5 Centrifuge as 5.4.13. Sample 2x 1ml of the supernatant for
bacteriology testing. Remove and keep aside at least 5ml of the
supernatant. Decant the rest of the supernatant to waste.
5.5.6 Place the tube in the clean room hatch.
5.5.7 Take samples of 2nd wash supernatant for bacteriology and 1ml for IL-
4 determination and remove the remainder of the supernatant.
5.5.8 Disaggregate the cell pellet by gently flicking the base of the universal.
5.5.9 Re-suspend the cells in 0.5ml saline, draw the cell suspension into a
2ml syringe securing the port with a syringe cap. Record the batch




Patient name and date of birth.
Unique Tissue Number bar-code
Total number of cells for injection.
Date of Preparation and the dosing regimen.
Prior to vaccination cells need to be irradiated to minimum 25Gy using a local
MCA accredited irradiation source. Refer to SOP No 99 327 013.
Place in the syringe transport container.
Stick a pre-prepared label onto the syringe container and arrange
delivery to the clinic.
The label must contain the following information:
5.6 CRYOPRESERVING THE CELLS
5.6.1 Calculate and then dispense the appropriate volumes of cells to give
the cell numbers required into universals and label with appropriate
cell number. Pre-chill the required volume of cryoprotectant medium.
5.6.2 Centrifuge the cells as 5.4.13.
5.6.3 Decant the supernatant to waste.
5.6.4 Disaggregate the cell pellet by gently flicking the base of the universal.
5.6.5 Add 0.5ml AB serum. Leave the resuspended cells on ice for 10-15
minutes.
5.6.6 Add 0.5ml cryoprotectant medium (90% AB serum, 10% DMSO),
dropwise with gentle mixing.
5.6.7 Place in a cryovial previously labelled with
Patient name and date of birth.
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Unique Tissue Number bar-code
Total number of cells for injection.
Date of Preparation and the dosing regimen.
5.6.8 Place the ampoules in the Mr Frosty cell freezer and store the -80°C
freezer for at least 4 hours before moving the vials to the liquid
nitrogen vapour phase of the 'Penguin' tank for long term storage.
5.6.9 Record the location in the inventory log and in processing record(
appendix 5).
5.7 PREPARING THE CRYOPRESERVED CELLS FOR INJECTION
5.7.1 Prepare 10ml complete RPMI, adding sufficient AB serum to make the
concentration of serum to 10%.
5.7.2 Remove the appropriate ampoules from the nitrogen tank.
5.7.3 Allow the vial(s) of frozen cells to thaw by placing it/them in a tray of
warm sterile water
5.7.4 Immediately after the vial(s) have thawed, transfer the contents to a
15ml centrifuge tube using a sterile pastette. Rinse out the vial(s) with
1.5ml of 10%AB serum in RPMI, so that the entire contents of the vial(s)
have been transferred to the centrifuge tube. Take 100]ul sample for
sterility testing
5.7.5 Add the remainder of the RPMI with 10% AB serum to the tube, very
gradually at first, using a pastette, and gently shaking the tube during
addition of medium.
5.7.6 Centrifuge the tube as in 5.4.13. Sample 2 x 1ml of the supernatant for
bacteriology testing and remove the remaining supernatant to waste.
5.7.7 Process as in 5.5.6 to 5.5.12 omitting 5.5.7.
5.7.8 Record batch numbers of reagents, cell numbers etc on appendix 6
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SOP Document 2
X TISSUE SERVICE























Telephone No 0131-5365751 Fax No: 0131-536-
Dendritic Cell Donor
Referral Form










Volume of Apheresis/Whole Blood/Bone Marrow withdrawn: ml











s 21 Ellen's Glen Road, Edinburgh EH 17 7QT
'XV/ 0131 536 5751/6




Volume of Leukaemia cell harvest Withdrawn: ml
Source of leukaemia cells: Peripheral blood/apheresis/'bone marrow
Date and Time of Retrieval:
Tissue Despatch
Transport by:
Received at Tissue Services by:




Enter Buffy Coat unit no here:
Phone Virology to confirm negative results on buffy coat/apheresis unit virology
Confirmed verbally: Y/N by TS staff Sign here:
Time and Date Processed:
Volume ofBuffy Coat or Apheresis Pack Received: ml Cabinet Safe/Unsafe: Sign:
Batch Record of Reagents & Equipment Used:-

























Growth medium added: check here □ Sign
Growth Phase
Observation Day 2 Date: Initials:
Observation Day 3 Date: Initials:
Observation Day 4 Date: Initials:
Observation Day 5 Date: Initials:
Observation Day 6 Date: Initials:
Observation Day 7 Date: Initials:
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Cell Harvest and Cryopreservation
Cabinet Safe/Unsafe: Sign:
Batch Record of Reagents & Equipment Used:-
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Check the flasks to ensure there are no signs of overt infection:
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APPENDIX VIII Validation of irradiation as a means of removing
the engraftment potential of primary AML blasts
Principle
To establish that y irradiation of primary leukaemia cells will remove any potential for
leukaemia re-engraftment following vaccination of patients with autologous dendritic-like
leukaemia cells
1.1. Method
Cryopreserved leukaemia cells derived from 10 patients with AML were thawed rapidly.
Following washing with complete medium a viable cell count was performed.
For each patient 5xl07-l0s leukaemia cells were resuspended in l mL phosphate buffered
saline (PBS) and then added to 2mL sterile syringes. The remaining cells were
resuspended in PBS and incubated at 37°C.
The 10 syringes were then irradiated to 25Gy using a Caesium 137 source.
A viable cell count was then performed for both the irradiated and non-irradiated
leukaemia cells. The cell density was adjusted to 2xl06/mL in PBS
250pL of the cell suspension was added to 2.5mL of Methocult GF H4535 (Stemcell
Technologies) in l5mL conical tubes and mixed by vortexing. The cell suspension was
allowed to stand for 10 minutes and then lmL was added in duplicate for each patient,
both irradiated and non-irradiated leukaemia cells, to the wells of a 4-well plate.
The plates were then incubated for 14 days at 37°C, 5%CC>2 in a humidified atmosphere.
The number of colonies per well was counted and the mean value for the two wells
recorded
1.2. Results
The mean colony number for the 10 individual samples of non-irradiated leukaemia cells
was 46 (range 3-114). Irradiation of leukaemia cells completely abolished their
clonogenic potential with no colonies seen in any wells that had been seeded with
leukaemia cells that had received 25Gy irradiation.
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APPENDIX IX: Data on adverse events from the Phase I clinical
trial of MUC-1 pulsed dendritic cells as immunotherapy for
patients with metastatic carcinoma

























Hb 105 14 days
5 Fatigue 7 days
6 Fatigue 14 days
7 Fatigue 3 months Fatigue 14 days
8
9 ? fever 1 night
10 Dry throat 24 hours
11
12
N.B. There were no grade 3 or 4 toxicities noted
APPENDIX X: Monitoring of immune function in patients with
AML
Patients fulfilling the entry criteria for the study will be pre-screened to ensure that it is
possible to generate cytokine differentiated DLLC from their peripheral blood.
The phenotype of undifferentiated AML cells and cytokine differentiated AML cells will
be assessed by flow cytometry using combinations of fluorochrome conjugated
antibodies to CDla, CD14, CD80, CD86, CD83, CD40, CD33, CD54 and CD95. IL-12
(p70) production by DLLC in response to various maturational agents will be measured
by ELISA.
Patients will donate 50mL peripheral blood at a number of time points through out the
study: at the time of the leukaemia cell harvest for the pre-screen, following completion
of chemotherapy (i.e. shortly before vaccination with autologous DLLC) and at 2, 4, 6
and 12 weeks following vaccination, according to the Trial Schedule (Appendix XII).
Patients remaining in remission at 12 weeks post vaccination will be monitored at 12
weekly intervals thereafter until relapse. This will allow for investigation of patients'
immune responses in general and specifically to AML cells before and after receiving
immunotherapy.
Blood samples will be diluted 1:1 with RPMI culture medium before separation of
PBMC on Ficoll/Hypaque. Following centrifugation plasma will be collected and stored
for analysis for immunosuppressive factors. Recovered PBMC will be washed twice,
where necessary separated from AML cells and counted before use. The phenotype of
isolated AML cells will be assessed by flow cytometry.
The phenotype and activation state of peripheral blood mononuclear cells (PBMC),
freshly isolated and following 7 days culture in the presence of culture medium (CM,
control), ConA and PF1A (mitogen), autologous AML cells, autologous cytokine
differentiated AML cells and allogeneic cytokine differentiated AML cells will be
measured by flow cytometric analysis (FACS).
Cells will be stained with combinations of antibodies to CD 19 (B lymphocytes), CD3
(total T lymphocytes), CD4 (helper T lymphocytes), CD8 (cytotoxic T lymphocytes) and
the activation markers CD25 (IL-2 receptor), CD45R0 (activation memory marker),
CD95L, HLA Class I and HLA-DR (MHC class II). Samples will be analysed using a
Becton Dickinson FACSCaliber.
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The proliferative responses of patients' T cells to mitogens, autologous undifferentiated
leukaemic cells and autologous DLLC will be assessed by performing standard tritiated
thymidine uptake assays.
To assess the generation of cytotoxic T lymphocytes PBMC will be cultured for 5 days
with culture medium alone, or medium supplemented with cytokines IL-2 and IL-7,
autologous DLLC plus IL-2 and IL-7 or allogeneic cytokine differentiated AML cells
plus IL-2 and IL-7. Cultured cells (effector cells) will be harvested and titrated at
various effector cell to target cell (AML cells) ratios, treated to remove dead cells prior
to use. Their ability to kill autologous AML cells will be measured after 3 hours
incubation using the LDH assay. In addition an assay of T cell interferon gamma
production will be used.
SUMMARY OF IMMUNE FUNCTION MONITORING
Immunophenotypic analysis of AML and DLLC
AML Cell surface moleculesCDla, CD 14, CD33, CD40, CD54, CD80,
CD83, CD86, CD95, HLA Class I and II
Cytokine secretionIL-12 (p70), IL-10, VEGF, TGFp
DLLC Cell surface moleculesCDla, CD14, CD33, CD40, CD54, CD80,
CD83, CD86, CD95, HLA Class I and II
Cytokine secretionIL-12 (p70), IL-10, VEGF, TGFp
Immunophenotypic analysis of lymphocyte numbers and activation status of T cells
T cells Numbers and proportionsCD3 positive, CD4:CD8 ratio
Activation status CD25, CD45RO
Response to mitogensCD25, CD45RO
Others CD95, HLA Class I and II
B cells Numbers CD 19 positive
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Proliferation assays
PBMNCs used as a source of autologous T cells
Mitogens ConA, PHA Proliferation measured by 3HTdR uptake
MLLR autologous AML Proliferation measured by 3HTdR uptake
autologous DLLC
Cytotoxicity assays
PBMNCs used as a source of autologous T cells
Co-culture autologous AML CTL generation measured by Cr 51 -release or
autologous DLLC ELISPOT assay
Abbreviations: AML=freshly thawed unmodified leukaemia cell
DLLC=leukaemia cells following cytokine induced differentiation
PBMNCs=peripheral blood mononuclear cells
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APPENDIX XI: Monitoring of Minimal Residual Disease (MRD)
Disappearance or reduction in the level of MRD in AML patients undergoing
vaccination with dendritic cells may provide evidence of an anti-leukaemic activity.
There is increasing evidence that during clinical remission, high or increasing levels of
MRD, as measured by quantitation of specific fusion transcripts, are predictive of
impending relapse. Conversely absent or very low levels of MRD correlate with durable
remission. Monitoring ofMRD will be carried out using real-time quantitative RT-PCR.
This sensitive technique will allow the accurate quantitation of low levels of MRD in
over 80% of AML patients. The bone marrow karyotypes of patients in the pilot study
will be known at presentation. Patients with t(8;21) and inv 16 will be monitored by
quantitation of AML 1-MTG8 and CBFB-MYH 11 transcripts respectively. However
the majority of AML patients will not have specific chromosomal translocations and
therefore the WT1 gene, which is over expressed in 80% of AML patients, will be used
as a marker ofMRD. The WT1 gene is being increasingly found to be a useful predictor
of clinical relapse and survival.
In this study all patients (de novo or at relapse) will have their DNA stored at the time of
screening for their suitability to enter the study. Those who become eligible for the
vaccination programme will have the WT1 gene expression assessed and/or checked for
the presence of specific fusion transcripts e.g. AML 1-MTG8 and CBFB/MYH 11.
Levels of the appropriate transcripts in both peripheral blood and bone marrow will be
quantitated using the Taqman machine (real-time RT-PCR) at specific time points (pre-
vaccination, day +14, day +28, day +84), as shown on the trial schedule and
subsequently at 3 monthly intervals during the first year and at 4 monthly intervals
during the second year of remission. The MRD work will be carried out in the































































































































































APPENDIX XIII: DECLARATION OF HELSINKI
Ethical Principles for Medical Research Involving Human Subjects
Adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964
and amended by the
29th WMA General Assembly, Tokyo, Japan, October 1975
35th WMA General Assembly, Venice, Italy, October 1983
41st WMA General Assembly, Hong Kong, September 1989
48th WMA General Assembly, Somerset West, Republic of South Africa,
October 1996
and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000
A. INTRODUCTION
1. The World Medical Association has developed the Declaration of Helsinki as a
statement of ethical principles to provide guidance to physicians and other
participants in medical research involving human subjects. Medical research
involving human subjects includes research on identifiable human material or
identifiable data.
2. It is the duty of the physician to promote and safeguard the health of the people.
The physician's knowledge and conscience are dedicated to the fulfillment of this
duty.
3. The Declaration of Geneva of the World Medical Association binds the physician
with the words, "The health ofmy patient will be my first consideration," and the
International Code of Medical Ethics declares that, "A physician shall act only in
the patient's interest when providing medical care which might have the effect of
weakening the physical and mental condition of the patient."
4. Medical progress is based on research which ultimately must rest in part on
experimentation involving human subjects.
5. In medical research on human subjects, considerations related to the well-being
of the human subject should take precedence over the interests of science and
society.
6. The primary purpose of medical research involving human subjects is to improve
prophylactic, diagnostic and therapeutic procedures and the understanding of the
aetiology and pathogenesis of disease. Even the best proven prophylactic,
diagnostic, and therapeutic methods must continuously be challenged through
research for their effectiveness, efficiency, accessibility and quality.
7. In current medical practice and in medical research, most prophylactic,
diagnostic and therapeutic procedures involve risks and burdens.
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8. Medical research is subject to ethical standards that promote respect for all
human beings and protect their health and rights. Some research populations are
vulnerable and need special protection. The particular needs of the economically
and medically disadvantaged must be recognized. Special attention is also
required for those who cannot give or refuse consent for themselves, for those
who may be subject to giving consent under duress, for those who will not
benefit personally from the research and for those for whom the research is
combined with care.
9. Research Investigators should be aware of the ethical, legal and regulatory
requirements for research on human subjects in their own countries as well as
applicable international requirements. No national ethical, legal or regulatory
requirement should be allowed to reduce or eliminate any of the protections for
human subjects set forth in this Declaration.
B. BASIC PRINCIPLES FOR ALL MEDICAL RESEARCH
10. It is the duty of the physician in medical research to protect the life, health,
privacy, and dignity of the human subject.
11. Medical research involving human subjects must conform to generally accepted
scientific principles, be based on a thorough knowledge of the scientific
literature, other relevant sources of information, and on adequate laboratory and,
where appropriate, animal experimentation.
12. Appropriate caution must be exercised in the conduct of research which may
affect the environment, and the welfare of animals used for research must be
respected.
13. The design and performance of each experimental procedure involving human
subjects should be clearly formulated in an experimental protocol. This protocol
should be submitted for consideration, comment, guidance, and where
appropriate, approval to a specially appointed ethical review committee, which
must be independent of the investigator, the sponsor or any other kind of undue
influence. This independent committee should be in conformity with the laws and
regulations of the country in which the research experiment is performed. The
committee has the right to monitor ongoing trials. The researcher has the
obligation to provide monitoring information to the committee, especially any
serious adverse events. The researcher should also submit to the committee, for
review, information regarding funding, sponsors, institutional affiliations, other
potential conflicts of interest and incentives for subjects.
14. The research protocol should always contain a statement of the ethical
considerations involved and should indicate that there is compliance with the
principles enunciated in this Declaration.
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15. Medical research involving human subjects should be conducted only by
scientifically qualified persons and under the supervision of a clinically
competent medical person. The responsibility for the human subject must always
rest with a medically qualified person and never rest on the subject of the
research, even though the subject has given consent.
16. Every medical research project involving human subjects should be preceded by
careful assessment of predictable risks and burdens in comparison with
foreseeable benefits to the subject or to others. This does not preclude the
participation of healthy volunteers in medical research. The design of all studies
should be publicly available.
17. Physicians should abstain from engaging in research projects involving human
subjects unless they are confident that the risks involved have been adequately
assessed and can be satisfactorily managed. Physicians should cease any
investigation if the risks are found to outweigh the potential benefits or if there is
conclusive proof of positive and beneficial results.
18. Medical research involving human subjects should only be conducted if the
importance of the objective outweighs the inherent risks and burdens to the
subject. This is especially important when the human subjects are healthy
volunteers.
19. Medical research is only justified if there is a reasonable likelihood that the
populations in which the research is carried out stand to benefit from the results
of the research.
20. The subjects must be volunteers and informed participants in the research project.
21. The right of research subjects to safeguard their integrity must always be
respected. Every precaution should be taken to respect the privacy of the subject,
the confidentiality of the patient's information and to minimize the impact of the
study on the subject's physical and mental integrity and on the personality of the
subject.
22. In any research on human beings, each potential subject must be adequately
informed of the aims, methods, sources of funding, any possible conflicts of
interest, institutional affiliations of the researcher, the anticipated benefits and
potential risks of the study and the discomfort it may entail. The subject should
be informed of the right to abstain from participation in the study or to withdraw
consent to participate at any time without reprisal. After ensuring that the subject
has understood the information, the physician should then obtain the subject's
freely-given informed consent, preferably in writing. If the consent cannot be
obtained in writing, the non-written consent must be formally documented and
witnessed.
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23. When obtaining informed consent for the research project the physician should
be particularly cautious if the subject is in a dependent relationship with the
physician or may consent under duress. In that case the informed consent should
be obtained by a well-informed physician who is not engaged in the investigation
and who is completely independent of this relationship.
24. For a research subject who is legally incompetent, physically or mentally
incapable of giving consent or is a legally incompetent minor, the investigator
must obtain informed consent from the legally authorized representative in
accordance with applicable law. These groups should not be included in research
unless the research is necessary to promote the health of the population
represented and this research cannot instead be performed on legally competent
persons.
25. When a subject deemed legally incompetent, such as a minor child, is able to
give assent to decisions about participation in research, the investigator must
obtain that assent in addition to the consent of the legally authorized
representative.
26. Research on individuals from whom it is not possible to obtain consent, including
proxy or advance consent, should be done only if the physical/mental condition
that prevents obtaining informed consent is a necessary characteristic of the
research population. The specific reasons for involving research subjects with a
condition that renders them unable to give informed consent should be stated in
the experimental protocol for consideration and approval of the review
committee. The protocol should state that consent to remain in the research
should be obtained as soon as possible from the individual or a legally authorized
surrogate.
27. Both authors and publishers have ethical obligations. In publication of the results
of research, the investigators are obliged to preserve the accuracy of the results.
Negative as well as positive results should be published or otherwise publicly
available. Sources of funding, institutional affiliations and any possible conflicts
of interest should be declared in the publication. Reports of experimentation not
in accordance with the principles laid down in this Declaration should not be
accepted for publication.
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH
COMBINED WITH MEDICAL CARE
28. The physician may combine medical research with medical care, only to the
extent that the research is justified by its potential prophylactic, diagnostic or
therapeutic value. When medical research is combined with medical care,
additional standards apply to protect the patients who are research subjects.
29. The benefits, risks, burdens and effectiveness of a new method should be tested
against those of the best current prophylactic, diagnostic, and therapeutic
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methods. This does not exclude the use of placebo, or no treatment, in studies
where no proven prophylactic, diagnostic or therapeutic method exists.
30. At the conclusion of the study, every patient entered into the study should be
assured of access to the best proven prophylactic, diagnostic and therapeutic
methods identified by the study.
31. The physician should fully inform the patient which aspects of the care are
related to the research. The refusal of a patient to participate in a study must
never interfere with the patient-physician relationship.
32. In the treatment of a patient, where proven prophylactic, diagnostic and
therapeutic methods do not exist or have been ineffective, the physician, with
informed consent from the patient, must be free to use unproven or new
prophylactic, diagnostic and therapeutic measures, if in the physician's judgement
it offers hope of saving life, re-establishing health or alleviating suffering. Where
possible, these measures should be made the object of research, designed to
evaluate their safety and efficacy. In all cases, new information should be
recorded and, where appropriate, published. The other relevant guidelines of this
Declaration should be followed.
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Phase l/ll study of vaccination with dendritic-like leukaemia cells
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Summary
Twenty-two patients with acute myeloid leukaemia were recruited into a
phase I/II clinical trial investigating the vaccination of patients in complete
remission (CR) with autologous dendritic-like leukaemia cells (DLLC). At
trial entry, leukaemia cells were harvested and tested for their ability to
undergo cytokine-induced dendritic cell differentiation. Patients were then
treated with intensive chemotherapy. Five patients achieved both CR and had
leukaemia cells that successfully underwent differentiation and therefore
proceeded to vaccination. Four escalating doses of DLLC were administered
weekly by subcutaneous injection. Vaccination was generally well tolerated
although one patient developed extensive eczema and an increased
antinuclear factor titre possibly indicating induction of autoimmunity.
Development of anti-leukaemic T-cell responses was assessed by enzyme-
linked immunospot analysis of gamma-interferon secreting T lymphocytes
and by human leucocyte antigen tetramer analysis for WT1-specific T cells.
Increases in anti-leukaemic T-cell responses were demonstrated in four
patients, but only two of the five remained in remission more than
12 months postvaccination. The study has demonstrated that generation of
DLLC is feasible in only a subgroup of patients and is currently neither
broadly applicable or clinically effective.
Keywords: acute myeloid leukaemia, immunotherapy, dendritic cells, min¬
imal residual disease.
Despite recent advances in the treatment of acute myeloid
leukaemia (AML), cure is only possible in the minority of
patients treated with intensive chemotherapy. This is despite
the fact that clinical complete remission (CR) rates are high,
amounting to around 80% in patients under 60 years (Hann
et al, 1997). The reason for this discrepancy is that relapse is
common, which is a consequence of the failure of chemo¬
therapy to eradicate minimal residual disease (MRD). There¬
fore there is a need to develop new approaches to tackling
MRD that circumvent leukaemia cell resistance to cytotoxic
agents. One potential strategy is to stimulate, through
vaccination, the patient's own immune system to recognise
leukaemic antigens leading to subsequent killing of the
leukaemia cells. Previous studies have shown that it is possible
to differentiate leukaemia cells into dendritic-like cells in vitro
and that these dendritic-like leukaemia cells (DLLC) have
enhanced immunostimulatory capacity and therefore might be
suitable to act as cellular vaccines. DLLC are capable of
stimulating the in vitro development of cytotoxic T lympho¬
cytes (CTL) that have thec ability to destroy unmodified
autologous leukaemia cells (Menssen et al, 1995; Charbonnier
et al, 1999; Choudhury et al, 1999). One advantage of using
DLLC, rather than targeting immunity to a specific leukaemia
peptide, is that there is potential to develop immunity to
multiple leukaemia antigens. This avoids one method of
immune escape whereby the leukaemia cells down-regulation
expression of a specific leukaemia antigen. However, one
obstacle to the use of DLLC as a broadly applicable leukaemia
vaccine is that the leukaemia cells are able to undergo DLLC
differentiation in only a subgroup of patients. Previous studies
have shown that only 25-40% of AML cases have leukaemic
blasts that successfully undergo DLLC differentiation (Robin¬
son et al, 1998; Cignetti et al, 1999; Brouwer et al, 2000;
Roddie et al, 2002). In order to establish whether DLLC
vaccination was feasible and safe we undertook a phase I/II
clinical trial of vaccination with autologous DLLC in patients
with AML who had achieved prior CR following intensive
combination chemotherapy.
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Vaccination with Dendritic-like Leukaemia Cells
Patients and methods
Patients
The trial protocol received approval from the local institu¬
tional review board and the UK Medicines and Healthcare
products Regulatory Authority (MHRA). Patients were recrui¬
ted from five UK centres. Patients enrolled into the study had
leukaemia cells harvested prior to the start of induction
chemotherapy. The method of harvest was dependent upon the
peripheral blood (PB) blast cell count at presentation. If the PB
blast count was >10 x 109/1, isovolaemic venesection of 100 ml
PB was performed, >1 to <10 x 109/1, leucaphaeresis on a
COBE spectra aphaeresis machine (Gambro BCT, Lakewood,
CO, USA) was performed, and for those with PB blast cell
count was <1 x 109/1, 20 ml of bone marrow (BM) was
aspirated. Patients were then treated with intensive combina¬
tion chemotherapy administered at the referring hospital. Only
patients who achieved CR (as defined by a blast cell count of
<5% in a normocellular BM) were considered as potentially
eligible to proceed to vaccination (Fig 1).
Vaccine production
Following collection the leukaemia cell harvest was transferred
immediately to a Good Manufacturing Practice accredited cell
manipulation facility where a mononuclear cell fraction (MC)
was prepared by density centrifugation over Ficoll (Histopaque
1077; Sigma Diagnostics, St Louis, MO, USA). An aliquot of
the harvest was tested in a prescreen to establish whether the
leukaemia cells would undergo differentiation to DLLC. The
remainder of the cell harvest was then cryopreserved for later
vaccine generation (Fig 1). The process used in the prescreen
and for generating the final cell vaccine product followed the
same standard operating procedure. In summary, leukaemia
cells were cultured in flasks in complete Roswell Park
Memorial Institute (RPMI) medium (CM) with 5% human
AB serum, 1% Glutamine (Gibco, Paisley, UK) and cytokines
granulocyte-macrophage colony stimulating factor (GM-CSF)
at 100 ng/ml and interleukin (IL)-4 (both R&D systems,
Abingdon, UK) at 20 ng/ml for 4 d. Medium was then
supplemented with a further 100 ng/ml of GM-CSF and
tumour necrosis factor-alpha (Peprotech, Rocky Hill, NJ,
USA) at 25 ng/ml and cells were cultured for further 3 d. In
the final 24 h of culture interferon-gamma (IFN-y; Boehringer,
Ingelheim, Germany) at 30 ng/ml and polylC (Sigma-Aldrich,
Gillingham, UK) 12-5 pg/ml were added.
Confirmation of successful DLLC differentiation was deter¬
mined by flow cytometric analysis using a FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA, USA) following
staining of the cells with the following murine monoclonal
antibodies (mab): CD40, CD80, CD86 and CD83 (all Caltag,
Burlingame, CA, USA). DLLC differentiation was deemed to
have occurred if >20% of cells expressed two or more of the
above markers. This phenotype was based on previous studies
that demonstrated that this correlated with acquisition of
functional dendritic cell characteristics, such as increased
allostimulatory capacity and production ofIL-12 (Roddie et al,
(A) Off study
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Fig 1. Clinical trial outline. (A) Laboratory protocol: at trial entry an aliquot of the leukaemia cell harvest was tested for their ability to undergo
successful dendritic-like leukaemia cells (DLLC) differentiation with the remainder being cryopreserved. In those patients eligible for vaccination
sufficient DLLC were generated to complete the vaccination programme. (B) Clinical protocol: following the leukaemia cell harvest patients were
treated with intensive chemotherapy aimed at achieving complete remission (CR). If remission was achieved, and their leukaemia cells were successful
at undergoing DLLC differentiation, vaccination was performed following haematopoietic recovery after the final cycle of chemotherapy. NR, no
response.
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2002). DLLC were generated just prior to the planned
vaccination programme. Confirmation of DLLC phenotype
was confirmed prior to vaccination. The first dose was
provided fresh with subsequent doses being cryopreserved
and then thawed prior to injection. DLLC were irradiated with
25-50 Gy from an MHRA accredited Caesium 137 source
prior to administration.
DLLC vaccination schedule
Vaccination was performed between 2 and 8 weeks following
haematopoietic recovery after the final cycle of chemotherapy.
Patients received four escalating doses ofDLLC of 0 125 x 106/
kg, 0-25 x 106/kg, 0 5 x 106/kg and 1 x 106/kg by subcuta¬
neous injection at weekly intervals.
Immunological evaluation
Autoimmunity. This was monitored by clinical evaluation and
by serial measurement of antinuclear factor (ANF).
Delayed-type hypersensitivity reaction. Intradermal injection of
1 x 106 autologous irradiated leukaemia cells was performed
pre- and at day 28 postvaccination.
Measurement of IFN-y secreting CTL by enzyme-linked
immunospot assay. Peripheral blood mononuclear cells
(PBMC) were used as a source of T cells for the purposes of
the assay; 107 cells were co-cultured with 106 irradiated
autologous leukaemia cells in CM supplemented with 1L-2
5 ng/ml and IL-7 5 ng/ml (both Peprotech). Cells were
harvested on day 7 for subsequent enzyme-linked
immunospot (ELISPOT) assay. Sterile Multiscreen-IP plates
(Millipore, Watford, UK) were coated overnight at 4°C with
50 pl/well anti-human IFN-antibody (Bender MedSystems,
Vienna, Austria) diluted to 10 pg/ml in carbonate buffer.
Coated plates were washed four times with phosphate-buffered
saline/0-05% Tween 20 and blocked with CM for 2 h at 37°C/5%
C02. Effector cells (100 pi) were added to triplicate wells at
graded concentrations, followed by 1 x 104 target cells/well
(100 pi) to E:T ratios of20:1,10:1,5:1 and 2-5:1. Target cells were
either unmodified autologous leukaemia cells or remission
PBMC. After 36 h cells were removed and biotinylated anti-IFN
avidin-conjugated alkaline phosphatase and 5-bromo-4-chloro-
3-indolyl-phosphate/nitro-Blue Tetrazolium (BCIP/NBT)
substrate (Sigma-Aldrich) were used for colorimetric
reactions. Spots were quantified using an automated ELISPOT
reader (AID Systems, Strassberg, Germany).
WT1/HLA-A2 tetramer positive CTL analysis. Numbers of
WTl-specific CTL were measured in the PB of unique patient
number (UPN)18, who was HLA-A*0201 positive. WT1-HLA-
A2 tetramer (Beckman Coulter, Fullerton, CA, USA) was
custom-made for the WT126 peptide (sequence
RMFPNAPYL) (Gao et al, 2000). Phycoerythrin (PE)-
conjugated WT1/HLA-A2 tetramer was incubated with
1 x 106 PBMC at final concentration of 50 pg/ml. Cells were
stained with fluorescein isothiocyanate (FITC)-conjugated CD8
mab (Caltag) and subsequently analysed by flow cytometry.
Measurement of regulatory T-cell numbers. Peripheral blood
mononuclear cells were stained with the following
combinations of mab; CD3-FITC alone, CD4-FITC + CD25-
PE and CD8-FITC + CD25-PE (all Caltag) and cells were
analysed by flow cytometry. Regulatory T cells were gated on
the basis of CD4 positivity and bright expression of CD25.
Minimal residual disease
Monitoring for MRD was performed by real-time quantitative
polymerase chain reaction (RT-PCR) for WT1 gene expression
prior to, and then at 14, 28 and 84 d following vaccination. In
four patients WT1 expression was measured in BM, with the
remaining patient having PB WT1 expression measured, due to
practical considerations. Total RNA was extracted from MCs
using TRI-Reagent (Sigma-Aldrich). Reverse transcription was
carried out using random hexamers (GE Healthcare, Amersham,
UK) and Superscript II (Invitrogen, Paisley, UK). Relative
quantitation of WT1 expression was performed by RT-PCR
using the AA-Ct method on an ABI 7900 HT thermal cycler
(Applied Biosystems, Foster City, CA, USA). cABL was used
as the endogenous control. The WT1 primers and Taqman
probe were as previously described (Ogawa et al, 2003). The
c.ABL primers and probe were ABL-146F; GATACGAAGG-
GAGGGTGTACCA, ABL-240R; CTCGGCCAGGGTGTTGAA
and ABL-183T; 5'-FAM-TGCTTCTGATGGCAAGCTCTA-
CGTCTCCT-TAMRA-3'. Fifty cycles of PCR were performed.
Absolute quantitation ofWT1 transcript was performed using
the ProfileQuant (Ipsogen, Marseille, France).
Results
Feasibility and safety
The clinical details of the 22 patients recruited into the study are
summarised in Table I; five patients were eligible to enter the
vaccination program. The reason for patients being unable or
unsuitable to proceed to DLLC vaccination was as a consequence
of one or more of the following: induction death or failure to
achieve CR (27%), insufficient cell numbers in the initial
leukaemia harvest (22%) (five of six marrow harvests), and
failure of leukaemia cells to undergo DLLC differentiation
(68%).
Vaccination was generally well tolerated. One patient, UPN
20, developed side effects likely to be attributable to the
vaccination. At day 14 postvaccination she had an extensive
recurrence of eczema. In addition, ANF that was positive at a
titre of 1/40 prevaccination, increased to a titre of 1/160
(nucleolar pattern) at day 84 and has remained at this level.
Two of the patients, UPN 12 and UPN 14, had clinical relapse of
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Table I. Clinical details of the patients recruited into the study.
Patient Age Presentation PB blast cell count Type of DLLC Treatment Eligible for
identifier (years) Sex status WHO type Cytogenetics (xl09/l) harvest differentiation outcome vaccination
UPN1 67 M De novo M4 46, XY 5-7 PB N CR N
UPN2 70 M Relapse Ml Complex 14-2 PB N ID N
UPN3 64 F De novo Ml 46, XX <1 BM N CR N
UPN4 65 M tMDS M2 Complex 17 PB Y RD N
UPN5 62 M De novo M5 46, XY md PB N RD N
UPN6 61 M tMDS M4 47, XY, +8 26-8 PB Y RD N
UPN7 67 F Relapse Ml 46, XY 3-98 BM N CR N
UPN8 74 F De novo Ml 46, XX 2-9 BM N CR N
UPN9 52 F Relapse M2 46, XX <1 BM N CR N
UPN10 62 M De novo M0 46, XY <1 BM N CR N
UPN11 62 M Relapse AML with mid 46, XY 36 PB N ID N
UPN12 60 M Relapse M0 46, XY 31 PB Y CR Y
UPN13 63 M De novo AML with mid 46, XY <1 BM N CR N
UPN14 61 F De novo M5 46, XX 50 PB Y CR Y
UPN15 69 M De novo M5 del 9 <1 BM N RD N
UPN16 40 M De novo M5 46, XY 26 PB Y CR Y
UPN17 30 F De novo M4 46, X 13 8 PB N CR N
UPN18 67 F De novo Ml 46, XX 36-8 PB Y CR Y
UPN19 65 M De novo AML with mid 47, XY, +8 1-5 LP N CR N
UPN20 43 F De novo M5 46, XY 37 PB Y CR Y
UPN21 70 M Relapse Ml 46, XY, add(8) 5-8 LP N CR N
UPN22 42 M De novo AML with mid 46, XX 7 PB N CR N
Patient and leukaemia characteristics; blast count in peripheral blood prior to the leukaemia cell harvest and method used for harvesting; success of
dendritic-like leukaemia cells (DLLC) differentiation in pre-screen; outcome of intensive therapy; eligibility for DLLC vaccination.
WHO, World Health Organization; tMDS, transformed myelodysplasia; mid, multilineage dysplasia; md, missing data; PB, peripheral blood; BM,
bone marrow; LP, leucaphaeresis product; CR, complete remission; ID, induction death; RD, primary refractory disease.
leukaemia shortly after the start of vaccination. The clinical
details of the five vaccinated patients are summarised in
Table II.
Immunological responses
Delayed-type hypersensitivity reaction. Delayed-type hyper¬
sensitivity responses were minimal or absent in all patients.
Analysis of IFN-y secreting CTLs by ELISPOT. In the first
patient to be vaccinated, UPN14, anti-leukaemic T-cell
responses were assessed by a cytotoxicity assay based on
chromium51 release. This assay was deemed to be too
insensitive and therefore replaced by the ELISPOT assay for
IFN-y-secreting CTL in all subsequent patients tested. All four
patients had measurable levels of anti-leukaemic CTL at some
point within the monitoring period (Fig 2).
Table II. Clinical details on the five patients who received dendritic-like leukaemia cells vaccination.
Patient Age Induction/consolidation Disease status LFS postvaccination OS postvaccination
identifier (years) Sex WHO type Cytogenetics therapy at vaccination Current status (months) (months)
UPN12 60 M M0 46, XY FLAGxl CR3 t 0 28
UPN14 62 F M5 46, XX FLAGx2/idACx2 CR1 t 2 3
UPN16 40 M M5 46, XY DAx2/hdACx2 CR1 CR1 16* 16*
UPN18 67 F Ml 46, XX DAx2/MidAC + ICE CR1 t 12 13
UPN20 43 F M5 46, XY DAx2/MACE + MidAC CR1 CR1 13* 13*
Patients and leukaemia characteristics; chemotherapy regime; disease status at start of vaccination; current status; duration of leukaemia-free and
overall survival from first vaccination.
WHO, World Health Organization; FLAG, fludarabine, cytarabine and granulocyte colony-stimulating factor; idAC, intermediate dose cytarabine;
DA, daunorubicin and cytarabine; hdAC, high-dose cytarabine; MdAC, mitoxantrone and cytarabine; ICE, idarubicin, cytarabine and etoposide;
MACE, amsacrine, cytarabine and etoposide; LFS, leukaemia-free survival from start of vaccination; OS, overall survival from start of vaccination.
*Alive in CR1; tpatient died.
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Fig 2. Results of monitoring for immunological responses and minimal residual disease in the five patients who underwent dendritic-like leukaemia
cells vaccination. (A) Frequencies of interferon-gamma-secreting cytotoxic T lymphocytes measured by enzyme-linked immunospot analysis [unique
patient number (UPN)12 did not have this analysis performed]. (B) Frequencies of regulatory T cells. Measurement of regulatory T cells was
performed by flow cytometric analysis gating on the CD4/CD25 dual-positive population. Total lymphocyte and CD8/CD25 dual-positive population
cell numbers are provided for comparison. (C) Levels of minimal residual disease as measured by gene expression ofWT1 (reported as expression
relative to K562 cell line in logarithmic scale).
Analysis of WT1-specific CTL. One of the five vaccination
patients was HLA-A*0201 positive and therefore suitable for
study. In this patient (UPN 18) at the start of vaccination there
was a very low frequency of WT1-specific CTL. Following
vaccination there was a progressive rise in WT1-specific CTL
PB with a maximum value of 0-35% of total T-cell numbers on
day 84.
Regulatory T-cell numbers. There was no consistent pattern
either in the regulatory T-cell frequency pre-vaccination or in
the change in this frequency following vaccination in the five
patients (Fig 2). In particular, initial regulatory T cells
frequencies did not appear to be appreciably different
between the two patients who had received fludarabine-based
induction regimes (UPN 12 and UPN 14) compared with those
that had received an anthracycline-based regime (UPN16,
UPN 18 and UPN20).
Monitoring ofMRD
All patients were in morphological remission at the time of
vaccination. However, two patients UPN12 and UPN 14 had
morphological relapse of their leukaemia shortly after the start of
the vaccination programme. In both patients this was mirrored
by rises in the level ofWT1 expression but particularly so in the
case of UPN14 (Fig 2). In the remaining three patients WT1
expression remained relatively constant following vaccination.
Discussion
This study has demonstrated the feasibility of vaccinating
patients with AML in CR with autologous DLLC. Vaccination
was generally safe, with only one of five patients developing
side effects that could be potentially attributable to DLLC
vaccination. In this patient eczema and an increased ANF titre
might indicate the induction of autoimmunity through
presentation of self-antigens by the DLLC. Whilst DLLC
vaccination was feasible it is not an approach that could be
broadly applicable. Of the patients recruited into the study
only 23% were eligible to proceed to vaccination. This was
primarily as a consequence of a failure of leukaemia cells to
differentiate into DLLC. Unless methods for improving the
proportion of AML cases that are able to undergo DLLC
differentiation can be found, different approaches to vaccin¬
ation will need to be tried. In our group we are currently
evaluating methods to load monocyte-derived dendritic cells
with autologous leukaemia antigens as a means of developing a
potentially more broadly applicable cell-based vaccine.
Four patients developed increased numbers of leukaemia-
specific IFN-y-secreting CTL following vaccination. In the one
HLA-A*0201-positive patient this was also accompanied by an
increase in WTl-specific CTL numbers. However, despite the
development of these anti-leukaemic immune responses,
evidence of clinical benefit has not been established. Indeed
in one patient leukaemic relapse developed despite an increase
in anti-leukaemic CTL activity. There could be a number of
reasons why this increase in anti-leukaemic activity failed to
prevent relapse in this patient. It is known that regulatory T
cells inhibit anti-cancer immune responses (Morse et al, 2002;
Casares et al, 2003; Wolf et al, 2003; Mesel-Lemoine et al,
2006). The rise in regulatory T-cell numbers seen in this
patient may have abrogated the anti-leukaemic response to a
degree that relapse could take place. Although regulatory T
cells may have a role in suppression of anti-leukaemic
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immunity a more likely explanation for the lack of clinical
benefit is that DLLC vaccination, as performed in this study,
failed to generate a clinically relevant level of anti-leukaemic
immune response. If this is the case then it is necessary to
develop ways to augment the vaccination method in order to
generate clinically relevant immunity. Possible means to
achieve this would be by improving the potency of the
dendritic-cell-based vaccine through use of agents that
promote dendritic cell maturation and/or polarisation or by
supporting any anti-leukaemic T-cell responses by systemic
administration of cytokines, such as IL-12 (Napolitani et al,
2005; Portielje et al, 2005). It might then be possible to convert
subclinical immune responses into ones that are clinically
effective, thus offering the promise of therapeutically beneficial
vaccines.
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We assessed the potential of tumour cell/dendritic cell fusion hybrids to
generate in vitro anti-leukaemic T-cell responses following co-culture with
autologous remission lymphocytes in six patients with acute myeloid
leukaemia (AML). Comparison was made to anti-leukaemic responses
induced by mature dendritic cells (mDC) co-cultured with autologous,
irradiated myeloid blasts. Fusion hybrids induced anti-leukaemic T-cell
immune responses in three of six patients. Tumour-pulsed mDC induced
T-cellular responses in two other patients. Only one of six patients remission
lymphocytes failed to develop leukaemia-directed immune responses
following stimulation with either construct. Anti-proliferative properties of
fusion hybrids against allogeneic lymphocytes were observed in mixed
lymphocyte-leukaemia reactions and were found not to be specific to the cell
fusion partners and did not prevent the ability of AML-mDC heterokaryons
to induce autologous anti-leukaemic cytotoxicity. We conclude that tumour
cell/dendritic cell fusion hybrids hold promise as a cellular vaccine for AML.
Keywords: cellular therapies, dendritic cells, vaccines, acute myeloid leuk¬
aemia, cytotoxicity.
There is a need for novel treatment strategies for the acute
myeloid leukaemias (AML), particularly in the older patient,
where current approaches aimed at eradicating minimal
residual disease (MRD), such as stem cell transplantation,
are not feasible because of unacceptably high levels of
treatment-related morbidity and mortality. Cellular therapy
strategies aimed at eradicating MRD will have to overcome the
immune escape mechanisms of leukaemic blasts, such as the
low expression of co-stimulatory molecules (Hirano et al,
1996), Fas ligand expression associated with activated
T-lymphocyte apoptosis (Buzyn et al, 1999) and secretion of
cytokines inhibiting the development of efficient immune
responses (Buggins et al, 1999).
Dendritic cell (DC)-based therapies hold promise for cancer
immunotherapy, as DCs are the most efficient antigen-
presenting cells and induce both primary and secondary
immune responses (Banchereau & Steinman, 1998). After
antigen uptake they migrate into secondary lymphoid organs,
mature and activate both helper and cytotoxic T cells
(Banchereau et al, 2000).
Dendritic-like leukaemic cells (DLLC) generated from
primary AML blasts by cytokine-induced differentiation offer
potential as autologous cellular vaccines, as they acquire
co-stimulatory and adhesion molecules and thereby stimulate
cytotoxic T-lymphocyte (CTL) responses to leukaemic tumour
antigens (Choudhury et al, 1997; Charbonnier et al, 1999;
Choudhury et al, 1999). In a significant number of cases,
however, AML blasts prove resistant to cytokine-driven
differentiation into DLLC (Robinson et al, 1998; Choudhury
et al, 1999; Brouwer et al, 2000; Harrison et al, 2001),
therefore limiting this approach, in our experience, to about
60% of cases (Roddie et al, 2002).
To overcome these limitations we investigated an alternative
approach to generate potent anti-leukaemic cytotoxic responses
by fusing autologous AML blasts to mature dendritic cells
(mDC) derived from peripheral blood monocytes of six AML
patients in complete morphological remission (CR), thus
generating heterokaryons that express leukaemic antigens
derived from the blast fusion partner as well as co-stimulatory
and adhesion molecules ofmDC. We demonstrate the potential
of these AML-DC fusion hybrids to induce in vitro T-cellular
responses against the patient's unmodified leukaemic cells.
Where possible, the potency of these constructs was compared to
mDC co-cultured with irradiated autologous leukaemic blasts,
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previously shown to generate leukaemia-specific T-cellular
cytotoxicity (Galea-Lauri et al, 2002; Spisek et al, 2002).
Materials and Methods
Patient samples
Samples from six AML patients (median age: 54 years, range:
24-70 years) were used in this study. Table I shows relevant
clinical and laboratory characteristics of these patients, in
whom DLLC maturation was either not achievable (n = 5), or
DLLC proved ineffective in stimulating anti-leukaemic CTL
[unique patient number (UPN) 3],
Leukaemic blasts
Leukaemic blasts were taken with informed consent at the time
of diagnosis. A highly purified population of leukaemic blasts
(>95%) was generated through Ficoll (Histopaque 1077; Sigma
Diagnostics, St Louis, MO, USA) density-gradient centrifuga-
tion and cells were immediately cryopreserved in 90% fetal calf
serum (FCS; Perbio, Cheshire, UK) +10% dimethyl sulphoxide
(DMSO; Sigma-Aldrich, Irvine, UK).
Remission samples
Remission samples were obtained after CR was confirmed
(defined as <5% of blasts in the bone marrow). Ficoll density-
gradient centrifugation was used to separate monocytes for the
generation of mature mDC and isolate responder T cells for
subsequent incubation with various autologous stimulators.
Generation of mDC from peripheral blood monocytes of
patients in complete morphological remission
Mature DC were generated from the adherent fraction of
peripheral blood mononuclear cells (PBMC) collected after the
resolution of cytopenias following combination intravenous
chemotherapy. Briefly, PBMC were suspended at 107/ml
in complete medium (CM), RPMI 1640 (Sigma-Aldrich)
Table I. Patient characteristics.
Sex/age Sample WHO/FAB DLLC
Patient (years) origin classification Karyotype maturation
UPN1 M/66 PB M4 46,XY No
UPN2 M/48 PB AML with 46,XY No
trilineage
dysplasia/M5a
UPN3 F/61 PB M5a 46,XX Yes
UPN4 F/24 PB M5a 46,XX No
UPN5 M/39 PB M4 46,XX No
UPN6 F/70 PB M5 46,XY No
WHO, World Health Organization; FAB, French-American-British;
PB, peripheral blood.
supplemented with 10% FCS, 100 U/ml penicillin/strepto¬
mycin (Sigma-Aldrich) and 2 mmol/1 l-glutamine (Sigma-
Aldrich), and incubated for 2 h at 37°C/5% COzin 75 cm2
culture flasks (Corning, Acton, MA, USA). Non-adherent
lymphocytes were subsequently removed and cryopreserved.
Adherent monocytes were resuspended with CM in the
presence of granulocyte-macrophage colony stimulating factor
(GM-CSF; Sandoz, Surrey, UK) at 100 ng/ml and interleukin-
4 (IL-4; R&D Systems, Abingdon, UK) at 15 ng/ml for 5 d.
The DC were then matured for a further 2 days by the
addition of tumour necrosis factor-alpha (TNF-a; Peprotech,
Rocky Hill, NJ, USA) at 25 ng/ml, Poly I:C (Sigma-Aldrich) at
12-5 pg/1 and interferon-gamma (IFN-y; Boehringer, Ingel-
heim, Germany) at 30 ng/ml. Mature DCs were immuno-
phenotyped by flow cytometry on day 7 and used fresh for the
generation of fusion hybrids with thawed autologous AML
blasts and co-incubation with irradiated AML blasts.
Generation ofDLLC from AML blasts
Complete medium as described above was used. Cell density was
adjusted to 1 x 106/ml and GM-CSF 100 ng/ml and IL-4 20 ng/ml
were added. After 3 d of culture at 37°C/5% C02, fresh GM-CSF
(100 ng/ml) and TNF-a 25 ng/ml was added. At day 6 ofculture,
further maturational agents Poly I: C at 12-5 pg/1 and IFN-y at
30 ng/ml were added and cells were harvested at day 7 of culture
for immunophenotypic characterization by flow cytometry and
microscopic analysis of cytospin preparations.
Immunophenotypic analysis of mDC, AML blasts, fusion
hybrids and DLLC
A 2 x 105 cells were used for phenotypic analyses using
fluorescein isothiocyanate (FITC)-conjugated monoclonal
antibodies (mAbs) against CD40, CD86, major histocompat¬
ibility complex (MHC) class I, CD33 and CD 14, phycoeryth-
rin (PE)-conjugated mAbs against CD80, CD83, CDllc and
CD34, and tricolour-conjugated mAbs against MHC class II
(Caltag, Burlingame, CA, USA). Cells were incubated with
antibodies for 20 min at 4°C, washed in phosphate-buffered
saline (PBS) and resuspended in 300 pi PBS/sodium azide for
analysis using a FACSCalibur flow-cytometer system (Becton
Dickinson, San Jose, CA, USA) and win mdi analysis software
(The Scripps Research Institute, La Jolla, CA, USA). Cell debris
was excluded by establishing appropriate forward and side
scatter gates and apoptotic cells were excluded on the basis of
propidium iodide uptake before the analysis for expression of
each phenotypic marker. Appropriate isotype-matched control
mAbs were always used.
Generation ofAML-mDC fusion hybrids
Thawed AML blasts and fresh mDC were mixed at a ratio of
1 : 1, not exceeding 5 x 106 each in CM at 37°C and
centrifuged for 5 min at 400 g to pellet. After removal of
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all supernatant, cells were fused by drop-wise addition of
500 pi of 50% Polyethylene Glycol (PEG)/10% DMSO (Sigma)
over a period of 1 min in a 37°C waterbath. The reaction was
stopped after a further minute by adding 1 ml of CM and
further dilution to 15 ml with CM heated to 37°C prior to use
as stimulators in autologous CTL assays and allogeneic mixed
lymphocyte leukaemia reactions (MLLR).
Assessment ofAML-mDC fusion efficiency
A series of experiments was conducted to establish the
efficiency of PEG-induced hybrid formation. Briefly, prior to
fusion the AML blasts were labelled with the red fluorescent
linker dye PKH 26 (Sigma) according to the manufacturers
instructions, whereas DC were labelled using the green Cell
Tracker 5-chloromethylfluorescein diacetate (CMFDA).
Unfused and fused cells were analysed by flow cytometry. Cells
presenting both membrane dyes after fusion, i.e. fluorescing in
both the FL1 and FL2 channels, were scored as fusion hybrids.
In addition, fluorescent microscopy using motorized micro-
focussing through the generated heterokaryons was undertaken
to visualize the double-fluorescent membrane of AML-DC
fusion hybrids. Separate images of cytospin preparations were
created using FITC, Texas Red and 4,6-diamidino 2-phenly-
indole (DAPI) excitation filters in a Zeiss Axioplan fluorescence
microscope (Zeiss, Jena, Germany) with motorised focus and
images were subsequently combined. Chroma filter sets, Vector
shield mounting medium and a Princeton Instruments Micro-
max digital camera were used.
Stimulation of leukaemia-specific lymphocytes by
co-culture with autologous AML-mDC fusion hybrids,
mDc cocultured with irradiated AML and DLLC
The non-adherent fraction of fresh or thawed remission blood
samples provided the source of autologous responder cells.
Unmodified AML blasts, AML-mDC fusion hybrids and mDC
mixed 1 : 1 with irradiated (26 Gy) AML blasts were used as
autologous stimulators. Dendritic-like differentiation was
achieved from the leukaemic blasts of one of six patients.
DLLC were generated as stimulators to autologous responder
T cells in this case. PBMC cultured in the absence of
stimulators or primed by unpulsed mDCs and AML-AML
fusions served as negative controls, as these were not expected
to stimulate leukaemia-directed cytotoxicity.
All stimulators received 26 Gy of irradiation from a 137Cs
source. Briefly, co-culture of 107 responder cells with 106
irradiated stimulators was prepared in 12-well plates at a cell
density of 106/ml effectors. CM was supplemented with IL-2
5 ng/ml and IL-7 5 ng/ml (Peprotech, Rocky Hill, NJ, USA).
Responder cells were re-stimulated at day 7 and day 14 using
the same stimulators that had been added at the beginning of
co-culture. CM and cytokines were half exchanged weekly.
Effectors were harvested on day 21 for subsequent cytotoxicity
assays against native, autologous AML blasts.
Allogeneic mixed leukaemia-lymphocyte reactions
Responder cells for allogeneic MLLR were obtained from the
non-adherent lymphocytes of healthy, unrelated donors, whose
PBMC had been separated by gradient density centrifugation
followed by 2 h plastic adherence. Adherent donor monocytes
were matured in a 7-day culture into mDC as described above
and subsequently fused to patient AML blasts to generate AML-
DC fusion hybrid stimulators. Unfused AML blasts and mDC as
well as AML co-cultured with mDCs served as stimulator
controls. AML-AML or mDC-mDC fusions and titrating
concentrations of PEG were also assessed regarding their ability
to stimulate the proliferation of lymphocytes allogeneic to the
AML blasts used. Responder cells were plated at 1 x 105/well in
CM in U-bottomed 96-well plates. Stimulators were added at
graded responder/stimulator ratios of 5 : 1, 10 : 1, 25 : 1 and
100 : 1. The proliferation of lymphocytes was determined by the
uptake of [3H]-thymidine (ICN Biochemicals, Basingstoke,
UK), added for the final 18 h of a 5-day co-culture at 37°C/5%
C02. Results were expressed as mean counts per minute
(cpm) ± standard deviation (SD) in triplicates.
5ICr-release cytotoxicity assay
Following re-stimulation co-culture with a variety of autolo¬
gous stimulators the resulting leukaemia directed in vitro
cytotoxicity was measured in a 4-h 5lCr-release cytotoxicity
assay in two patients, where uptake of the isotope by their
native AML blasts was demonstrable. Briefly, 1 x 106 AML
blasts were incubated for 1 h at 37°C/5% C02 with 3-7 MBq
51Cr (ICN Biochemicals, Basingstoke, UK), washed three times
with CM and 1 x 104 labelled targets were subsequently co-
cultured with autologously activated lymphocytes in 200 pi
CM in 96-well U-bottomed plates at effector : target (E : T)
ratios of 50 : 1, 25 : 1, 12-5 : 1 and 6-25 : 1. After 4 h, 25 pi of
cell free supernatent were collected and mixed with 150 pi of
scintillant (Ecolite+; ICN Biochemicals, Basingstoke, UK).
Scintillation was analysed using a liquid scintillation and
luminescence counter (1450 microbeta trilux; Wallac, Turku,
Finland). Specific lysis was calculated using the following
formula: (counts per minute) [(cpm experimental relea¬
se - cpm spontaneous release)/(cpm maximal release - cpm
spontaneous release) xlOO], Spontaneous 51Cr release was
determined from wells containing target cells and medium
only. Maximum 5lCr release was gained by lysing target cells
with 100 pi of 2% Triton x 100/sample well. Spontaneous
release was <15% of maximum release. All assays were
performed in triplicates and expressed as mean cpm ± SD.
IFN-y enzyme-linked immunospot (ELISPOT) assay. 1FN-
ELISPOT assays were used to assess in vitro T-cell responses to
autologous AML blasts in four patients (UPN3-UPN6). Sterile
Multiscreen-IP plates [polyvinylidenedifluoride (PVDF) mem¬
branes; Millipore, Watford, UK] were coated overnight at 4°C
with 50 pl/well anti-human IFN-antibody (Bender MedSys-
tems, Vienna, Austria) diluted to 10 pg/ml in carbonate buffer.
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A AML blasts stained with PKH26 B Dendritic Cells stained with CMFDA
C AML-DC fusions are double stained
AML-DC
Fig 1. Flow-cytometric assessment of AML-DC fusion efficiency.
Coated plates were washed four times with PBS/0'05% Tween
20 and blocked with CM for 2 h at 37°C/5% CCb. Effector cells
(100 jj.1) were added to triplicate wells at graded concentrations,
followed by 1 x 104target cells/well (100 pi) to E : T ratios of
20 : 1, 10 : 1, 5 : 1 and 2-5 : 1. After co-culture for 36 h at
37°C/5% COs cells were removed from the assay and biotin-
ylated anti-IFN-avidin conjugated alkaline phosphatase and
BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/p-nitro
blue tetrazolium) substrate (Sigma Aldrich) were used for the
colorimetric reaction. Spots were quantified using an auto¬
mated ELISPOT reader (AID Systems, Strassberg, Germany).
Statistical analysis
Statistical analysis of 51Cr cytotoxicity and ELISPOT assay
results was performed using Student's t-test. P < 0-05 were
considered significant.
Results
Flow cytometry and fluorescence microscopy confirm
AML-mDC fusion
Before testing the immune-stimulatory function of AML-
mDC fusion hybrids, a series of experiments was conducted to
assess the efficiency of fusion using PEG/DMSO.
Single stained DC
Flow-cytometric analysis following membrane staining of
the fusion partners with different fluorescent dyes (CMFDA
for DC and PKH 26 for AML blasts respectively) enabled the
identification of fusion hybrids as double-stained cells. Fusion
Dual 5taming on fused membrane
Fig 2. Fluorescent microscopic sections through an AML-DC fusion
cell. A series of fluorescent microscopic images cross-section a mem¬
brane-stained AML-DC fusion cell. Motorized-focussing through the
heterokaryon reveals dual membrane staining from both fusion part¬
ners. The dendritic cell was stained with the green fluorescent mem¬
brane dye CMFDA. The AML blast was stained with the red membrane
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Patient AML Monocyte derived AML-mDC
blasts dendritic cells fusion cells
Log fluorescence
Fig 3. AML-DC fusion hybrids express a biphenotypic flow-cytometric profile. AML blasts and DCs were stained before and after fusion using a
panel of monoclonal antibodies against AML and DC associated antigens. The fusion hybrids express AML restricted antigens (CD34) as well as DC
associated antigens and co-stimulatory molecules (CD86.CD80). Results of a representative experiment are shown. Fusion hybrids were not gated.
efficiency was between 20% and 30% (mean 26%). Figure 1
shows a representative result of one experiment.
Fluorescence microscopy confirmed that the membrane
was derived from both fusion partners on the membrane-
stained heterokaryons that were generated. Motorized micro-
focussing sections through fusion hybrids on cytospin
preparations were visualized. Figure 2 shows sections through
a fusion hybrid. As the common membrane of the fusion
hybrid came into focus, red (AML) and green (mDC) stained
membrane elements were seen.
Additionally, a bi-phenotypic flow-cytometric profile of the
fusion hybrids was demonstrated by analysis of the fusion
partners before and fusion hybrids after fusion. Figure 3 shows
representative results of one patient. Unfused AML blasts and
mDC were stained with mAbs against the leukaemia-associated
antigens CD34 and CD33 and the DC-associated antigens
CD86 and CD80 prior to PEG fusion. Immediately after fusion
the hybrids expressed both AML- and DC-associated mem¬
brane antigens.
Fusion hybrids induce AML-directed T-cell responses
51Cr-release cytotoxicity assays were performed in two
patients, where good 51Cr uptake by autologous AML blast
targets was shown (UPN1, UPN2).
In the remaining four patients (UPN2-4) an IFN-y
ELISPOT assay was used to demonstrate T-cell responses
against native, autologous AML blasts induced by priming co-
culture with the various autologous stimulators (Table II). The
ELISPOT assay has been shown to reliably detect the number
of antigen-specific T cells in experiments in which known
quantities of antigen-specific T cells were added to bulk PBMC
preparations (Schmittel et al, 1997).
In three patients, AML-mDC fusion hybrids proved the
strongest inducers of anti-leukaemic T-cell responses, using
51Cr-release cytotoxicity assays (UPN1, UPN2) and ELISPOT
IFN-y assay (UPN3) respectively.
In UPN1 (Fig 4) PBMC primed with fusion hybrids, but not
with either unfused AML blasts (P < 0-0001) or mDC
344 © 2005 Blackwell Publishing Ltd, British Journal of Haematology, 129, 340-349
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Table II. Immunoassays performed and results
generated. Patient Immunoassay performed Best stimulator construct
UPN1 Chromium release
UPN2 5lChromium release
UPN3 IFN-y ELISPOT assay
UPN4 IFN-y ELISPOT assay
UPN5 IFN-y ELISPOT assay
UPN6 IFN-y ELISPOT assay
Results shown
AML-DC fusion hybrids Fig 4
AML-DC fusion hybrids Fig 4
AML-DC fusion hybrids Fig 5
AML-pulsed mDC Fig 6
AML-pulsed mDC Fig 6





























Fig 4. AML-mDC fusion hybrids generate anti-leukaemic cytotoxicity
in co-culture with autologous remission PBMCs. 51Cr-release assays of
UPN1 and UPN2 are shown. Remission PBMCs (1 x 107) were
stimulated weekly x3, using 1 x 106 irradiated autologous AML-mDC
fusion hybrids (o) and with either DC mixed with irradiated AML (■),
unfused DC (<>) and AML (A), or inappropriate AML-AML fusion
hybrids (+) as negative controls.
(P < 0-0001), resulted in 47% target lysis at the E : T ratio of
50 : 1 in a 5lCr-release assay. The cytotoxicity induced by
mDC pulsed with tumour cell bodies was significantly lower at
24% at the same E : T ratio (P = 0 0005).
In UPN2, fusion hybrids generated 7-3% AML-directed
cytotoxicity, compared with 3-8% induced by unfused AML
(P = 0 005), 1% cytotoxicity induced by unstimulated PBMC
(P = 0-001) and 0-4% by inappropriate AML-AML fusion
hybrids (P = 0 003) at the highest E : T ratio of 50 : 1 (Fig 4).
In a third patient (UPN3), IFN-y responses to autologous
AML blasts increased more than 3-5-fold in effectors primed by
co-culture with fusion hybrids compared with those primed
with AML blasts alone (P = 0 0002), DLLC (P = 0-0003) or
unprimed effectors (P = 0 0002) at the highest effector :
stimulator ratio of 20 : 1 (Fig 5A).
Flow-cytometric characteristics of remission PBMC used
in this ELISPOT IFN-y release assay are demonstrated in
Fig 5B.
mDC co-cultured with irradiated whole tumour cell bodies
may provide an alternative cellular vaccine construct
In two patients (UPN4, UPN5) AML-pulsed mDC proved
better stimulators of anti-leukaemic T-cell responses than
AML-DC fusion hybrids in IFN-y ELISPOT assays (Fig 6).
The stimulatory differences observed between these constructs
were significant in both patients (P = 0-003 in UPN4,
P = 0 009 in UPN5).
However, mDC pulsed with tumour cell bodies showed a
significant advantage over immune responses induced by
unmodified AML blasts only in UPN5 (P = 0-02), whereas the
differences observed did not reach statistical significance in
UPN4 (P = 0-15). In both patients, fusion hybrids failed to
induce T-cell responses exceeding those to unmodified AML
blasts.
Suppression of lymphocyte proliferation by fusion hybrids
is not specific to fusion partners
Assessing the immune-stimulatory properties of fusion hybrids
we observed that the proliferation of lymphocytes was
suppressed by AML-DC fusion hybrids in [3H]-thymidine
uptake assays, where AML blasts allogeneic to the mDC and
responder lymphocytes were used. A representative result of
three experiments is shown in Fig 7A. This anti-proliferative
property was, however, not specific to AML-DC fusion, but
was also induced by allogeneic AML-AML as well as autol¬
ogous mDC-mDC heterokaryons (Fig 7B,C). Importantly, the
induction of tumour-specific T-cell cytotoxicity by AML-DC
fusion hybrids was maintained regardless, further emphasizing
their potency as cellular stimulators of anti-leukaemic
responses.
Discussion
The heterogeneity of the AMLs poses a challenge for the
generation of a DC-based vaccine, as few leukaemia-specific or
tumour-associated antigens can be expected to be expressed in
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Fig 5. (A) Anti-leukaemic T-cell responses induced by AML-DC fusion hybrids (UPN3) exceed those of other autologous stimulators in an IFN-y
ELISPOT assay. Results of triplicate wells at the effector : stimulator ratio of 20 : 1 are shown. Co-culture with AML-DC fusions (JE) induces a more
than 3-fold increase in T-cell IFN-y release, compared with T cells stimulated by AML (■), DLLC (H) and unstimulated (□) T cells. (B) Flow-
cytometric characteristics of PBMC responders used in ELISPOT IFN-y release immuno-assay (UPN3). A lymphocyte gate was applied, cells were
incubated with monoclonal antibodies against CD3 (tricolour-conjugated) and additionally with either anti-CD19, CD8, CD4 or CD56 (PE-con-
jugated) to characterize the remission lymphocytes used.
all cases and remain stable over the course of the disease and
chemotherapy regimens. Strategies focussing on the generation
of CTL responses against single, specific tumour antigens are
therefore fraught with the risk of possible tumour immune
escape because of clonal evolution and tolerance to known and
also unknown tumour antigens, resulting in relapse originating
from MRD.
Whole tumour-based vaccine strategies attempt to circum¬
vent this problem by inducing polyvalent immune responses
against a large number of antigens expressed by leukaemic
blasts. DLLC derived from AML blasts by sequential cytokine
incubation have been demonstrated to acquire co-stimulatory
molecules that are mostly lacking in native AML blasts and are
necessary to induce CTL responses. This approach to genera¬
tion of a cellular vaccine is, however limited by the resistance
to cytokine maturation in a significant number of cases
(Choudhury et al, 1997; Harrison et al, 2001; Roddie et al,
2002).
In this study we have taken the approach of fusing whole
tumour cells to autologous DC. Thus hybridomas were
constructed that expressed both tumour-derived antigens
and DC-derived co-stimulatory molecules. We showed that
AML-mDC fusion hybrids and, to a lesser degree, mDC
co-cultured with irradiated AML blasts were capable of
inducing leukaemia-directed in vitro cytotoxic responses in
autologous remission PBMC. Both of these vaccine constructs
can be readily generated with little technical difficulty and are
therefore attractive alternatives to DLLC.
Spisek et al (2002) have previously described the induc¬
tion of leukaemia-specific response by cross-presentation of
late-apoptotic leukaemic blasts by autologous DC of
non-leukaemic origin. Tumour-mDC fusion hybrids have
346 © 2005 Blackwell Publishing Ltd, British Journal of Haematology, 129, 340-349
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Fig 6. In two patients (UPN4, UPN5) AML-pulsed mDC (■) were
better stimulators of anti-leukaemic T-cell responses than AML-DC
fusion hybrids (■), autologous AML blasts (■) and unpulsed mDC































been generated and successfully used as vaccines in the
prevention and treatment of murine models of breast
carcinoma (Gong et al, 1997; Gong et al, 1998; Gong et al,
2000; Chen et al, 2003) and induction of in vitro cytotoxicity
has been demonstrated in B-cell chronic lymphocytic
leukaemia (Kokhaei et al, 2003) and multiple myeloma
(Raje et al, 2004). Evidence for their effectiveness as vaccine
constructs in AML, however, is limited. Galea-Lauri et al
(2002) have previously reported one case of successful in
vitro induction of CTL responses to AML blasts by
Fig 7. (A) AML-pulsed mDC (BE), but not AML-mDC fusion hybrids
(■) stimulate proliferation of T cells autologous to the mDC and
allogeneic to the AML blasts. (B) A similar antiproliferative effect is
induced by allogeneic AML-AML fusion (E) and (C) autologous
mDC-mDC hybrids (E), suggesting a mechanism not specific to
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autologous fusion hybrids and support this finding by
assessment of DC loading strategies with antigens derived
from the U937 leukaemic cell line, including U937-DC
fusion hybrids (Galea-Lauri et al, 2002).
We have been able to elicit leukaemia-directed T-cell
responses in three of six patients whose remission PBMC were
co-cultured with autologous AML-mDC fusion hybrids. In
two cases, anti-leukaemic cytotoxicity generated by fusion
hybrids was demonstrated by 51Cr-release assay (Fig 4), in a
third case T-cell responses to fusion hybrids exceeded those of
other autologous stimulators in an IFN-y ELISPOT assay
(Fig 5A).
In further two of three patients, where AML-mDC fusion
hybrids proved ineffective in stimulating leukaemia-directed
cytotoxicity above the level induced by native AML blasts,
however, mDC cocultured with irradiated AML blasts did
induce anti-leukaemic T-cell responses (Fig 6).
The determinants of successful CTL generation by either
strategy require further investigation. We have shown that
PEG-generated fusion hybrids exert anti-proliferative effects
on co-cultured lymphocytes. This appeared to be independent
of the fusion partners and was not induced by titrated addition
of PEG to cultured PBMC alone. In spite of this anti¬
proliferative property AML-mDC fusion hybrids remain
capable of generating potent anti-leukaemic cytotoxic
responses, further emphasizing the potential of these hetero-
karyons as cellular vaccines. Their efficacy might be further
enhanced by exclusion of non-viable hybrids by means of
immunomagnetic selection prior to co-culture, while positive
selection of fused from unfused cells based on their charac¬
teristic forward and side-scatter profile (Galea-Lauri et al,
2002) could be achieved using a cell-sorting facility. Purified
hybrid cells from DC and tumour cell fusions have previously
been shown to be more effective in inducing an immune
response (IFN-y) when compared with fusion mixture
(Li et al, 2001). Furthermore, residual unhybridized AML
blasts may anergize T cells.
All these parameters could affect the proliferation response
when using DC fusion hybrids to stimulate autologous anti-
leukaemic T cells.
In conclusion this study provides preclinical data on
developing a DC-based vaccination strategy for AML. AML-
mDC fusion hybrids can be generated with relative ease
and hold promise as a novel potential cellular vaccine,
providing an alternative to whole tumour cell pulsed mDC
or DLLC.
Acknowledgements
We are grateful to Mark Upton (CADAMA, UK) for
technical assistance by providing access to an automated
digital imaging system (AID ELISpot Reader System).
Fluorescence microscopy was performed at the MRC
Fluman Genetics Unit in Edinburgh with assistance from
Paul Perry.
References
Banchereau, J. & Steinman, R.M. (1998) Dendritic cells and the control
of immunity. Nature, 392, 245-252.
Banchereau,)., Briere, F„ Caux, C., Davoust, J., Lebecque, S„ Liu, Y.J.,
Pulendran, B. 8< Palucka, K. (2000) Immunobiology of dendritic-
cells. Annual Review of Immunology, 18, 767-811.
Brouwer, R.E., van der Hoom, H.M., Kluin-Nelemans, H.C., Zelderen-
Bhola, S., Willemze, R. &. Falkenburg, J.H. (2000) The generation of
dendritic-like cells with increased allostimulatory function from
acute myeloid leukemia cells of various FAB subclasses. Human
Immunology, 61, 565—574.
Buggins, A.G., Lea, N., Gaken, J., Darling, D., Farzaneh, F„ Mufti, G.J.
8( Hirst, W.J. (1999) Effect of costimulation and the micro-
environment on antigen presentation by leukemic cells. Blood, 94,
3479-3490.
Buzyn, A., Petit, F., Ostankovitch, M., Figueiredo, S., Varet, B., Guillet,
J.G., Ameisen, J.C. 8< Estaquier, J. (1999) Membrane-bound Fas
(Apo-l/CD95) ligand on leukemic cells: a mechanism of tumor
immune escape in leukemia patients. Blood, 94, 3135-3140.
Charbonnier, A., Gaugler, B., Sainty, D., Lafage-Pochitaloff, M. 8<
Olive, D. (1999) Human acute myeloblasts leukemia cells differ¬
entiate in vitro into mature dendritic cells and induce the differ¬
entiation of cytotoxic T cells against autologous leukemias. European
Journal of Immunology, 29, 2567-2578.
Chen, D„ Xia, J., Tanaka, Y„ Chen, H„ Koido, S„ Wernet, O.,
Mukherjee, P., Gendler, S.J., Kufe, D. & Gong, J. (2003)
Immunotherapy of spontaneous mammary carcinoma with fusions
of dendritic cells and mucin 1-positive carcinoma cells. Immunology,
109, 300-307.
Choudhury, A., Gajewski, J.L., Liang, J.C., Popat, U., Claxton, D.F.,
Kliche, K.O., Andreeff, M. 8< Champlin, R.E. (1997) Use of leukemic
dendritic cells for the generation of antileukemic cellular cytotoxi¬
city against Philadelphia chromosome-positive chronic myelogen¬
ous leukemia. Blood, 89, 1133-1142.
Choudhury, B.A., Liang, J.C., Thomas, E.K., Flores-Romo, L., Xie,
Q.S., Agusala, K., Sutaria, S., Sinha, I„ Champlin, R.E. 8r Claxton,
D.F. (1999) Dendritic cells derived in vitro from acute myelogenous
leukemia cells stimulate autologous, antileukemic T-cell responses.
Blood, 93, 780-786.
Galea-Lauri, J., Darling, D., Mufti, G., Harrison, P. 8< Farzaneh,
F. (2002) Eliciting cytotoxic T lymphocytes against acute myeloid
leukemia-derived antigens: evaluation of dendritic cell-leukemia cell
hybrids and other antigen-loading strategies for dendritic cell-based
vaccination. Cancer Immunology, Immunotherapy, 51, 299-310.
Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. (1997) Induction of
antitumor activity by immunization with fusions of dendritic and
carcinoma cells. Nature Medicine, 3, 558-561.
Gong, J., Chen, D., Kashiwaba, M„ Li, Y., Chen, L., Takeuchi, H., Qu,
H., Rowse, G.J., Gendler, S.J. & Kufe, D. (1998) Reversal of tolerance
to human MUC1 antigen in MUC1 transgenic mice immunized
with fusions of dendritic and carcinoma cells. Proceedings of the
National Academy of Sciences of the United States of America, 95,
6279-6283.
Gong, J., Apostolopoulos, V., Chen, D., Chen, H., Koido, S., Gendler,
S.J., McKenzie, l.F. & Kufe, D. (2000) Selection and characterization
of MUC1-specific CD8+ T cells from MUC1 transgenic mice
immunized with dendritic-carcinoma fusion cells. Immunology, 101,
316-324.
348 © 2005 Blackwell Publishing Ltd, British Journal of Haematology, 129, 340-349
AML-DC Fusion Hybrid Vaccine
Harrison, B.D., Adams, J.A., Briggs, M., Brereton, M.L. 8c Yin, J.A.
(2001) Stimulation of autologous proliferative and cytotoxic T-cell
responses by "leukemic dendritic cells" derived from blast cells in
acute myeloid leukemia. Blood, 97, 2764-2771.
Hirano, N., Takahashi, T., Takahashi, T., Ohtake, S., Hirashima, K.,
Emi, N., Saito, K., Hirano, M., Shinohara, K., Takeuchi, M., Take-
tazu, F., Tsunoda, S., Ogura, M., Omine, M., Saito, T., Yazaki, Y.,
Ueda, R. 8c Hirai, H. (1996) Expression of costimulatory molecules
in human leukemias. Leukemia, 10, 1168-1176.
Kokhaei, P., Rezvany, M.R., Virving, L., Choudhury, A., Rabbani, H.,
Osterborg, A. & Mellstedt, H. (2003) Dendritic cells loaded with
apoptotic tumour cells induce a stronger T-cell response than
dendritic cell-tumour hybrids in B-CLL. Leukemia, 17, 894-899.
Li, J., Holmes, L.M., Franek, K.J., Burgin, K.E., Wagner, T.E. & Wei, Y.
(2001) Purified hybrid cells from dendritic cell and tumor cell
fusions are superior activators of antitumor immunity. Cancer
Immunology, Immunotherapy, 50, 456—462.
Raje, N., Hideshima, T., Davies, F.E., Chauhan, D., Treon, S.P., Young,
G., Tai, Y.T., Avigan, D., Gong, J., Schlossman, R.L., Richardson, P.,
Kufe, D.W. & Anderson, K.C. (2004) Tumour cell/dendritic cell
fusions as a vaccination strategy for multiple myeloma. British
Journal of Haematology, 125, 343-352.
Robinson, S.P., English, N., Jaju, R., Kearney, L., Knight, S.C. 8c Reid,
C.D. (1998) The in-vitro generation of dendritic cells from blast cells
in acute leukaemia. British Journal ofHaematology, 103, 763-771.
Roddie, P.H., Horton, Y. 8c Turner, M.L. (2002) Primary acute mye¬
loid leukaemia blasts resistant to cytokine-induced differentiation to
dendritic-like leukaemia cells can be forced to differentiate by the
addition of bryostatin-1. Leukemia, 16, 84-93.
Schmittel, A., Keilholz, U. & Scheibenbogen, C. (1997) Evaluation of
the interferon-gamma ELISPOT-assay for quantification of peptide
specific T lymphocytes from peripheral blood. Journal of
Immunological Methods, 210, 167-174.
Spisek, R., Chevallier, P., Morineau, N., Milpied, N., Avet-Loiseau, H.,
Harousseau, J.L., Meflah, K. 8c Gregoire, M. (2002) Induction of
leukemia-specific cytotoxic response by cross-presentation of late-
apoptotic leukemic blasts by autologous dendritic cells of non-
leukemic origin. Cancer Research, 62, 2861-2868.





DC development & T-cell
interaction in vivo
DCs in leukemia: part of the

















Leukaemia Research Fund, John






mattdPklammermatt. demon, co. uk
Keywords:
acute myeloid leukemia, cellular
vaccine, cytotoxic T cells,
dendritic cells, immunotherapy
Review
For reprint orders, please contact reprints@future-drugs.com
Current progress in the
development of a eel I-based
vaccine for the immunotherapy of
acute myeloid leukemia
Matthias Klammerf and Patrick H Roddie
Evidence that immunological control contributes to the elimination of residual leukemia
has emerged from allogeneic hematopoietic stem cell transplantation. This review
assesses the current understanding of immunobiology of acute myeloid leukemia and how
dendritic cells and T cells may be harnessed using in vitro and in vivo priming techniques.
Preclinical and clinical dendritic cell vaccine trials reported to date are considered and
the prospects for immunotherapy with dendritic cell-based vaccine constructs evaluated.
Expert Rev. Vaccines 5(2), 211-222 (2006)
Current concepts of immune-mediated
treatment modalities for acute
myeloid leukemia
Acute myeloid leukemia (AML) is a biologi¬
cally and clinically heterogeneous disease char¬
acterized by a clonal, neoplastic proliferation
of hematopoietic progenitor cells. Immuno¬
logical control of this disease, resulting in
spontaneous remission, is exceedingly rare, but
has been reported after bacterial infections |1J,
and the discovery of tumor-related antigens
recognized by cytotoxic lymphocytes has fur¬
ther highlighted the role of an immune
response seen in patients with leukemia.
Intensive multiagent chemotherapy, how¬
ever, has been the backbone of AML treat¬
ment for decades. Complete remissions are
achievable with this approach in 70-80% of
patients below 60 years of age. However, dis¬
ease relapse originating from minimal resid¬
ual disease (MRD) results in an overall
5-year survival of less than 30% [2J. Superior
long-term disease-free survival of 50-60%
can be achieved in patients that have under¬
gone allogeneic hematopoietic stem cell
transplantation (HSCT) and, in recent
years, evidence has emerged that much of
the therapeutic benefit of this procedure is
derived from an immunologically mediated
graft-versus-leukemia (GvL) effect. This has
led to the development of reduced intensity,
nonmyeloablative transplant conditioning
regimes, designed to allow donor engraft-
ment, rather than direct tumor cytotoxicity,
and the use of donor-lymphocyte infusion
(DLI) as a means to treat relapse, following
allogeneic HSCT [3.4], proving that immune
surveillance of residual leukemic blasts by
donor T lymphocytes is possible.
More up-to-date evidence points towards
the role of natural killer (NK) cells in control¬
ling and eradicating leukemia in a situation of
haplotype-mismatched, haploidentical trans¬
plantation. Mismatch for killer immuno-
globulin-like receptors (KIR) between donor
and recipient pairs in this particular subgroup
is associated with activation of donor-derived
NK cells that contribute to immune control
of MRD and lower relapse risk compared
with KIR-matched donor-recipient pairs |5-7).
Recently, a number of specific peptides have
been identified that may represent appropri¬
ate targets for immune responses in the con¬
text of allogeneic HSCT. The hematopoiesis-
specific minor histocompatibility antigens
(HA)-l and -2 may act as malignancy-specific
targets in the context of allogeneic
HSCT |8-10|.
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These treatment modalities provide a model for the success-
integration of immunotherapeutic approaches to MRD in
rrent clinical practice and have improved long-term clinical
tcomes. However, there is a need for novel treatment strate-
is, in particular for older patients, owing to the unacceptably
;h morbidity and mortality associated with HSCT
proaches. In clinical practice, the development of GvL is
en associated with significant graft-versus-host disease
vHD). Unfortunately, GvHD remains a major cause of
nsplantation-related mortality (TRM) and limits the use of
>CT to younger patients without significant comorbidity.
In recent years, a better understanding of the mechanisms
'olved in the immune escape of tumors together with the
mtification of tumor-associated antigens (TAAs) in AML,
:h as the Wilms' tumor gene product WT1 |11-13],
3teinase-3 114-16] and protein products of abnormal fusion
aes, such as B-cell antigen receptor (BCR)-ABL in chronic
'eloid leukemia (CML) and PML-RARa in AML [17,181, have
smoted new immunotherapeutic approaches to leukemia
tside the setting of HSCT. Dendritic cells (DCs), as profes-
nal antigen-presenting cells (APCs) that are able to elicit a
:otoxic response from naive T cells, have been at the center of
erest in developing a cellular vaccine for AML.
: development & T-cell interaction in vivo
vivo DCs form a heterogeneous group of subsets, continu-
y produced from myeloid and lymphoid hematopoietic
icursors in the bone marrow, and widely distributed as
mature DCs into lymphoid and nonlymphoid
>ues 119-22]. Immature DCs, including epidermal Langer-
as cells, splenic marginal zone DCs and interstitial DCs in
nlymphoid tissues, continually sample self-antigen to
lintain T-cell tolerance. However, immature DCs can also
:e up foreign antigens. When triggered by pathogens, the
item-recognition receptors expressed by immature DCs
lse them to mature in the presence of inflammatory 'dan-
• signals', such as tumor necrosis factor (TNF), interferon
N)-a or bacterial lipopolysaccharide (LPS) 123). Mature
3s are able to initiate primary T-cell immune responses by
ivating naive T cells [19.24] because they express high
ounts of cell-surface major histocompatibility complex
HC) and costimulatory molecules 119-22], as well as adhe-
n molecules and chemokine receptors (CCRs), such as
IR-7 and -8 |25], enabling them to migrate to the second-
lymphoid tissues, where they present antigen to T cells,
e APCs are thought to take up exogenous antigens,
luding apoptotic tumor cells, and present these to lym-
ocytes via a classical MHC class II pathway, but 'cross-
sentation' of these antigens through MHC class I mole-
es has also been demonstrated. Such cross-presentation
; been associated with the stimulation of CD4+ T-helper
i) cells and CD8+ cytotoxic T lymphocytes (CTLs),
;ether providing the best conditions for cell-mediated
otoxicity. T-cell activation requires two different signals
1URE 1). The first signal is provided by the interaction of
the MHC molecule peptide with the corresponding T-cell
receptor. The second signal consists of the binding of costim¬
ulatory molecules on the APC with their respective ligands
on the T cell. CD40 and B7 on the APC interact with CD40
ligand and CD28 on the T cell to mediate T-cell activation.
The remarkable functional heterogeneity of DC subsets is
due to their maturational state, the microenvironment to which
the DCs are exposed in various tissues in vivo, and a variety of
other factors, such as the strength of the T-cell receptor-MHC
class II interaction and antigen density, which are also known
to influence the ability of DC to induce!
• An interleukin (IL)-l 2-driven type 1 T-cell (Thl) response,
promoting T-cellular cytotoxicity
• A Th2 T-cell response, polarizing towards antibody-mediated
immunity
• To induce anergy of a T cell following a tolerizing interaction
with a DC
This review will consider the way in which DC function and
interaction with other components of the immune system
(T cells, NK cells) may be altered or defective in patients with
AML, favoring tumor escape from immunological surveillance,
as previously demonstrated in animal models of malignancy
and in cancer patients 126-29],
DCs in leukemia: part of the problem or the solution?
The role of DCs in cancer has been described in numerous
studies of a variety of tumors [30-32], postulating an associa¬
tion of good clinical prognosis with the presence of DCs in
tumor tissues. However, functional defects, mainly lack of
expression of costimulatory molecules in tumor-associated
DCs, have also been identified in more recent animal model
studies and in cancer patients [26-29]. In leukemia, similar to
other malignancies, release of immunosuppressive cytokines,
such as IL-10 [33,34], transforming growth factor
(TGF)-P (35-37), and vascular endothelial growth factor
(VEGF), and other known soluble factors, such as soluble
IL-2 receptor [38], soluble TNF receptor [39] and soluble Fas
ligand [40], as well as other, as yet unspecified factors [41], have
been implicated in creating an immunosuppressive micro-
environment that may not favor the induction of cell-medi¬
ated immunity. Recent investigations have shed more light on
the ontogeny of both myeloid and plasmacytoid DCs in the
peripheral blood of patients with AML and myelodysplastic
syndrome (MDS) [42.43]. Although both DC subsets are
present in MDS, albeit in lower numbers compared with
those in normal blood, both populations are demonstrably
derived from the malignant clone [42]. Likewise, in the periph¬
eral blood of AML patients, both DC subsets have been iden¬
tified [43]; however, the identification of subsets by immuno-
phenotypic characteristics may be complicated by the fact
that DCs and leukemic blasts share many markers, hence
leukemic blasts can be misidentified as DCs on the basis of
abberant expression of DC-associated markers on the surface
of leukemic blasts that are not DCs.
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Figure 1. Mechanisms of T-cell activation. (A) Recognition of
MHC-peptide complexes on the surface of an APC by a TCR in the presence of
a second costimulatory signal mediated by B7 leads to T-cell activation and
proliferation. (B) Absence of B7 expression by leukemia cells results in an
absent costimulatory signal following TCR binding of MHC-peptide complex
with consequent T-cell anergy.
APC: Antigen-presenting cell: CTL: Cytotoxic T lymphocyte: IL: Interleukin:
MHC: Major histocompatability complex; TCR: T-cell receptor.
In vitro, cytokine-driven differentiation of AML blasts to a
dendritic-like phenotype (AML-DC) can be achieved in a
proportion of patients [44-48]. As these AML-DCs arise from
the leukemic clone, they offer potential as autologous cellu¬
lar vaccines, expressing both leukemic antigens and DC-
characteristic, costimulatory molecules that are mostly lack¬
ing in native leukemic blasts. Coculture experiments of
AML-DC with autologous T cells have induced antileuke¬
mic cytotoxicity [49]. However, as DC populations originat¬
ing from leukemic blasts in vivo are part of the malignancy
and may potentially also produce 'tolerogenic' signals, the
question arises if AML-DC in vivo might be implicated in
the disease process and, if so, would their use in therapy be
advisable? The fact that the malignant cells are DC precur¬
sors, and therefore components of the immune interaction
one attempts to study, complicates the characterization of
immune responses to AML. Studies of antileukemic T-cell
responses in leukemic patients in remission [45,501 and those
with fulminant disease [12,511 have been undertaken. CTLs
directed against tumor-associated antigens, such as WT1 and
proteinase 3, have been demonstrated at some point of the
disease process. Such observations have led some investiga¬
tors to the suggestion that immune responses to tumor might
be actively inhibited in advancing disease [52,53], while others
have postulated that, in patients with malignancy, immune
responses to TAAs are only initiated in disseminated, over¬
whelming disease and are only detectable at low levels in a
situation of low tumor burden [54,551. In either case, immune
control of the tumor ultimately would be ineffective, but the
exact immunosuppressive mechanisms remain unclear.
Could DCs derived from malignant precursors, one of the
unique features of AML, be part of the pathology of AML? If
AML-DCs respond to stimuli in their environment with a
capacity similar to that of normal marrow precursor-derived
DCs, then the pathology in AML may not be at the level of
the DC itself, but with the responder T and NK cells. In this
case, the use of AML-DCs in therapy of AML may be of ben¬
efit. In cases where AML-DCs differ from normal DCs in
their responses to stimuli, AML pathology may in part be
attributed to the AML-DC itself and their use in therapy of
the disease may be less effective. Semimature DCs may trig¬
ger regulatory T cells (Tregs), such as IL-10-producing CD'D
CD25+ cells, capable of silencing the immune response,
whereas specific manipulation of malignant cells into APCs
with a mature phenotype may trigger the immune system to
suppress or eradicate leukemia.
Cellular vaccine design strategies in AML
Any successful cellular vaccine needs to overcome the reduced
immunogenicity of leukemic cells. This requires the generation
of vaccine cells in large numbers to express leukemia-specific
antigens in the context of adequate costimulation. Two princi¬
pal strategies have been pursued in DC-based leukemia vaccine
generation:
• Improving the antigen-presenting capacity of leukemia cells
themselves: this can be achieved by either transfer of genes
that encode the necessary costimulatory molecules into
leukemic blasts [56-64] or by cytokine-driven leukemic blast
maturation into AML-DC [44-491
• Utilizing the superior T-cell stimulatory capacity of non-
leukemic DCs: either first, by adoptive immunotherapy,
using ex v/Vo-generated CTLs specific for TAAs, or second,
through vaccination protocols with professional APCs
expressing defined TAAs (FIGURE 2) [65-70]
To deliver leukemia-associated antigens, DCs can be gener¬
ated ex vivo from either monocytes [71,72] or CD34+ hemato¬
poietic progenitor cells [73-75], They can be pulsed as immature
DCs ex vivo with tumor antigens, matured with cytokines and
then injected as cellular vaccines. Reported approaches for this
purpose include the following:
• Pulsing DCs with leukemic blast lysates [76,77)
• Pulsing DCs with irradiated or apoptotic blasts [75.78]
• Pulsing DCs with synthetic peptides from tumor-associated
antigens (e.g., WT1 in AML, PR1 in AML/CML |ll-16,79])
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Pulsing DCs with tumor-specific antigens derived from pro¬
tein products of abnormal fusion genes, (e.g., BCR-ABL in
CML, PML-RARa and DEK-CANin AML 117.i8.801)
Loading DCs with tumor-derived RNA or DNA [811
Fusing DCs with leukemic blasts, generating AML-DC
hybridomas [82,83]
\ML-DC as cellular vaccine
t strategy explored by several investigators over the last
lecade 144,47,49,65-70) is the differentiation and maturation of
aukemic blasts into dendritic-like cells (AML-DCs). This
strategy followed the emerging knowledge of DC develop¬
ment from myeloid progenitors. A variety of different
cytokine cocktails, including granulocyte-macrophage col¬
ony-stimulating factor (GM-CSF), IL-4, IL-13, TNF-a, fer¬
ritin light chain (FLT)-3 ligand and immunomodulators,
such as soluble CD40 ligand, have been proposed to induce
dendritic-like differentiation and maturation. The 'essential
cocktail', identified for generating DCs from blood mono¬
cytes, consisting of GM-CSF and IL-4 [841, has been comple¬
mented by CD40 ligand or TNF-a to induce differentiation
in 18 out of 19 primary AML samples in a seminal study by
Choudhury and colleagues (47|. The resulting AML-DC
CTL













Ex vivo generation of tumor-specific CTLs DC vaccination
Figure 2. Two strategies for generating antitumor immunity. (A) CTLs are generated ex vivo by coculture of autologous or allogeneic T cells with APCs that
expressed a defined tumor antigen. Tumor antigen-specific CTLs are then injected intravenously into the patient. (B) DCs are generated from the patient and are
engineered to express a defined tumor antigen. The DCs are then injected into the patient (either by the s.c., i.d. or i.v. route) and stimulate the in vivo development
of tumor-specific immunity.
APC: Antigen-presenting cell; CTL: Cytotoxic T lymphocyte; DC: Dendritic cell; i.d.: Intradermal; i.v.: Intravenous; s.c.: Subcutaneous; TA: Tumor antigen.
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showed the characteristic morphology, immunophenotypic
properties and T-cell stimulatory properties of mature DCs.
Importantly, coculture of autologous T lymphocytes with the
AML-DC induced cytotoxic responses directed against the
native leukemic blasts, but not against normal autologous
cells. Several other studies have confirmed these findings in a
proportion of AML blasts investigated [46,85). The hetero¬
geneity of AML, however, is reflected in the fact that a signif¬
icant proportion of AML samples prove resistant to cytokine-
induced differentiation into fully mature AML-DCs. There
are, to date, no published clinical vaccination studies utiliz¬
ing AML-DCs as cellular vaccines in AML. The authors have
recently completed a Phase I/II clinical vaccination study
using autologous dendritic-like leukemic cells (AML-DCs)
in adult patients with AML in remission, following multi-
agent chemotherapy, demonstrating the clinical feasibility of
this approach and showing antileukemic immune responses
following AML-DC vaccination [86]. Using stringent criteria
for the generation of AML-DCs from AML blasts, seven out
of 22 samples could be differentiated and matured using
GM-CSF, IL-4, TNF-a, Poly I:C and IFN-y. Five patients
both achieved complete remission and also had leukemia
cells that were permissive to differentiation, and were there¬
fore eligible to proceed to vaccination. Four escalating doses
of dendritic-like leukemia cells were administered weekly by
subcutaneous injection. An increase in antileukemic T-cell
responses was demonstrated in four patients. Of the five
patients, two are in continued complete remission of greater
than 12 months' duration following vaccination. The
remaining patients had relapse of their leukemia.
DC-based vaccination
Clinical Phase I/II study protocols utilizing tumor antigen-
loaded DCs have, in principle, documented the feasibility of
this approach and demonstrated variable degrees of immuno¬
logical and clinical in vivo responses in patients with melanoma,
prostate and ovarian cancer |87-92], Partial regressions of solid
tumors have been demonstrated in a proportion of patients in
these studies, with occasional complete responses demonstrated.
These early reports are encouraging, but difficult to compare
and reproduce, owing to methodological differences in all
aspects of study design.
Few clinical vaccination trials in leukemia are published.
T-cellular cytotoxic responses to TAA-derived peptides have
been studied in the most depth. Molldrem and colleagues
have demonstrated that human leukocyte antigen (HLA)-A2-
restricted CTLs raised against PR1 peptide, a human leuke¬
mia-associated antigen derived from proteinase-3, an aber¬
rantly expressed protein in myeloid leukemia cells, preferen¬
tially killed leukemic over normal hematopoietic precursors
(79% cytotoxicity against CML cells, 54% lysis of AML
blasts) [15]. A later study investigated the correlation between
the presence of PR1-specific T cells [50], detected by
PR1-HLA-A2 tetrameric complexes in the peripheral blood
of leukemic patients following treatment with IFN-a and
allogeneic bone marrow transplantation, giving first-time evi¬
dence of the role of T-cell immunity in clearing malignant
leukemic cells. A subsequent clinical vaccination study with
PR1 peptide and adjuvant GM-CSF in 35 patients with
AML, CML and MDS elicited both immunologically demon¬
strable (60% of patients) and clinical responses in patients
with refractory and relapsed myeloid leukemia [93].
In AML, there are, to date, no published clinical trials
exploiting DC based vaccination strategies as an adjuvant ther¬
apeutic approach for MRD following multiagent intensive
chemotherapy, where, in the authors' opinion, the chances of
immunological control of disease recurrence appear most
promising. The only clinical DC vaccination study, undertaken
by Lee and colleagues, utilized blast cell lysate-pulsed DCs in
two patients in relapse following autologous HSCT [76]. In this
setting, immunological responses to vaccination are difficult to
differentiate from those directed against advancing leukemic
tumor burden, but evidence of delayed hypersensitivity and
increased mixed lymphocyte responses (MLRs) were attributed
to the subcutaneous vaccination protocol.
A larger number of preclinical studies have been conducted,
exploiting various DC-loading protocols.
Schui and colleagues pulsed DCs with tumor lysates and
have induced autologous antileukemic cytotoxicity in cocul-
tured T cells in five out of 25 patients only, while in other
patients, an inhibitory effect was seen [77]. Spisek and colleagues
demonstrated the ability of nonleukemic DCs loaded with late
apoptotic leukemic blasts to induce in vitro leukemia-specific
T-cellular cytotoxicity in three patients [78]; direct comparison
with the cytotoxicity induced by AML-DC was only possible in
one patient and was found to be similar. An earlier study by
Fuji and colleagues showed the induction of antileukemic
CTLs by CD34+-derived DC clusters pulsed with autologous,
irradiated blasts [75].
In AML and advanced lymphoblastic leukemia, HLA-A2-
binding peptides derived from the Wilms' tumor gene-
encoded transcription factor WT-1 [94] stimulate a specific
antileukemic T-cell response [14,16,95]. Similarly, DCs loaded
with mucin (MUC)-l protein, an epithelial mucin that is
overexpressed in AML and multiple myeloma, facilitate the
generation of antitumor T-cell responses in vitro.
In a subgroup of leukemia patients, chromosomal transloca¬
tions are demonstrable in the leukemic clone, resulting in gene
rearrangements and giving rise to fusion gene protein products,
(e.g., BCR-ABL in CML and PML-RARa in AML) [17,18].
These proteins are potential targets of an immune response.
They are attractive for immunotherapy, as they represent true
tumor-specific antigens. Furthermore, as some of these fusion
proteins are essential for the malignant transformation of the
clone, tumor escape through antigen loss in response to selective
immunological pressure is unlikely. However, in spite of these
attractive features, the potentially immunogenic site of a fusion
protein is only located in the amino acid sequences immediately
flanking the fusion site. Cleaving by proteases is necessary to
arrive at candidate antigenic peptides. Those peptides will have
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fit the binding motif of a given patient's HLA molecules in
Jer to elicit CTL responses. This HLA restriction makes it
likely that a universal antigenic peptide sequence derived
im a fusion protein that would be useful in the majority of
tients presenting with a given chromosomal translocation will
found.
The authors compared the potency of AML-DC fusion
brids to that of DCs pulsed by irradiated tumor bodies to
iuce in vitro leukemia-specific, autologous cytotoxicity in
tients with AML 182]. Remission monocytes are matured into
Ss and then fused to autologous AML blasts using
lyethylenglycol (PEG) as the fusing agent, or by electropora-
n. The resulting constructs express the full repertoire of
ikemic antigens on their surface in conjunction with DC-
rived costimulatory molecules. There is no need to establish
; HLA type of the patient; in contrast to approaches using
lsing of DCs with specific peptides or antigens, no prior
unification of TAAs expressed by the individual leukemia
ists is required and the fusion technology using PEG is well
ablished and simple, making this approach more easily appli-
tle. It also avoids the technical difficulties and safety con¬
ns that surround the use of viral vectors to generate geneti-
ly modified leukemic cells for vaccination. Fusion hybrids
luced the strongest cytotoxic responses in three out of six
tients studied [82]. DCs pulsed by tumor bodies were superior
two other patients. Only one patient failed to generate
/[L-directed cytotoxicity in response to either construct. The
thors conclude that AML-DC fusion hybrids hold promise
a cellular vaccine for AML.
optive immunotherapy
lis approach using ex wVo-generated CTLs has been
aloited in several clinical and preclinical studies. Mutis and
leagues have built on the recognition of minor histocom-
tibility antigen (mHAg) mismatch as important factors in
; development of GvHD and GvL in allogeneic HSCT [9].
me mHAgs show ubiquitous tissue distribution, others,
:h as the mHAgs HA-1 and -2, are only expressed in
natopoietic cells |96|. These antigens are therefore attractive
.As for immunotherapy, as they should selectively direct an
ageneic cytotoxic response against hematopoietic tumor
Is. Donor-derived DCs from a HA-1 or -2-mismatched
nor are pulsed with HA-1 or -2 peptides corresponding to
i recipient's mHAg type. These DCs are cocultured ex vivo
:h donor lymphocytes to generate CTLs specific for these
atides. Subsequently, the patients undergo an allogeneic
iCT from their HLA-compatible, but HA-1- or -2-mis-
tched donor. After complete engraftment of donor-derived
natopoiesis, the ex wVo-generated mHAg-specific CTLs are
used into the patient with antileukemic cytotoxic effect,
hout causing GvHD. This approach is limited to a small
mber of patients that are undergoing an allogeneic HLA-
tched HSCT from a donor with HA-1 or -2 disparity,
ire widely applicable strategies have used the characteriza-
n of TAAs demonstrated to induce CTL responses specific
to tumor cells in hematological malignancies. The transcrip¬
tion factor WT1, which is widely expressed on the leukemic
cells from patients with AML and CML, has been demon¬
strated to be a potential target for in vitro CTL generation.
Using APCs pulsed with HLA-A2-restricted WT1 peptides,
CTLs were generated from peripheral blood mononuclear
cells that showed exquisite specificity of action against CD34+
leukemia cells, but spared normal CD34+ progenitors (14).
Some of the limiting factors to successful translation of this
type of ex vivo CTL generation into clinical practice include
the very prolonged period of culture necessary to obtain clini¬
cally relevant numbers of CTLs, with all the attendant diffi¬
culties that this entails, and the limitations set by MHC class-
restricted DC presentation of tumor peptides that may not
always be available for every HLA type.
Considerations for delivering a DC-based vaccine for AML
Many facets of DC-based vaccines in AML remain unknown,
as the clinical application of this approach is in its infancy.
From experiences with earlier DC vaccination studies in solid
tumor malignancies, it may be deduced that the state of
MRD, achieved following conventional chemotherapy or
HSCT, is a desirable setting for the trial of leukemia cell vac¬
cines. Patients with MRD have a low tumor burden. DC-
induced CTL responses are likely to be overwhelmed by rap¬
idly advancing leukemia |97] and, importantly, immunologi¬
cal control of MRD has been demonstrated to be associated
with superior long-term survival and lower relapse rates orig¬
inating from residual leukemia in allogeneic HSCT. Preclini¬
cal studies have emphasized the importance of vaccinating
with fully mature DCs in order to avoid tolerogenic
responses associated with immature or semimature forms.
Optimal dose, scheduling and route of delivery remain con¬
troversial. DCs are frequently administered subcutanuously,
intradermally or by direct injection into lymphatics/draining
lymph nodes. Recent studies suggest that immature DCs
migrate less than mature DCs. De Vries and colleagues dem¬
onstrated that, in general, less than 5% of intradermally
administered mature DCs reach the draining lymph
node |98]. From these data, it can be speculated that increased
migration would increase the efficacy of DC vaccines.
Attempts to increase migration include the concomitant use
of inflammatory cytokines to condition tissues [99]. Matrix
metalloproteinases and Toll-like receptor (TLR) ligands
might also enhance DC migration [100].
Any ex vivo manipulation of human cells must be under¬
taken conforming to Good Manufacturing Practice (GMP)
standards laid down in the USA and the EU. Facilities com¬
plying with these standards are regulated in the USA by the
Center for Biologies Evaluation and Research. In the UK, the
Department of Health, through the Medicines and Health¬
care Regulatory Authority, has established an inspectorate
whose remit includes cellular therapy. Investigators have to
ensure that clinical vaccination studies using cellular products
are compliant with standards that are already established in
3 Expert Rev. Vaccines 5(2), (2006)
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the commercial pharmaceutical industry. This includes
cytokines used in the process that must be of clinical grade
standard and cell culture media that should only contain
human serum protein or ideally be serum free. The use of
fetal calf serum is no longer deemed appropriate.
For any vaccination approach that uses leukemia-derived DCs,
prevention of re-engraftment of viable, potentially proliferating
cells is of importance. The authors established that 25 Gy of
y-irradiation from a caesium-137 source, routinely used for irra¬
diation of blood products, completely abolished the proliferative
potential of AML blasts in tissue culture and have irradiated all
AML-DC vaccines with this dose prior to inoculation.
Monitoring responses to DC vaccination in AML
The use of objective criteria to describe clinical responses, as
codified by the WHO, and in solid tumor response evaluation
schemes (RECIST) [ 101J would advance the field of DC
immunotherapy. Many early studies are compromised by a lack
of standardization of clinical responses and no demonstration
of specific antineoplastic immune responses.
In a proportion of myeloid leukemias, recurrent chromo¬
somal abnormalities (translocations and inversions) can be
detected. Those can be used to quantify the residual tumor
burden using highly sensitive, quantitative reverse tran¬
scriptase (RT)-PCR assays. In cases without demonstrable
cytogenetic defects, stably expressed TAAs, such as WT-1 [94),
have been used to quantify MRD from blood and bone mar¬
row. These assays represent minimally invasive, sensitive and
validated tools, applicable to the monitoring of treatment
responses post-chemotherapy and -HSCT. They can be uti¬
lized to objectively quantify treatment responses to DC
immunotherapy in a similar way.
Any future attempt to increase the effectiveness of vaccination
will also depend on the ability to measure the development of
antileukemic T-cell immune responses with a high degree of sen¬
sitivity and specificity. In recent years, it has become possible to
visualise antigen-specific T-cells under flow cytometry by using
soluble, fluorescently labelled multimeric HLA-peptide com¬
plexes [102] that bind stably, specifically and avidly to antigen-spe¬
cific cells. The authors have combined tetramer assays for WT1-
recognizing T cells with highly sensitive assays of T-cellular
IFN-y responses to autologous AML blasts (ELISPOT) in com¬
bination with RT-PCR for WT-1 assays of tumor burden to
monitor the impact of AML-DC vaccination (TABLE 1) [103).
T regs have been investigated in many recent studies owing to
their apparent immunomodulatory role in infection, auto¬
immunity and inhibitory effect on anticancer immune
responses [104-107). Conversely, evidence has emerged that effec¬
tive anticancer immunity can be restored by suppression of Treg
numbers [106,108], Correlating the number of Tregs before, dur¬
ing and following DC vaccination with the variation of measur¬
able antileukemic cytotoxicity and MRD burden may provide
insight into the role of these cells in dampening antileukemic
immune responses.
Expert commentary
The clinical application of DC-based vaccination therapy is still in
its infancy. We have, in the first clinical study of its kind, demon¬
strated that leukemia-derived AML-DCs are a feasible, safe cellu¬
lar vaccine for AML that has induced immunological responses in
four out of five vaccinated patients. Differentiation resistance to
cytokines in a significant proportion of leukemic blasts, however,
limits the broad applicability of AML-DC. Several recent studies
attempt to circumvent this problem by transducing an autologous
vaccine with genes expressing costimulatory molecules and
IL-2 [56,57]. Rousseau and colleagues constructed an autologous
vaccine from leukemic blasts admixed with skin fibroblasts trans¬
duced with adenoviral vectors encoding human IL-2 and human
CD40 ligand [56). Ten patients (including seven children) with
high-risk AML (n = 4) or lymphoblastic leukemia (n = 6) in cyto¬
logic remission (after allogeneic stem cell transplantation [n = 9]
or chemotherapy alone [n = 1]) received up to six subcutaneous
Table 1. Methods of monitoring in vitro and in vivo responses to dendritic cell-based vaccination.
Method Advantages Disadvantages
Delayed type hypersensitivity reaction
(skin test)
In vitro cytotoxicity assay (Cr51 -release)
In vitro IFN-y release assay (ELISPOT)
HLA-tetramer analysis of tumor antigen-
specific circulating CTLs
MRD monitoring
(quantitative RT-PCR of tumor-associated
antigens/chromosomal translocations)
Easy to monitor and quantify
Demonstrates specific T-cellular cytotoxic
target cell lysis
Sensitive assay, automated reading of
responses on plate
Very sensitive, specific analysis of
antitumor-directed CTLs
Sensitive, quantifiable assessment of
residual tumor burden




IFN-y release is surrogate marker of T-cellular
cytotoxicity
Not available for every HLA type
Not applicable to every leukemia patient
CTL: Cyotoxic T lymphocyte; ELISPOT: Enzyme-linked immunosorbent spot; HLA: Human leukocyte antigen; IFN: Interferon; MRD: Minimal residual disease; RT-PCR: Reverse
transcriptase polymerase chain reaction.
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:ctions of the IL-2/CD40 ligand vaccine. Immunization pro-
:ed a 10- to 890-fold increase in the frequencies of MHC-
xicted T cells reactive against recipient-derived blasts, demon-
iting that, even in heavily treated patients, including recipients
illogeneic stem cell transplants, recipient-derived antileukemia
cines can induce immune responses reactive against leukemic
its. These studies represent the current clinical experience with
ellular autologous AML vaccine. The challenge for future
>roaches will be to translate the antileukemic immune
3onses observed into demonstrable clinical benefit. This may
achieved by optimizing dosing, timing and sequencing of vac-
e administration, as well as potentiating the vaccine through
use of adjuvants and addressing the suppressive effect of Tregs.
y future vaccination strategy will have to address the possibility
various immunological tumor escape mechanisms and the
blem of targeting dormant tumor cells [109]. It remains uncer-
i whether the antileukemic role of NK cells observed in alloge-
c stem cell transplantation can be replicated in autologous vac-
e constructs, but a recent study in a murine model suggests that
an. NK cells that are activated by CXCL10 can kill dormant
tor cells that resist CTL-mediated lysis [110).
j-year view
our opinion, 'whole cell -based DC vaccines (e.g., fusion
irids, nonleukemic DCs pulsed with autologous tumor
ites or apoptotic tumor cell bodies) provide the most
mising therapeutic strategy in the immediate future. These
constructs circumvent the obstacle of differentiation resist¬
ance encountered when using AML-DCs, and provide poly¬
valent' immune stimulation, making tumor immune escape
by antigen drift less likely. They do not require detailed analy¬
sis of the individual leukemic antigens presented and are not
HLA restricted, thereby representing an easier, albeit individu¬
alized, vaccine design. Approaches based on transducing an
autologous cellular vaccine with genes encoding costimulatory
molecules and IL-2 also appear promising [56.57], providing
concerns about safety using a virally transduced vaccine can be
addressed. Looking further ahead, the emerging knowledge of
important, immunogenic leukemia-associated antigens, in par¬
ticular those that are integral to the leukemogenic process,
might well reveal a number of peptides loadable to a wide
range of HLA types, making this vaccine approach more
widely applicable. Ultimately, in vivo loading of leukemic anti¬
gens and achieving activation of the patient's own DCs by tar¬
geting specific DC TLRs would seem an ideal mode of vaccine
delivery. New, emerging adjuvants might greatly enhance the
immune stimulation achieved by in vivo DC targeting.
Regardless of the chosen vaccine design, standardization of DC
generation, antigen loading and maturation, as well as evaluation
of the vaccination response, will be essential to allow observations
from different clinical studies to be compared. Only then might
an effective cellular vaccine, delivering a sustained clinical benefit
to patients with low tumor burden AML post chemotherapy,
emerge from the plethora of current hypotheses.
(ey issues
Evidence that immunological control contributes to the elimination of residual leukemia has emerged from allogeneic
hematopoietic stem cell transplantation.
Current strategies for the generation of a cellular, autologous vaccine are based on either attempts to improve the
antigen-presenting capacity of leukemia cells themselves or on adoptive immunotherapy, using ex wVo-generated cytotoxic T cells
specific for tumor-associated antigens (TAAs) or through vaccination protocols with professional antigen-presenting cells, such as
dendritic cells (DCs), expressing defined TAAs.
Clinical experience with antileukemic cellular vaccines is limited at present.
Encouraging antileukemic immune responses have been demonstrated in various preclinical and clinical vaccination studies, but
have so far not resulted in lasting clinical benefit, possibly because of tumor immune escape mechanisms.
Standardization of DC generation, antigen loading, maturation and vaccine administration/scheduling is essential to ensure
comparability of future clinical studies and increase the efficacy of antileukemia vaccines of the future.
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